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ABSTRACT 
 
Fireflies are beetles that generate yellow-green light when their luciferase 
enzyme activates and oxidizes its substrate, D-luciferin. This bioluminescent 
reaction is widely used as a sensitive reporter both in vitro and in vivo. However, 
the light-emitting chemistry is limited by the properties of the small molecule D-
luciferin. Our lab has developed a panel of synthetic luciferin analogs that 
improve on the inherent characteristics of D-luciferin. My thesis work focuses on 
harnessing these novel substrates to further expand the utility and molecular 
understanding of firefly bioluminescence.  
The first part of my thesis focuses on using synthetic luciferins to improve 
bioluminescence imaging beyond what is possible with D-luciferin. Our 
substrates emit red-shifted light compared to D-luciferin, bringing the wavelength 
to a range that is more able to penetrate through tissue, but at a cost of lower 
signal intensity. I developed mutant luciferases that increase the maximal photon 
flux with the synthetic luciferins over what is achievable with the wild-type 
luciferase, and furthermore discriminate between substrates based on their 
chemical structures. Additionally, I have expanded the bioluminescence toolkit by 
harnessing the intrinsic properties of the luciferins to non-invasively and 
specifically assay the activity of a single enzyme (fatty acid amide hydrolase) in 
live mice. Therefore, my work presents an effective way to generally improve 
vi 
 
upon bioluminescent reporters, but also to measure the activity of a specific 
enzyme of interest in the context of a living organism. 
The second part of my thesis employs synthetic luciferins to more deeply 
probe the light-emitting chemistry of bioluminescence. Our synthetic substrates 
reveal latent luciferase activity from multiple luciferase homologs that are inactive 
with D-luciferin. These enzymes, the fatty acyl-CoA synthetases, are predicted to 
be luciferase’s evolutionary predecessors, but it was not clear how the light 
emitting chemistry originated. My work shows that the luciferase must activate 
the luciferin and provide oxygen access, but the light emitting chemistry is a 
fundamental property of that activated intermediate. In summary, the work 
described herein not only expands our understanding of firefly bioluminescence, 
but also broadens its practical applications to shine bioluminescent light on the 
dark corners of biology. 
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CHAPTER I: 
Introduction 
 
Firefly bioluminescence 
Bioluminescence is defined as the production of light from a living 
organism. Phylogenetic analysis suggests that this fascinating process has 
evolved independently over 30 times (Greer and Szalay, 2002; Hastings, 1983), 
in species such as bacteria, dinoflagellates, fungi, and fish. However, some of 
the best characterized bioluminescent organisms are insects. Light emission 
from insects is almost exclusively found in beetles from the order Coleoptera, 
including click beetles (Elateridae family), railroad worm beetle larvae 
(Phengodidae family), and fireflies and glow worms (Lampyridae family) (Day et 
al., 2009). While as many as 2,000 bioluminescent beetles have been identified 
(Herring, 1979), most of the characterization of insect bioluminescence was 
performed on a single species, the North American firefly, Photinus pyralis (Conti 
et al., 1996; de Wet et al., 1987).  
The firefly and all other bioluminescent beetles use an enzyme called 
luciferase to catalyze light emission (Fraga, 2008; Greer and Szalay, 2002; 
Hastings, 1998; Wilson and Hastings, 1998). Each beetle has a distinct but 
homologous version. However, all beetles share the same substrate, D-luciferin. 
Light emission occurs when luciferase binds D-luciferin, in the presence of Mg-
ATP, to catalyze the formation of an intermediate luciferyl-adenylate (Fraga, 
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2008) (Figure 1.1). This activated adenylate allows for the formation of a 
resonance stabilized carbanion at the C4 carbon of D-luciferin, which can react 
with oxygen by single electron transfer (Branchini et al., 2015; Mofford et al., 
2014a). Oxygen then displaces AMP, forming a high energy dioxetanone ring 
that spontaneously breaks down to an excited state oxyluciferin by releasing 
carbon dioxide (Fraga, 2008). Finally, the excited state product relaxes to the 
ground state by releasing a photon of light, resulting in bioluminescence (Figure 
1.1). Conversely, the luciferyl adenylate can be oxidized to produce 
dehydroluciferyl adenylate and hydrogen peroxide via an off-pathway reaction 
that does not emit light (Fraga et al., 2006) (Figure 1.1). Firefly luciferase is able 
to catalyze light emission with a final quantum yield of 41% (Ando et al., 2008), 
resulting in the brilliant light emitted by the firefly in the night sky. 
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Figure 1.1. Firefly luciferase-catalyzed light emission from D-luciferin. (A) 
Luciferase binds D-luciferin and Mg-ATP to catalyze the formation of the luciferyl 
adenylate intermediate. (B) After adenylation: 1) D-luciferyl adenylate stabilizes 
the formation of a carbanion; 2) the carbanion reacts with oxygen, forms the high 
energy dioxetanone ring, and releases AMP; 3) the ring decomposes, releasing 
CO2 and producing the excited state oxyluciferin; 4) the excited state product 
relaxes to the ground state via photon emission. (C) Oxidation of the luciferyl 
adenylate intermediate can also form the off-pathway products dehydroluciferyl 
adenylate and hydrogen peroxide that do not emit light. 
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The origins of firefly luciferase and light emission 
It has long been apparent that firefly luciferase shares biochemical 
characteristics with ligases such as acyl-CoA synthetases, aminoacyl-tRNA 
synthetases, and plant p-coumarate-CoA ligases (McElroy et al., 1967; 
Pietrowska-Borek et al., 2003) (Figure 1.2). Indeed, luciferase is able to catalyze 
the synthesis of dehydroluciferyl adenylate and dehydroluciferyl CoA from 
dehydroluciferin through a mechanism identical to an acyl-CoA synthetase 
(Figure 1.2). Recently, luciferase was shown to act as a long chain fatty acyl-
CoA synthetase (ACSL) (Oba et al., 2003), accepting fatty acid substrates in 
addition to luciferins. Moreover, the crystal structure of luciferase (Conti et al., 
1996; Sundlov et al., 2012) shows similarities to other acyl-CoA synthetases 
(Conti et al., 1997; Gulick et al., 2003; Reger et al., 2008). Thus, luciferase was 
classified as a member of the acyl-adenylate/thioester-forming superfamily 
(Chang et al., 1997; Oba et al., 2005). 
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Figure 1.2. Mechanisms of the adenylate-forming superfamily. (A) Luciferase 
binds dehydroluciferin and Mg-ATP to catalyze the formation of an intermediate 
adenylate that is then displaced by CoA to produce dehydroluciferyl-CoA. (B) 
Acyl-CoA synthetases bind fatty acids and Mg-ATP to catalyze the formation of 
an intermediate adenylate that is then displaced by CoA to produce the acyl-CoA 
product. (C) Aminoacyl-tRNA synthetases bind their respective amino acid and 
Mg-ATP to catalyze the formation of an intermediate adenylate that is then 
displaced by the appropriate tRNA to form the aminoacyl-tRNA product. (D) p-
Coumarate-CoA ligases bind p-coumaric acid and Mg-ATP to catalyze the 
formation of an intermediate adenylate that is then displaced by CoA to produce 
the acyl-CoA product. 
 
It is hypothesized that luciferase evolved from a gene duplication event of 
an ACSL (Oba et al., 2006a). Upon duplication, the original gene retained its 
native function, leaving the copy free to mutate and evolve a new function (Ohno, 
1970). The chemistry to adenylate a free carboxylate is clearly present in an 
ACSL, yet the origin of the oxidative chemistry of luciferase is less obvious. 
Originally, oxidation of the intermediate adenylate was proposed to be achieved 
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non-catalytically (Day et al., 2004), since luciferyl adenylates are readily oxidized 
without enzyme in basic DMSO (Seliger and McElroy, 1962). However, the level 
of light generated without enzyme is not sufficient to explain the intense glow that 
is observed from the firefly, suggesting that the oxidative step must also be 
catalyzed. Further evidence in favor of catalytic oxidation is the observation that 
only the D-isomer of luciferin is able to emit light (Fraga, 2008). Moreover, only 
the D-luciferyl adenylate can be oxidized to form the off-pathway dehydroluciferyl 
adenylate product (Fraga et al., 2006) (Figure 1.1). Oxygen has been shown to 
generally access ligand binding sites (Baron et al., 2009). The structure of 
luciferase suggests that oxygen has access from only one direction (Nakatsu et 
al., 2006); although, a putative oxygen binding site in luciferase has not been 
identified (Branchini et al., 1998). 
 
Light emission from D-luciferin 
In nature, all beetles utilize D-luciferin as the substrate for their respective 
luciferases. However, the color of light emitted can range from green (530 nm) to 
red (635 nm) (Hastings, 1996). These variations are due to differences in the 
local environment of the luciferase binding pocket. It was originally proposed that 
variations to the binding orientation of D-luciferin caused the different 
wavelengths. In this model, the angle between the benzothiazole and thiazoline 
rings would alter the potential energy of the excited state oxyluciferin. It was 
proposed that an angle of 0° between the two would produce the highest energy 
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state and emit higher energy green light. An angle of 90° would be the lowest 
energy state, thus emitting red light. However, subsequent structural studies 
have invalidated this hypothesis (Nakatsu et al., 2006). Instead, the structure and 
protonation state of the oxyluciferin determines the wavelength of light emitted. 
Oxyluciferin can adopt one of six possible conformations (Figure 1.3). The 
phenolic hydroxyl on the benzothiazole can exist as either a protonated phenol or 
a deprotonated phenolate. The carbonyl on the thiazoline ring can tautomerize to 
either the keto or enol conformation, and the enol can be further deprotonated to 
its respective enolate (Figure 1.3). Bound to firefly luciferase, the phenolic 
hydroxyl exists as a phenolate. When the carbonyl is in the keto form, 
oxyluciferin emits red light (635 nm). The enol and enolate forms emit at 560 nm 
and 590 nm, respectively (Branchini et al., 2002; Naumov et al., 2009; White et 
al., 1980). Thus, the local environment in the active site of the luciferase 
determines the relative abundance of each conformation and the wavelength of 
light emitted. 
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Figure 1.3. All possible keto-enol structures of oxyluciferin. 
 
 
Firefly luciferase burst kinetics 
Luciferase-catalyzed light emission is characterized by “burst kinetics” 
where, upon rapid injection of enzyme to substrate, there is a burst of light within 
the first few seconds, followed by a decay in the sustained level of light emission 
(DeLuca and McElroy, 1974) (Figure 1.4). This decay is due to product inhibition, 
where slow dissociation of the final products inhibits subsequent rounds of 
catalysis (Fraga, 2008). The slow dissociation of both the oxyluciferin and AMP 
light emitting products and the “dark” dehydroluciferyl adenylate (L-AMP) product 
contribute to the inhibition. While L-AMP only accounts for approximately 16% of 
the oxidized product (Fraga, 2008), it is a much more potent inhibitor than 
oxyluciferin (L-AMP Ki = 3.8 ± 0.7 nM, oxyluciferin Ki = 0.50 ± 0.03 µM) (Ribeiro 
and Esteves da Silva, 2008). Its non-competitive inhibition forces luciferase into a 
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closed conformation (Nakatsu et al., 2006). This inhibition can be relieved by the 
addition of Coenzyme A (CoA), which reacts with L-AMP to form L-CoA, a less 
potent inhibitor (Fraga et al., 2006) (Figure 1.4). 
 
 
Figure 1.4. Burst kinetics profile of firefly luciferase injected into D-
luciferin. Rapid injection of luciferase to D-luciferin produces a burst of light 
followed by a decay caused by product inhibition. The addition of CoA at 60 s 
relieves some product inhibition, resulting in a second burst and a decrease in 
the subsequent decay. Figure adapted from (Fraga, 2008). 
 
Bioluminescence in biology 
“Among reaction products, the photon is undoubtedly the most important; 
few can argue that if not for the light, Luc would not have been rescued from the 
obscure beetle biochemistry.” (Fraga, 2008) 
The light-emitting chemistry of bioluminescence has been widely adopted 
to report on otherwise invisible biological processes (Badr and Tannous, 2011) 
both in vitro (Fan and Wood, 2007) and in vivo (Prescher and Contag, 2010). For 
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example, by placing a luciferase gene under the control of a promoter sequence 
of interest, it is possible to monitor the gene expression controlled by that 
promoter by luciferase expression and subsequent light emission with D-luciferin 
(Hill et al., 2001). Conversely, by generating a “pro-luciferin” whose light emitting 
chemistry is dependent upon enzymatic activity (i.e., linking the luciferin to a 
short peptide that can be cleaved by a specific protease), the activity of that 
enzyme can be monitored via light emission (Hickson et al., 2010; Moravec et al., 
2009). 
Firefly bioluminescence offers several advantages over fluorescence and 
other optical reporter techniques. Fluorescent proteins can be genetically 
encoded, much the same way as a luciferase can; and fluorescent dyes can be 
modified and cleaved by enzymes of interest, similar to a small molecule luciferin 
(Fernández-Suárez and Ting, 2008). However, all fluorescence-based assays 
require an external photon to supply the energy needed for the excited state 
product, as opposed to the chemical reaction used in bioluminescence. It is the 
need for exogenous light that limits the application of fluorescence compared to 
bioluminescence. Endogenous molecules such as hemoglobin absorb and even 
fluoresce visible light (Mobley and Vo-Dinh, 2003; Zhao et al., 2005). Therefore, 
the external light source will not only excite your target fluorophore, but also the 
endogenous cellular chromophores, resulting in high background 
autofluorescence and a low signal-to-noise ratio. Moreover, the absorbed light 
can also damage these endogenous molecules, causing phototoxicity and cell 
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death. Without the need for an external photon, bioluminescence does not 
produce any background autoluminescence or phototoxicity, resulting in a higher 
signal-to-noise ratio and a lower cell mortality rate. 
While bioluminescence offers several advantages over fluorescence, there 
are relatively few bioluminescent reporters available, compared to the broad 
pallet of fluorescent proteins and dyes. Indeed, despite the number of organisms 
that have evolved bioluminescence, the number of luciferase/luciferin systems 
employed for use as reporters is limited by the number of luciferins discovered 
(Greer and Szalay, 2002; Welsh and Noguchi, 2012). As mentioned above, all 
beetle luciferases share D-luciferin as a substrate. The other commonly used 
luciferin for bioluminescence imaging is coelenterazine, the substrate for many 
marine luciferases. Most often, the Renilla luciferase from the sea pansy, Renilla 
reniformis, is used in conjunction with coelenterazine. However, coelenterate 
bioluminescence is inferior to beetle bioluminescence due to the coelenterazine 
substrate: coelenterazine is larger, less water soluble, and more toxic than D-
luciferin, limiting its use in live cells and organisms (Welsh and Noguchi, 2012). 
Additionally, while D-luciferin must be adenylated before oxidation, 
coelenterazine does not need to be activated, resulting in a low level of auto-
oxidation and higher background luminescence. Therefore, D-luciferin in 
conjunction with firefly luciferase has become the preferred bioluminescent 
reporter system for use in the biological sciences. Renilla luciferase and 
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coelenterazine are often used as a second/control reporter when investigating 
multiple biological events simultaneously (Welsh and Noguchi, 2012). 
 
Limitations of firefly bioluminescence: emission wavelength 
Undoubtedly, firefly bioluminescence has become an invaluable tool for 
studying biology. However, it is not without some caveats. First, the wavelength 
of light that is emitted is not ideal, especially for in vivo imaging. Cellular 
components and other endogenous molecules such as hemoglobin, absorb 
visible light (Weissleder and Ntziachristos, 2003; Zhao et al., 2005) (Figure 1.5). 
Therefore, a large portion of the light emitted by luciferase is absorbed by the 
surrounding tissue and will not penetrate through the animal for detection. Near-
infrared (near-IR) light (650-900 nm) is less well absorbed by these endogenous 
molecules and is able to further penetrate through tissue (Mobley and Vo-Dinh, 
2003; Weissleder and Ntziachristos, 2003) (Figure 1.5). The broad emission 
spectrum of luciferase contains a portion of light in this range and is thus still able 
to be used. However, red-shifting the emission wavelength of luciferase to 
increase the intensity of near-IR light would make for a more sensitive reporter 
system. This optimal optical window is another reason that beetle 
bioluminescence is preferred over coelenterate bioluminescence. Coelenterazine 
emits blue-shifted light compared to D-luciferin, so even more light will be 
absorbed by the surrounding tissue (Haddock et al., 2010) (Figure 1.5). 
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Figure 1.5. Interaction of light with tissue. (A) The absorption coefficient of 
light in tissue, assuming normally oxygenated tissue (saturation of 70%), 50 mM 
hemoglobin, and a composition of 50% water and 15% lipids. The emission 
range of several common imaging reagents are shown. The insert shows 
autofluorescence spectra obtained in vivo at different excitation wavelengths. (B) 
The mouse images show experimentally measured photon counts through the 
body of a nude mouse at 532 nm (left) and 670 nm (right). Figure adapted from 
(Weissleder and Ntziachristos, 2003). 
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Diverse factors can impact the wavelength of light emitted with D-luciferin 
(Seliger and McElroy, 1964). For example, the presence of divalent cations, such 
as Cd2+ and Zn2+, can red-shift the peak wavelength of light emitted with firefly 
luciferase. Additionally, lowering the pH of the solution to ~6, or increasing the 
temperature of the solution from ambient to 37 °C also red-shift the emission 
profile. Finally, the origin of the luciferase can impact the wavelength of light 
emitted. The railroad worm luciferase from the lateral lanterns of Phrixothrix 
vivianii catalyzes emission of green light (542 nm), while the luciferase from the 
head lanterns of Phrixothrix hirtus results in red light emission (628 nm) (Viviani 
et al., 1999). In the lab, the environmental parameters can be readily 
manipulated. However, living organisms hold the concentration of divalent 
cations, pH, and temperature constant. Therefore, the luciferase and luciferin are 
the preferred targets for altering the emission profile in vivo.  
 
Red-shifting firefly bioluminescence using the luciferase 
Several labs have focused on using red-shifted beetle luciferases from 
either click beetles (Wood et al., 1989) or railroad worms (Viviani and Ohmiya, 
2000). These luciferases favor emission by the keto form of oxyluciferin (Figure 
1.3), thus emitting red-shifted light relative to firefly luciferase. Others have 
generated firefly luciferase mutants that also red-shift the light with D-luciferin 
(Branchini et al., 2005a, 2010a; Mezzanotte et al., 2011). Alternatively, Branchini 
et al., developed a chimeric enzyme between the luciferases of Photinus pyralis 
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and Luciola italia that improves the overall intensity of light with D-luciferin 
(Branchini et al., 2014). While the chimera may not red-shift the peak wavelength 
of light emitted, the increased intensity may still improve the level of photon flux 
that penetrates through the tissue. All of these strategies produce luciferases that 
catalyze light emission in a more desirable range; however each luciferase is still 
fundamentally limited by the photophysical properties of D-luciferin itself.  
 
Red-shifting firefly bioluminescence using the luciferin 
An alternative strategy is to design and synthesize synthetic luciferin 
analogs that emit at longer wavelengths than D-luciferin. This can be done in one 
of two ways: 1) through bioluminescence resonance energy transfer; 2) through 
chemical alteration of the luciferin structure. Bioluminescence resonance energy 
transfer (BRET) uses the energy of the excited state oxyluciferin to excite a 
second fluorophore that will then emit light at an even longer wavelength (Pfleger 
et al., 2006). This technique is often used to measure protein-protein interactions, 
since the donor luciferase and the acceptor fluorophore must be in close 
proximity. Here, by either directly labeling firefly luciferase with a near-IR 
fluorophore (Branchini et al., 2010b), or conjugating the luciferin to a near-IR dye 
(Kojima et al., 2013), BRET can be a source of near-IR light. However, the need 
to modify luciferase with a near-IR dye limits its use as a genetically encodable 
reporter; and attaching a near-IR dye to the luciferin will limit water solubility and 
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cell permeability of the luciferin. Also, there is a loss of signal intensity with BRET 
that may counter any benefit from the red-shift in peak wavelength. 
Our lab and others have instead focused on direct chemical modification 
of the luciferin substrate. The energy difference between the excited and ground 
states determines the wavelength of light emitted (Naumov et al., 2009), and it is 
well known that replacing the 6ʹ-hydroxyl of D-luciferin with a more electron-
donating amino group red-shifts the peak wavelength of light emitted (White et 
al., 1966). Our lab therefore designed synthetic luciferin analogs that replace the 
6ʹ-hydroxyl of D-luciferin with cyclic alkylamino groups fused to the 5ʹ and 6ʹ 
positions of the benzothiazole (Reddy et al., 2010) (Figure 1.6). These 
alkylamino substituents are more strongly electron-donating than either the 
original hydroxyl or the amine, which should red-shift the peak emission 
wavelength even more. Additionally, by restricting molecular motion of the 
arylamine by cyclization back to the benzothiazole, the modified luciferins should 
maintain a high quantum yield. Indeed, these substrates displayed red-shifted 
light emission relative to D-luciferin, and also increased the total photon flux 
when used with Promega’s Ultra-Glo luciferase (Auld et al., 2009) and P450-Glo 
buffer (Reddy et al., 2010). However, when used with WT firefly luciferase 
without the P450-Glo buffer, each of these luciferins displayed much weaker light 
than D-luciferin, due to an increased affinity for luciferase and corresponding 
increase in product inhibition (Reddy et al., 2010). 
 
17 
 
 
Figure 1.6. Chemical structures of D-luciferin and previously reported 
synthetic luciferins. (A) D-luciferin. (B) White et al., 1966. (C) Reddy et al., 
2010. (D) Branchini et al., 1989. (E) Iwano et al., 2013. (F) Conley et al., 2012. 
(G) Woodroofe et al., 2012. (H) McCutcheon et al., 2012. Peak emission 
wavelengths reported are shown in parentheses.  
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Other groups have more drastically modified the luciferin structure. 
Branchini et al. was one of the first to alter the core of D-luciferin. They showed 
that it was possible to exchange the benzothiazole of D-luciferin for either a 
naphthalene or quinoline (Branchini et al., 1989) (Figure 1.6). These luciferins 
emit light upon treatment with firefly luciferase at 524 nm and 608 nm, 
respectively, albeit at a lower intensity than D-luciferin. Subsequently, others 
have developed electronically modified luciferins by substituting single atoms in 
either the benzothiazole or thiazoline rings of D-luciferin (Conley et al., 2012; 
McCutcheon et al., 2012; Woodroofe et al., 2012) (Figure 1.6). All remain 
substrates for luciferase and display altered emission profiles, but none improve 
on the bioluminescence obtained with D-luciferin. Finally, Iwano et al. completely 
removed the benzothiazole in favor of a simpler aromatic system with extended 
π-conjugation to the thiazoline ring (Iwano et al., 2013) (Figure 1.6). This 
strategy has produced the first example of a peak emission wavelength in the 
near-IR, at 675 nm. However, as with all the other synthetic substrates, shifting 
the peak wavelength is accompanied by a loss of signal intensity. While all of 
these new substrates demonstrate how promiscuous luciferase is, no example of 
a synthetic luciferin has shown improvement over WT luciferase and D-luciferin 
under saturating luciferin and ATP conditions.  
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Limitations of firefly bioluminescence: the properties of D-luciferin 
An added benefit of many synthetic luciferins is increased cell permeability 
and/or higher affinity for luciferase. When used in live cells and organisms, firefly 
luciferase will be retained inside the cell. Therefore, a luciferin must first cross the 
membrane in order to emit light. D-luciferin is small and relatively polar, therefore 
it is capable of moderate diffusion across cell membranes. However, D-luciferin 
only has a modest affinity for luciferase (Km = ~7 µM) (Harwood et al., 2011) and 
is thus unlikely to reach saturating conditions when used in live cells and 
organisms. Many of the synthetic luciferins developed thus far show increased 
hydrophobicity relative to D-luciferin which should increase cell permeability. 
Cyclic alkylamino luciferins also have increased affinity for luciferase (Km < 0.1 
µM) (Harwood et al., 2011), allowing sufficient substrate to enter the cells to 
saturate the enzyme.  
 
Limitations of firefly bioluminescence: other reporter options 
Finally, as mentioned above, the number of distinct bioluminescent 
reporters is lacking. There has been some success in spectrally isolating beetle 
luciferase signals by using luciferases that emit at different wavelengths (i.e., 
green and red) (Branchini et al., 2005a, 2010a). However, this analysis can be 
complicated when used in vivo. The light that is emitted from a luciferase within a 
live mouse is naturally red-shifted by the body temperature of the mouse, and by 
its tissues absorbing lower wavelength light (Zhao et al., 2005). Thus, the green 
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luciferase will naturally shift toward the red so the two signals will not be as 
resolved as they would be in vitro. 
Currently, multiplexed assays using bioluminescence can be performed by 
reporting on one event with firefly luciferase/D-luciferin and on the second with 
Renilla luciferase/coelenterazine. These two systems are completely orthogonal, 
meaning that there is no activity from a luciferase with the other substrate (e.g., 
Renilla luciferase does not emit light with D-luciferin and vice versa). This 
technique works very well, despite the flaws of Renilla luciferase, but is limited to 
these two luciferase/luciferin pairs.  
 
Firefly luciferase and acyl-CoA ligases 
Apart from using luciferase as a tool to report on biological function, work 
has also been done to understand the evolution of insect bioluminescence. 
Firefly luciferase is a member of the acyl-adenylate/thioester-forming superfamily 
(Chang et al., 1997). Other members of this family include acyl- and acetyl-CoA 
synthetases, aminoacyl-tRNA synthetases, and plant p-coumarate-CoA ligases, 
none of which emit light (McElroy et al., 1967; Pietrowska-Borek et al., 2003). All 
members catalyze the synthesis of their respective products via intermediate 
adenylates after reaction with ATP (Figure 1.2). Since the structure of luciferase 
was solved (Conti et al., 1996), it has become apparent that the members of this 
family share a similar tertiary structure. Luciferase is divided into two domains: a 
large N-terminal domain that contains the luciferin and ATP binding pockets, and 
21 
 
a small C-terminal catalytic domain. Catalysis occurs at the interface between the 
two (Conti et al., 1996; Sundlov et al., 2012). Many other members of this family 
share this organization (Conti et al., 1997; Gulick et al., 2003; Reger et al., 2008).  
In addition to catalyzing light emission from D-luciferin, firefly luciferase is 
also a long chain fatty acyl-CoA synthetase able to synthesize fatty acyl-CoA 
from long chain fatty acids, ATP, and CoA (Oba et al., 2003). Analysis of 
luciferase’s fatty acyl-CoA synthetase activity shows a similar substrate 
preference to mammalian ACSLs, preferring saturated medium-chain fatty acids 
(C8-C14) and unsaturated long-chain fatty acids (C16-C20) (Oba et al., 2005). 
However, upon phylogenetic analysis of fatty acyl-CoA synthetases from 
mammals, insects, plants, fungi, and bacteria, it appears that luciferase is not 
evolutionarily related to the mammalian enzymes (Oba et al., 2005) (Figure 1.7 
and Table 1.1). Oba et al. hypothesize that luciferase and other insect fatty acyl-
CoA synthetases share a distinct ancestor from their mammalian counterparts.  
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Figure 1.7. Phylogenetic tree of acyl-CoA synthetase genes. The tree was 
constructed by the neighbor-joining method using amino acid sequences. 
Abbreviated names are listed in Table 1.1. Numbers indicate bootstrap values 
from 1,000 replicates. Only bootstrap values over 50% are indicated. Horizontal 
branch lengths indicate genetic distances. The genes that possess a peroxisomal 
targeting sequence (PTS1) at the C-terminus are marked with *. A shaded clade 
shows the PTS1 family. Figure adapted from (Oba et al., 2005). 
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Table 1.1 Acyl-CoA synthetases used in Figure 1.7.  
 
aThe PTS1 signal was searched by the PTS1 predictor. Genes were identified 
as: possess the PTS1 (+), do not possess the PTS1 (-), or could not classify (±). 
Table adapted from (Oba et al., 2005) 
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While luciferase may share a common ancestor to insect ACSLs, retain 
ACSL activity, and emit light via an activated adenylate, it is still a mystery where 
the oxidation function originated. Only very weak light emission has ever been 
seen from an ACSL upon treatment with D-luciferin (Viviani et al., 2013). 
However, Oba et al. have shown that it is possible to elicit light emission from a 
fatty acyl-CoA synthetase after mutagenesis of the luciferin binding pocket, albeit 
at much lower intensity than luciferase (Oba et al., 2009). Still, their results 
suggest that it may just be the binding affinity and/or orientation of D-luciferin 
limiting light emission from an ACSL, instead of lack of functional ability. 
Despite the lack of endogenous light-emitting capabilities, luciferase 
homologs, such as ACSLs, could be a source of genetic diversity for generating 
improved bioluminescent reporters. Branchini et al. demonstrated that a chimeric 
enzyme of the luciferases from P. pyralis and L. italia could improve the light 
emitted from D-luciferin (Branchini et al., 2014). This was the first example of an 
engineered luciferase improving on WT. These enzymes are both luciferases and 
emit light independently when treated with D-luciferin. However, extending this 
strategy to luciferase homologs may also produce beneficial effects. 
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Scope of my thesis 
Firefly bioluminescence is a fascinating phenomenon that has been 
harnessed to report on otherwise invisible biological processes. Our lab has 
developed a panel of synthetic luciferin analogs based on the general core 
structure of the native firefly substrate, D-luciferin. The overall goal of my thesis 
has been to use these substrates to better understand the fundamental 
properties of bioluminescence, as well as to improve its practical applications and 
push the boundaries of what is possible. 
My first goal was two-fold. First, I wanted to generally improve and expand 
bioluminescence imaging reagents by increasing the intensity of light that is 
emitted from luciferase with our synthetic luciferins. Second, I wanted to develop 
mutant luciferases that efficiently and selectively utilize specific synthetic 
luciferins in order to add a third reporter system for use with firefly luciferase and 
Renilla luciferase. In CHAPTER II, I report the synthesis and characterization of 
10 additional synthetic luciferins based off of the structures of CycLuc1 and 
CycLuc2 (Reddy et al., 2010). Several of these new luciferin analogs improve the 
near-IR photon flux in live cells >10-fold with WT firefly luciferase. Additionally, 
we identify a triple mutant luciferase that 1) is almost completely inactive with D-
luciferin in vitro and in live cells; and 2) selects for and improves the signal 
intensity of several synthetic luciferins to levels comparable to WT luciferase with 
D-luciferin. Therefore, we have improved upon what is achievable with WT 
luciferase and D-luciferin by increasing the light emitted in the near-IR and have 
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taken the first step toward developing a third bioluminescent reporter for use in 
conjunction with current technologies. 
For my next thesis goal, I chose to investigate latent luciferase activity 
from fatty acyl-CoA synthetases using our synthetic luciferins. In CHAPTER III, I 
report on the identification and characterization of CG6178, an ACSL from 
Drosophila melanogaster. CG6178 is the first latent luciferase discovered, 
capable of emitting light with the synthetic luciferin CycLuc2 but not with D-
luciferin. In CHAPTER IV, I continue that work with the expanded panel of 
synthetic luciferins from CHAPTER II and show: 1) CG6178 luciferase activity 
extends to synthetic luciferins other than CycLuc2; and 2) the ACSL AbLL from 
Agrypnus binodulus also possesses latent luciferase activity, but with altered 
substrate selectivity to CG6178. However, neither of these enzymes emit light 
with the intensity needed for use as a reporter. Therefore, in CHAPTER V, I 
evaluate luciferase/CG6178 and luciferase/AbLL chimeric enzymes for the 
improved substrate selectivity of the ACSLs but with the high photon flux of 
luciferase. Here we find that by exchanging the C-terminal domain of luciferase 
for that of an ACSL, we can select against D-luciferin, while improving signal 
intensity of and substrate selectivity for synthetic luciferins. 
Finally, the third goal of my thesis research was to expand the 
bioluminescence toolkit and develop an assay for a specific enzyme. Luciferase 
has been shown to possess ACSL activity and we have also identified two 
ACSLs that possesses luciferase activity. Therefore, we hypothesized that the 
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luciferins were binding the active site by mimicking a fatty acid and would be 
ideally suited to probe the chemistry of enzymes that release a fatty acid. In 
CHAPTER VI, I show that by replacing the carboxylate of a luciferin substrate 
with an amide, the resulting pro-luciferin becomes a specific substrate for the 
drug target fatty acid amide hydrolase (FAAH). Since a luciferin amide is not a 
substrate for luciferase, only in the presence of FAAH activity will the amide be 
hydrolyzed and support light emission. These sensors readily translate from in 
vitro, to live luciferase-expressing cells, to live luciferase-expressing mice and 
are specific for FAAH in each case. 
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CHAPTER II: 
Aminoluciferins Extend Firefly Luciferase Bioluminescence into the  
Near-Infrared and Can Be Preferred Substrates over D-Luciferin 
Mofford, D.M. et. al. (2014) JACS, 136(38), 13277–13282. 
 
 
 
Summary  
Firefly luciferase adenylates and oxidizes D-luciferin to chemically 
generate visible light and is widely used for biological assays and imaging. Here 
we show that both luciferase and luciferin can be reengineered to extend the 
scope of this light-emitting reaction. D-Luciferin can be replaced by synthetic 
luciferin analogs that increase near-infrared photon flux >10-fold over that of D-
luciferin in live luciferase-expressing cells. Firefly luciferase can be mutated to 
accept and utilize rigid aminoluciferins with high activity in both live and lysed 
cells yet exhibit 10,000-fold selectivity over the natural luciferase substrate. 
These new luciferin analogs thus pave the way to an extended family of 
bioluminescent reporters. 
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Introduction 
Fireflies are beetles that have evolved the remarkable ability to emit visible 
light based on a chemical reaction. Instead of a photon of light, firefly luciferase 
uses adenosine triphosphate and the chemical energy of oxygen to convert its 
substrate D-luciferin into an excited-state molecule of oxyluciferin (Fraga, 2008) 
(Figure 2.1A). This bioluminescent reaction has been widely used as a biological 
reporter both in vitro (Fan and Wood, 2007) and in vivo (Prescher and Contag, 
2010). Although bioluminescence has much lower background than fluorescence 
and is more sensitive for in vivo imaging, it has been limited by the relative lack 
of luciferases and luciferins compared to the broad palette of fluorescent probes.  
 
 
 
Figure 2.1. Luciferase mechanism and substrates. (A) Firefly luciferase 
catalyzes the adenylation and oxidation of its native substrate D-luciferin to emit 
a photon of light. (B) Previously synthesized aminoluciferin analogs. (C) New 
aminoluciferins from this work. 
30 
 
In nature, D-luciferin is the only luminogenic substrate for beetle 
luciferases. Over the past few years, many new luciferin analogs have been 
described, including several that yield peak light emission well into the red 
(Conley et al., 2012; Iwano et al., 2013; Kojima et al., 2013; Reddy et al., 2010; 
Takakura et al., 2010, 2011). Synthetic luciferins thus have the potential to 
extend bioluminescence imaging to wavelengths where tissue is more 
transparent to light. However, there is already a significant red and near-infrared 
component to luciferase emission with D-luciferin, and shifting the peak 
wavelength does not necessarily mean that the overall level of red light has 
actually increased (Branchini et al., 2005a; Kojima et al., 2013; Viviani et al., 
1999). The synthetic luciferin CycLuc1 (Figure 2.1) performs better than D-
luciferin for bioluminescence imaging in live mice, primarily due to its improved 
ability to access the luciferase rather than a red-shift in light emission (Evans et 
al., 2014). Therefore, substrates that combine this ready access to intracellular 
luciferase in live cells with a redshift in total emission are expected to be 
candidates to further improve in vivo performance (Adams and Miller, 2014).  
Structural differences between luciferins could also potentially allow the 
creation of orthogonal luciferases. Although mutant firefly luciferases that exhibit 
luciferin selectivity have been reported, D-luciferin remains a light-emitting 
substrate (Harwood et al., 2011).  Surprisingly, recent work has identified the 
Drosophila fatty acyl-CoA synthetase CG6178 as a latent luciferase that emits 
light with CycLuc2 but not D-luciferin (Mofford et al., 2014a). While this 
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demonstrates that it is possible to retain luciferase activity in beetle luciferase 
homologues that are unresponsive to D-luciferin, higher rates of photon emission 
are desirable for use as reporters.  
With all of these considerations in mind, we synthesized compact, rigid 
aminoluciferins modeled after CycLuc1 and CycLuc2 (Harwood et al., 2011; 
Reddy et al., 2010) (Figure 2.1). We found that these new substrates could 
greatly increase the total photon flux of near-IR light from live luciferase-
expressing cells over D-luciferin. Moreover, high photon flux was observed from 
a newly identified mutant luciferase that gave virtually no light emission with the 
natural substrate. Chemical modification of the luciferin substrate can thus 
extend the scope of bioluminescence beyond what is possible with D-luciferin 
(Adams and Miller, 2014). 
 
Results and Discussion 
Synthesis of new rigid aminoluciferins. The synthetic aminoluciferins 
CycLuc1 and CycLuc2 have 5ʹ,6ʹ-fused five-membered indoline rings (Figure 
2.1B). To evaluate the effect of this ring fusion on bioluminescence, we 
synthesized new luciferin analogs with fused six-membered rings of varying 
composition. Luciferin analogs CycLuc3 and CycLuc4, containing a six-
membered oxazine ring, were readily accessed following a slight modification of 
the CycLuc1 synthesis paradigm (Reddy et al., 2010) (Scheme 2.1).  
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Scheme 2.1. Synthesis of CycLuc3 and CycLuc4 
 
CycLuc5 and CycLuc6 were designed to emit light at longer wavelengths 
and to test the scope of substrates that could be accommodated by the luciferase 
(Scheme 2.2). These bulky, lipophilic analogs incorporate 2,2,4-trimethyl-
dihydroquinoline, a scaffold that has been widely used to red-shift the emission of 
many classes of fluorophores, including coumarins (Panchuk-Voloshina et al., 
1999), rhodamines (Belov et al., 2009; Panchuk-Voloshina et al., 1999), and 
oxazines (Pauff and Miller, 2011). Attempted synthesis of intermediate 16 by 
trifluoroacetylation of the corresponding nitroarene as in Scheme 2.1 failed, 
presumably due to a combination of steric hindrance and electronic deactivation 
(Williamson and Ward, 2005). We therefore synthesized the Boc-protected 
compound 14 (Bonger et al., 2009), which suffers the same steric hindrance but 
was anticipated to be less electronically deactivated. Gratifyingly, 
trifluoroacetylation of this intermediate was successful (Williamson and Ward, 
2005), and subsequent TFA deprotection readily afforded 16. Elaboration as 
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shown in Scheme 2.2 afforded the desired luciferin analogs CycLuc5 and 
CycLuc6.  
 
 
Scheme 2.2. Synthesis of CycLuc5 and CycLuc6 
 
The corresponding saturated tetrahydroquinoline aminoluciferins analogs 
CycLuc7 and CycLuc8 were synthesized using the same general synthetic route 
as CycLuc1−CycLuc4 (Figure 2.1C and Scheme 2.3). Surprisingly, attempts to 
access the 5ʹ,6ʹ-fused ring - differing from CycLuc1 by only a single methylene - 
primarily yielded the 6ʹ,7ʹ-fused product in a >8:1 ratio. Nonetheless, elaboration 
of 32b to the 5ʹ,6ʹ-fused cyclic alkylaminoluciferins CycLuc7 and CycLuc8 
proceeded uneventfully. The 6ʹ,7ʹ-fused product 32a was similarly converted into 
6ʹ,7ʹ-fused cyclic alkylaminoluciferins CycLuc9 and CycLuc10. 
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Scheme 2.3. Synthesis of CycLuc7−CycLuc10 
 
Finally, 5ʹ,6ʹ-fused cyclic aminoluciferins CycLuc11 and CycLuc12 were 
synthesized as bulkier and more lipophilic analogs of CycLuc7 and CycLuc8, 
where the gem-dimethyl substituents also direct exclusive formation of the 5ʹ,6ʹ-
fused isomers (Figure 2.1C and Scheme 2.4). 
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Scheme 2.4. Synthesis of CycLuc11 and CycLuc12 
 
Luciferase activity in vitro. At the outset of this work, it was anticipated 
that some subset of the rigid luciferin analogs would not be well accommodated 
by the luciferase. However, all of the new aminoluciferin analogs are substrates, 
further underscoring the generality of the light emission chemistry and the 
tolerance of luciferase for modifications.  
When purified firefly luciferase is treated with D-luciferin or an 
aminoluciferin, a high initial rate of light emission (burst) is observed in the first 
few seconds, which is then followed by a substantial decrease in the rate of 
sustained light output. This effect is more pronounced for high-affinity 
aminoluciferins than for D-luciferin itself, and all of the new substrates exhibited 
this same general behavior under saturating substrate conditions (Figure 2.2 and 
Figure 2.3). Relative to D-luciferin with the wild-type (WT) luciferase, the initial 
rate of photon flux ranged from a high of 43% for CycLuc4 to a low of 2% for 
CycLuc11. This initial rate is high compared to luciferin analogs in which the 
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benzothiazole has been replaced (Iwano et al., 2013; McCutcheon et al., 2012; 
Woodroofe et al., 2012). However, aminoluciferins have reduced emission 1 min 
after substrate addition, consistent with product inhibition as the primary factor 
limiting the light emission in vitro (Reddy et al., 2010; Woodroofe et al., 2008) 
(Figure 2.2 and Figure 2.3).  
 
 
Figure 2.2.  Initial and sustained bioluminescence intensity with purified 
WT luciferase. (A) Initial rates of emission from WT luciferase (0.2 nM) with 
each luciferin analog (250 µM) relative to D-luciferin. (B) Relative emission from 
A 1 min after substrate addition. The assays were performed in triplicate and are 
represented as the mean ± SEM. 
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Figure 2.3. Burst kinetics profiles of all luciferins with each luciferase. 
Purified enzyme (0.2 nM final) was rapidly injected into substrate (250 μM final). 
Light emission was recorded every 0.2 s for 1 s pre-injection and 120 s post-
injection. Background luminescent signal in the absence of substrate is shown for 
reference (in gray). The assays were performed in triplicate and are represented 
as the mean ± SEM and presented on the same log scale. 
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Bioluminescence emission wavelengths. Peak bioluminescence 
emission for the aminoluciferins ranged from 594 to 642 nm (Figure 2.4, Figure 
2.5, and Table 2.1). As expected, CycLuc6 yielded strongly red-shifted 
bioluminescence (636 nm), exceeding that of red-emitting mutant firefly 
luciferases (Branchini et al., 2005a), railroad worm (beetle) luciferase (Viviani et 
al., 1999), and the red-shifted emission from 6ʹ-Me2NLH2 (Reddy et al., 2010). 
However, we were surprised to find that CycLuc10 yielded an even more red-
shifted peak (642 nm). To determine whether these differences are inherent to 
each luciferin, we measured the fluorescence emission wavelengths of the 
substrates. The fluorescence and bioluminescence emission wavelengths of 
aminoluciferins were found to be strongly correlated, suggesting that the 
bioluminescence wavelength is primarily dictated by the photophysical properties 
of the luciferin (Figure 2.6). Bioluminescence is red-shifted by 50−75 nm from 
the substrate fluorescence in phosphate-buffered saline, which is expected since 
the oxyluciferin emitter produced in the luciferase has increased conjugation with 
respect to the substrate.  
 
Figure 2.4. Bioluminescence emission spectra for WT luciferase with 
selected substrates. 
39 
 
 
Figure 2.5. Normalized emission spectra of all luciferins with each 
luciferase. 
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Table 2.1. Fluorescence and bioluminescence emission wavelengths of all 
luciferins. 
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Figure 2.6. Fluorescence peak emission wavelength of each aminoluciferin 
correlates with the bioluminescence peak wavelength for each luciferase. 
Fluorescence vs bioluminescence values were fit by linear regression. Pearson 
correlation values are r = 0.83 (WT), r = 0.92 (R218K) and r = 0.91 (triple 
mutant). 
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The fluorescence emission of acyclic monoalkylated aminoluciferins 
generally ranges from 520 to 540 nm (Woodroofe et al., 2008), more red-shifted 
than that of 6ʹ-aminoluciferin (517 nm) but less so than for dialkylated substrates 
such as 6ʹ-Me2NLH2 (554 nm). CycLuc6 fluoresces at still longer wavelength 
(567 nm), while CycLuc10 is the most red-shifted of all the luciferin analogs (576 
nm). While this was initially surprising, Atkins and Bliss have described similar 
behavior for aminocoumarin derivatives (Atkins and Bliss, 1978). 
 
Mutation of luciferase modulates emission. We have previously found 
that the luciferase active-site mutant R218K increases the rate of light emission 
from CycLuc1, CycLuc2, 6ʹ-MeNHLH2, and 6ʹ-Me2NLH2 (Harwood et al., 2011). 
This effect is not particularly selective, as it is observed with all of the 
aminoluciferins (Figure 2.3, Figure 2.7, and Figure 2.8). For instance, CycLuc7 
exhibits higher initial and sustained emission rates with R218K compared to WT 
(Figure 2.7). The R218K mutant also resulted in a slight red-shift in 
bioluminescence for most substrates, pushing the maximal emission wavelength 
for CycLuc10 to 648 nm (Figure 2.5 and Table 2.1).  
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Figure 2.7. Burst kinetics profiles of D-luciferin and CycLuc7 treated with 
purified WT and mutant luciferases. Purified enzyme (0.2 nM final) was rapidly 
injected into substrate (250 μM final). Light emission was recorded every 0.2 s for 
1 s pre-injection and 120 s post-injection. Background luminescent signal in the 
absence of substrate is shown for reference (in gray). The assays were 
performed in triplicate and are represented as the mean ± SEM and presented 
on the same log scale. 
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Figure 2.8. Initial and sustained bioluminescence intensity with purified WT 
and mutant luciferases. (A) Initial rates of emission within the first 2 s of 
substrate addition from the indicated luciferase (0.2 nM) with each luciferin 
analogs (250 µM) relative to WT with D-luciferin. (B) Relative emission from A 1 
min after substrate addition. The assays were performed in triplicate and are 
represented as the mean ± SEM. 
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Toward orthogonal luciferases. In principle, chemical and structural 
differences in luciferin substrates could be exploited to create new orthogonal 
luciferases. However, active-site mutations such as R218K and L286M raise the 
Km of D-luciferin but do not prevent its utilization as a substrate (Harwood et al., 
2011). A more selective point mutant, S347A, raises the Km and lowers the rate 
of emission from D-luciferin, possibly because it removes a hydrogen-bonding 
interaction with the benzothiazole nitrogen that may be more important for D-
luciferin binding and orientation than for aminoluciferins (Branchini et al., 2003; 
Harwood et al., 2011). Yet D-luciferin remains a substrate for this mutant 
luciferase as well. Thus, previous work has not established whether high 
luciferase activity can be retained in luciferase mutants that do not yield light 
emission from D-luciferin.  
Here we find that the combination of R218K, L286M, and S347A renders 
D-luciferin essentially inactive. The purified triple-mutant luciferase dramatically 
reduced both the initial and sustained rates of photon emission from D-luciferin 
by >10,000-fold (Figure 2.3 and Figure 2.7). Gratifyingly, this is not due to a lack 
of luciferase activity, as the photon flux from CycLuc2, CycLuc7, and CycLuc11 
actually increased compared to that of the WT enzyme (Figure 2.3 and Figure 
2.8). CycLuc7 is the optimal substrate for the triple-mutant luciferase in vitro, 
achieving 46% of the initial rate of D-luciferin with WT luciferase. This result 
demonstrates that high luciferase activity can be maintained in a luciferase 
mutant that is essentially unresponsive to the native substrate D-luciferin. 
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Furthermore, product inhibition has largely been eliminated, as there is little 
diminution in flux after the initial burst (Figure 2.3, Figure 2.7, and Figure 2.8).  
 
Luciferin emission in live luciferase-expressing cells. We next 
compared the aminoluciferins to D-luciferin in live WT luciferase-expressing 
Chinese Hamster Ovary (CHO) cells. Under these conditions, the luciferin 
substrate must cross the cell membrane to access the luciferase. In marked 
contrast to what is observed in vitro, almost all of the alkylated aminoluciferins 
yield higher flux than D-luciferin when assayed at a concentration <30 μM 
(Figure 2.9 and Figure 2.10). At high substrate concentration (250 μM), the 
relative emission from D-luciferin is still equaled or exceeded by those of 
CycLuc1, CycLuc10, and CycLuc12 (Figure 2.9). However, if the cell membrane 
is removed by cell lysis, D-luciferin is the superior substrate at both high and low 
doses, suggesting that substrate access is the primary factor limiting luciferins in 
live cells (Figure 2.11).  
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Figure 2.9. Photon flux from luciferase-expressing CHO cells. (A) Live cells 
expressing the indicated luciferase and treated with high or low doses of luciferin. 
(B) Comparison of total and near-IR photon flux from WT luciferase with the 
indicated luciferins. (C,D) Comparison of photon flux from WT and triple-mutant 
luciferase with D-luciferin or CycLuc7 in live cells (C) or lysed cells (D). All 
assays were performed in triplicate and are represented as the mean ± SEM. 
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Figure 2.10. Photon flux from live luciferase-expressing CHO cells. Cells 
were incubated with the indicated concentration of each substrate. Note that the 
y-axis scale differs at different substrate concentrations. The assays were 
performed in triplicate and are represented as the mean ± SEM. 
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Figure 2.11. Total photon flux from lysed luciferase-expressing CHO cells. 
Lysate was treated with the indicated concentration of substrate. Note that the y-
axis scale at different substrate concentrations differs. The assay was performed 
in triplicate and is represented as the mean ± SEM. 
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Near-IR photon flux in live cells. The peak emission wavelengths of 
aminoluciferins are red-shifted in vitro. To assess the near-IR emission from each 
luciferin in live cells, we measured the relative photon flux passing through a 
Cy5.5 filter (695−770 nm). All of the aminoluciferins exhibited greater relative 
photon flux in the near-IR than D-luciferin (Figure 2.9B and Figure 2.12). For 
every substrate except 6ʹ-aminoluciferin and CycLuc3, this translated to a higher 
total near-IR photon flux from live cells than D-luciferin under both low-dose and 
high-dose conditions (Figure 2.12). CycLuc10 gave the greatest fraction of near-
IR light emission: 13.9% of the total photon flux, >10-fold higher than that of D-
luciferin (Figure 2.9B). However, total near-IR flux of CycLuc10 was slightly 
exceeded by that of CycLuc12. Thus, the substrate that yields the highest cellular 
near-IR light emission is a function of substrate access (affinity and cell 
permeability) as well as wavelength.  
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Figure 2.12. Total photon flux from live and lysed luciferase-expressing 
CHO cells with and without a Cy5.5 bandpass filter. Cells were treated with 
250 μM or 1.95 μM luciferin and imaged with either no filter or through a Cy5.5 
bandpass filter. The assay was performed in triplicate and is represented as the 
mean ± SEM. 
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Mutant luciferases in live and lysed cells. Transfection of CHO cells 
with R218K luciferase instead of WT luciferase improved relative photon flux 
from synthetic luciferins compared to D-luciferin (Figure 2.9 and Figure 2.10). 
CycLuc2 yielded the highest signal in live cells, and most alkylated 
aminoluciferins were superior to D-luciferin at both low and high substrate 
concentrations (Figure 2.9 and Figure 2.10). Further highlighting the importance 
of factors other than peak emission wavelength on the total emission of red-
shifted photons in live cells, CycLuc2 yielded the highest Cy5.5-filtered signal at 
250 μM, while CycLuc6 was best at low concentration (Figure 2.9 and Figure 
2.12). The longer emission wavelength of CycLuc6 (Figure 2.4) and its higher 
cell permeability likely lead to its superior flux at low concentrations, while the 
higher maximal rate of photon emission for CycLuc2 ultimately prevails at high 
substrate concentration (Figure 2.8). Thus, the best-performing substrates are 
context-dependent.  
No signal above background could be measured from live cells expressing 
the triple-mutant luciferase after treatment with D-luciferin (Figure 2.9C). In 
contrast, CycLuc2, CycLuc7, and CycLuc11 achieve high photon flux (Figure 
2.9). The triple mutant possesses lower affinity for its substrates compared to WT 
or R218K luciferase, yielding reduced photon flux at low substrate concentration 
(Figure 2.9 and Figure 2.10). However, in lysed cells, the lower affinity of the 
triple mutant improved the signal from CycLuc7 and CycLuc11 due to its 
lessened product inhibition (Figure 2.9D and Figure 2.11). CycLuc7 is the best 
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substrate in cell lysates, achieving ∼20% of the D-luciferin signal with the WT 
luciferase (Figure 2.9 and Figure 2.11). Mutant and WT luciferase protein 
expression is equivalent in transfected cells by Western blot (Figure 2.13), and 
the differences between luciferases in cell lysates (Figure 2.11) generally mirrors 
what is observed with equal concentrations of purified proteins in vitro (Figure 
2.8). The triple-mutant luciferase is thus a significant step toward orthogonal 
bioluminescent reporters of gene expression in both live and lysed cells, as it 
yields high light output with (alkylated) aminoluciferins but little to no signal with 
D-luciferin. We speculate that the triple mutant primarily discriminates between 
substrates by lowering substrate affinity and removing an interaction important 
for orienting the native substrate (S347). Luciferin analogs possessing high 
affinity for luciferase and an alternative “handle” for proper orientation remain 
effective substrates (Harwood et al., 2011; Mofford et al., 2014a). Given that the 
mutations that comprise the triple mutant were originally identified to individually 
improve luciferase activity with CycLuc1 (Harwood et al., 2011), it is likely that 
further improvements in selectivity and function are possible for this broadened 
palette of luciferins. Ironically, the identification of a luciferase that emits strongly 
with D-luciferin but does not respond to synthetic luciferins has been more 
elusive. The development of fully orthogonal luciferin−luciferase reporter pairs 
will therefore require further work, perhaps by eschewing D-luciferin altogether in 
favor of two or more synthetic substrates. 
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Figure 2.13. Western blot analysis of luciferase expression. (A) Purified 
recombinant luciferases are equally recognized by an anti-luciferase antibody. 
(B) CHO cell lysates transfected with WT or mutant luciferases yield equivalent 
expression. α-tubulin is shown as a loading control. 
 
 
Conclusion 
There is reason to expect that substrate performance in live cells, rather 
than with purified protein or cell lysates, is more predictive of in vivo behavior. In 
recent collaborative work we have found that CycLuc1 allows dramatically 
improved bioluminescence imaging in live mice compared to the standard 
imaging conditions with D-luciferin (Evans et al., 2014). Tumor cells can be 
imaged with 20−200-fold less substrate than D-luciferin, and luciferase 
expression deep in the brain that cannot be detected with D-luciferin is 
detectable with CycLuc1 (Evans et al., 2014). Many of the substrates described 
here provide higher total and red-shifted photon flux in live cells, suggesting that 
they may also have superior properties for in vivo imaging. Differences in 
substrate affinity, lipophilicity, and functionality are also anticipated to affect the 
pharmacokinetics of the luciferins in vivo, perhaps allowing tuning of 
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bioluminescent half-lives and/or tissue distribution. Moreover, we have found that 
mutation of luciferase can essentially eliminate light output from the native D-
luciferin substrate while retaining or improving light emission from one or more 
aminoluciferin substrates to levels comparable to or, in live cells, superior to that 
of D-luciferin with the WT luciferase. Thus, these synthetic luciferins and mutant 
luciferases not only expand the palette of luminogenic molecules but transcend 
the emission properties of D-luciferin and firefly luciferase. They are therefore 
expected to have significant potential for bioluminescence imaging applications 
both in vitro and in vivo. 
 
Materials and Methods 
Collaborators 
Gadarla Randheer Reddy of the Miller Lab:    
 Design and synthesis of all synthetic luciferins  
 
General 
Chemicals were purchased from Aldrich, TCI, Oakwood, or Matrix 
Scientific unless otherwise noted. Data were plotted with GraphPad Prism 6.0. 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury 
400 MHz NMR spectrometer. Small molecule mass spectral data were recorded 
on a Waters QTOF Premier spectrometer. D-luciferin was obtained from 
Anaspec and 6ʹ-aminoluciferin was obtained from Marker Gene Technologies 
56 
 
Inc. CycLuc1, CycLuc2, 6ʹ-MeNHLH2, and 6ʹ-Me2NLH2 were synthesized as 
previously described (Reddy et al., 2010). Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). Immobilized glutathione 
(Thermo Scientific) was used for glutathione S-transferase (GST)-tagged protein 
purification.  
 
Plasmid constructs 
R218K luciferase was created as previously described (Harwood et al., 
2011). The triple mutant R218K/L286M/S347A was generated by introducing 
L286M and S347A mutations identified in Harwood et al. into the R218K 
luciferase, using the Quickchange site-directed mutagenesis kit (Stratagene). 
 
Luciferase expression and purification 
Luciferases were expressed and purified as GST-fusion proteins from the 
vector pGEX6P-1 as previously described (Harwood et al., 2011). Briefly, JM109 
cells were grown at 37 °C until the OD600 reached 0.5-1, induced with 0.1 mM 
IPTG, and incubated with shaking at 20 °C overnight. Cells were pelleted at 5000 
RPM in a Sorvall 2C3C Plus centrifuge (H600A rotor) at 4 °C for 15 min, then 
flash frozen in liquid nitrogen and purified immediately or stored at -80 °C. The E. 
coli pellets from 1 L of culture were thawed on ice, resuspended in 25 mL lysis 
buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% Tween 20) containing 1 
mM phenylmethylsulfonyl fluoride, and disrupted by sonification (Branson 
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Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the resulting cell lysate 
was clarified by centrifugation at 35,000 rpm in a Beckman 50.2 Ti rotor for 60 
min at 4 °C. The supernatant was batch-bound to immobilized glutathione for 1 hr 
at 4 °C, and the beads were washed with lysis buffer containing 10 mM DTT, 
followed by wash buffer (50 mM Tris [pH 8.1], 250 mM NaCl, and 10 mM DTT) 
and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 150 mM NaCl, 1 mM 
TCEP). Twenty units of PreScission Protease (GE Healthcare) were added, and 
incubation continued overnight at 4 °C to cleave the GST-fusion and elute the 
untagged luciferase protein. 
 
Purified protein luminescence assays 
Luminescence assays were initiated by adding 30 μL of purified luciferase 
in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 
mg/mL BSA) to 30 μL 2x substrate in substrate buffer (20 mM Tris [pH 7.4], 0.1 
mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 3915). 
Imaging was performed one minute after enzyme addition using a Xenogen IVIS-
100 at a final enzyme concentration of 10 nM and final substrate concentrations 
ranging from 0.122 to 250 μM. Data acquisition and analysis was performed with 
Living Image® software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate. 
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Bioluminescence emission scans 
Each purified luciferase in enzyme buffer was rapidly injected into a 
cuvette containing substrate in substrate buffer to a final enzyme concentration of 
100 nM and a final substrate concentration of 10 μM. The emission from 400 to 
800 nm was recorded in a SPEX FluoroMax-3 fluorimeter with closed excitation 
slits 10 s after injection. 
 
Burst kinetics assays 
Using a Turner Biosystems 20/20n luminometer, 40 μL of purified 
luciferase in enzyme injection buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 0.625 
mM TCEP, and 0.5 mg/mL BSA) was rapidly injected into a clear Eppendorf tube 
containing 10 μL of substrate in substrate injection buffer (20 mM Tris [pH 7.4], 
0.1 mM EDTA, 20 mM MgSO4, and 10 mM ATP) to a final enzyme concentration 
of 0.2 nM and a final luciferin substrate concentration of 250 μM. Measurements 
were taken every 0.2 s for 1 s pre-injection and 120 s post-injection. Data 
acquisition was performed with SIS for 2020n v1.9.0 software. Data are reported 
as Relative Light Units (RLU). To correct for the wavelength sensitivity of the 
PMT in the 20/20n, total flux was also measured using the IVIS-100 as described 
above with a final enzyme concentration of 10 nM and a final substrate 
concentration of 250 μM. Data from the IVIS and from the 20/20n at the 60 s time 
point were normalized to the WT + D-luciferin value. The correction factor of each 
enzyme/substrate pair was calculated by dividing the normalized IVIS data by the 
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normalized 20/20n data. All 20/20n data were then multiplied by their respective 
correction factors. 
 
Cell culture 
Chinese hamster ovary (CHO) cells were grown in a CO2 incubator at 
37°C with 5% CO2 and were cultured in F-12K Nutrient Mixture (GIBCO) 
supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin. 
 
Transfections 
The WT firefly luciferase luc2 gene (Promega) and codon optimized 
mutants were cloned into the BamHI and NotI sites of pcDNA 3.1 and transfected 
into CHO cells for live and lysed cell experiments. Transient transfections were 
performed at RT using Lipofectamine 2000 on cells plated at 60–75% confluency 
in 96-well black tissue culture-treated plates (Costar 3916) for live cell assays, or 
6-well plates for lysed cell assays. For live cells, 0.075 μg DNA/well was 
transfected; for lysed cells, 2.25 μg DNA/well was transfected. Assays were 
performed in triplicate 24 hr after transfection. 
 
Live and lysed CHO cell luminescence assays 
Transfected CHO cells were washed with HBSS. For live cell imaging, the 
cells in 96-well plates were incubated with 60 μL of substrate in HBSS at final 
concentrations ranging from 0.122 to 1,000 μM. Imaging was performed using 
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the IVIS-100 with no emission filter, three minutes after addition of substrate. 
Additional images were taken through a Cy5.5 bandpass filter (695-770 nm) four 
minutes after substrate addition. Cells grown in 6-well plates were first lysed for 
20 min at RT with Passive Lysis Buffer (1 mL per well). Luminescence assays 
were initiated by adding 30 μL of lysate to 30 μL of 2x substrate in lysed cell 
substrate buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, 4 mM ATP, 
6 mg/mL BSA, 250 μM Coenzyme A, and 33 mM DTT) in a black 96-well plate 
(Costar 3915) with final substrate concentrations ranging from 0.122 to 250 μM. 
Imaging was performed with the emission filter open one minute after addition of 
substrate. Additional images were taken through the Cy5.5 filter two minutes 
after substrate addition. 
 
Western blot 
Transfected CHO cells in 6-well plates were washed with HBSS and lysed 
for 20 min at RT with Passive Lysis Buffer (250 μL per well). Cell debris was 
pelleted by centrifugation at 13,000 RPM at 4°C for 10 minutes. Total protein 
concentration of the supernatant was determined using Coomassie Plus Bradford 
Reagent and 18 μg total lysate protein was used for electrophoresis. Samples 
were prepared by adding 167 mM DTT and 1x SDS gel loading buffer to each 
lysate to a final volume of 27 μL. Samples were run on 10% SDS-PAGE, 
transferred to a nitrocellulose membrane, and incubated in blocking buffer (5% 
nonfat dry milk in western wash buffer [10 mM Tris (pH 7.4), 150 mM NaCl, 0.1% 
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Tween-20]) for 45 minutes. Luciferase primary antibody (Promega, Cat. # 
G7451) was diluted 1:1000 in blocking buffer to 6 mL final volume and incubated 
with the membranes at room temperature for 2 hours. Membranes were washed 
with Western wash buffer (4 x 6 mL) and incubated at room temperature with 6 
mL secondary anti-goat antibody-HRP (Santa Cruz, Cat. # SC-2033) diluted 
1:4000 in blocking buffer. The membranes were again washed (4 x 6 mL) and 
incubated with SuperSignal West Dura Extended Duration Substrate (Pierce) for 
5 minutes. The chemiluminescence was imaged using an LAS-3000 CCD 
camera and quantified by Multi Gauge software (FujiFilm). Antibody was then 
stripped by washing the membranes with Stripping Buffer (100 mM glycine, 20 
mM magnesium acetate, 50 mM potassium chloride, pH 2.2 [Bio-Rad]; 2 x 10 
mL), and western wash buffer (3 x 6 mL). Membranes were then re-blocked and 
incubated overnight at 4 °C with 6 mL primary anti-α-tubulin antibody (Sigma 
Aldrich, Cat. # T9026) diluted 1:3000 in blocking buffer. Membranes were 
washed with western wash buffer (4 x 6 mL) and incubated at room temperature 
with 6 mL secondary anti-mouse antibody-HRP (GE Healthcare, Cat. # 
RPN4201) diluted 1:10000 in blocking buffer for 45 minutes. The membranes 
were again washed and incubated with SuperSignal West Dura Extended 
Duration Substrate for 5 minutes. The chemiluminescence was imaged using an 
LAS-3000 and quantified by Multi Gauge software. Purified recombinant 
enzymes were tested using the same procedure by loading 50 ng for 
electrophoresis and incubating with primary luciferase antibody overnight at 4 °C. 
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CHAPTER III: 
Latent Luciferase Activity in the Fruit Fly Revealed by a Synthetic Luciferin 
Mofford, D.M. et. al. (2014) PNAS, 111(12), 4443–4448. 
 
 
Summary 
Beetle luciferases are thought to have evolved from fatty acyl-CoA 
synthetases present in all insects. Both classes of enzymes activate fatty acids 
with ATP to form acyl-adenylate intermediates, but only luciferases can activate 
and oxidize D-luciferin to emit light. Here we show that the Drosophila fatty acyl-
CoA synthetase CG6178, which cannot use D-luciferin as a substrate, is able to 
catalyze light emission from the synthetic luciferin analog CycLuc2. 
Bioluminescence can be detected from the purified protein, live Drosophila 
Schneider 2 cells, and from mammalian cells transfected with CG6178. Thus, the 
non-luminescent fruit fly possesses an inherent capacity for bioluminescence that 
is only revealed upon treatment with a xenobiotic molecule. This result expands 
the scope of bioluminescence and demonstrates that the introduction of a new 
substrate can unmask latent enzymatic activity that differs significantly from an 
enzyme’s normal function without requiring mutation. 
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Introduction 
Bioluminescence in insects is almost exclusively confined to a small 
subset of beetles, including click beetles (Wood et al., 1989), railroad worm 
beetle larvae (Viviani et al., 1999), and perhaps the best known example, the 
firefly Photinus pyralis (Fraga, 2008). However, all insects express long-chain 
fatty acyl-CoA synthetases (ACSLs) that share high homology to beetle 
luciferases and are hypothesized to be their evolutionary antecedents (Day et al., 
2009; McElroy et al., 1967; Viviani et al., 2013). These two classes of enzymes 
are both members of the adenylate-forming superfamily (Chang et al., 1997) and 
share the ability to make AMP esters of fatty acids as well as the ability to 
displace the AMP ester with CoASH (Oba et al., 2003) (Figure 3.1). Beetle 
luciferases differ from other insect ACSLs in their ability to chemically generate 
light by adenylating and oxidizing D-luciferin, a small molecule naturally found in 
bioluminescent beetles. How this additional activity developed is unknown, 
although weak bioluminescence has been reported by treating a beetle ACSL 
with D-luciferin (Prado et al., 2011; Viviani et al., 2013).  
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Figure 3.1. Firefly luciferase and long-chain fatty acyl-CoA synthetases 
catalyze similar two-step mechanisms. (A) Firefly luciferase catalyzes the 
formation of an activated AMP ester of its native substrate, D-luciferin. 
Subsequent oxidation within the luciferase binding pocket generates an excited-
state oxyluciferin molecule that is responsible for light emission. (B) Long-chain 
fatty acyl-CoA synthetases catalyze the formation of activated AMP esters from 
long-chain fatty acids such as arachidonic acid. AMP is then displaced by 
CoASH to form the fatty acyl-CoA product.  
 
 
We have previously found that mutation of firefly luciferase can improve 
light emission from synthetic luciferin substrates while concurrently reducing light 
emission from D-luciferin (Harwood et al., 2011). This suggested that the 
requirements for D-luciferin bioluminescence and for bioluminescence with 
synthetic luciferin substrates are not the same in mutant luciferases and, by 
extension, in luciferase homologs. Consequently, we reasoned that even though 
insect ACSLs from non-bioluminescent organisms outside the order of beetles 
fail to emit light with D-luciferin, this does not necessarily mean that they are 
incapable of luciferase activity. Clearly, the catalytic machinery needed to form 
AMP esters from carboxylic acids is present in ACSLs (Figure 3.1), potentially 
allowing access to an adenylate of a luciferin analog. Furthermore, oxygen has 
ready access to ligand binding sites in proteins (Baron et al., 2009), and luciferin 
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active esters in basic DMSO are known to be readily oxidized to generate an 
excited-state molecule that can emit light (Seliger and McElroy, 1962; White et 
al., 1971). We therefore speculated that ACSLs lack luciferase activity with D-
luciferin because D-luciferin is a poor ligand for ACSLs and/or binds in a 
geometry that is not conducive to adenylation. If this hypothesis were true, 
treatment with a suitable synthetic luciferin substrate that possessed higher 
affinity and/or conformational rigidity could potentially reveal latent luciferase 
activity in an ACSL. 
 
Results  
To test the idea that ACSLs could have latent luciferase activity, we turned 
to the Drosophila fatty acyl-CoA synthetase CG6178 (Oba et al., 2004) (Figure 
3.2). The fruit fly Drosophila melanogaster is a widely used insect model 
organism from the order Diptera. With the exception of fungus gnats from the 
Mycetophilidae family (Viviani et al., 2002), no members of this order of insects 
are bioluminescent. Furthermore, none of the Diptera expresses a beetle-like 
luciferase, and CG6178 has been shown to lack luciferase activity with D-luciferin 
(Oba et al., 2004). We therefore incubated purified CG6178 protein with a panel 
of synthetic luciferins that we previously designed to emit red light with firefly 
luciferase (Harwood et al., 2011; Reddy et al., 2010) (Figure 3.3). Strikingly, the 
rigid luciferin substrate CycLuc2 revealed latent luciferase activity in CG6178. 
The peak emission wavelength is in the red (610 nm), nearly identical to that of 
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CycLuc2 with firefly luciferase, and consistent with the predicted effect of the 
luciferin structure on its photophysical properties (Reddy et al., 2010) (Figure 
3.4). By contrast, no light emission was observed after treatment of CG6178 with 
D-luciferin or 6ʹ-aminoluciferin. CycLuc1 – differing by a single methyl group from 
CycLuc2 – is a much weaker light emitter with CG6178, as is the dialkylated but 
less rigid substrate 6ʹ-Me2NLH2. Only the D-enantiomer of CycLuc2 results in 
bioluminescence (Figure 3.5), consistent with the stereoselective oxidation of D-
luciferin observed with firefly luciferase (Nakamura et al., 2005), where oxygen 
has access to only one side of the binding pocket (Fraga, 2008; Sundlov et al., 
2012). The addition of CoASH, frequently used as an additive in luciferase 
assays (Fraga, 2008), significantly reduces the light emission observed from 
CG6178 (Figure 3.5). 
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Figure 3.2. Amino acid alignment between CG6178 (Drosophila 
melanogaster) and FLuc (Photinus pyralis). Primary sequences of D. 
melanogaster CG6178 and P. pyralis luciferase were aligned with ClustalX 
(Larkin et al., 2007). The alignment was then displayed using Geneious version 
6.1.6 software. CG6178 shows 38% identity to FLuc. Motifs 1, 2, and 3 are 
conserved among members of the acyl-adenylate superfamily (Chang et al., 
1997). Residues within 5 Å of the dehydroluciferin portion of DSLA in the P. 
pyralis luciferase crystal structure (PDB ID code 4G36) were identified as forming 
the luciferin binding pocket and are marked with “#.” 
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Figure 3.3. CG6178 is a latent luciferase when treated with the synthetic 
luciferin CycLuc2. (A) Chemical structures of D-luciferin and all synthetic 
luciferins. (B) Photon flux from CG6178 (20 nM) treated with the indicated 
substrate (125 μM). The assay was performed in triplicate and is represented on 
a log scale as the mean ± SEM and compared by t test to a no substrate control. 
ns, not statistically significant; *** P < 0.001, **** P < 0.0001. 
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Figure 3.4. CycLuc2 emits red-shifted light compared with D-luciferin with 
both FLuc and CG6178. Emission profiles for purified FLuc and CG6178 were 
generated as described in Materials and Methods. CycLuc2 emits at a similar 
wavelength with both FLuc and CG6178. 
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Figure 3.5. Effect of CycLuc2 chirality and CoA addition on CG6178 
bioluminescence. (A) Chemical structures of D-CycLuc2 and L-CycLuc2. (B) 
CG6178 (20 nM) was treated with L-CycLuc2 (150 μM), D-CycLuc2 (125 μM), or 
D-CycLuc2 (125 μM) with CoA (125 μM). The assay was performed in triplicate 
and is represented as the mean ± SEM and compared using the unpaired t test 
to a no-substrate control. ns, not statistically significant; *** P < 0.001,                    
**** P < 0.0001. 
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To emit light, the luciferin substrate must be converted to an active ester 
and then oxidized to the excited-state oxyluciferin. Using radiolabeled ATP, Oba 
et al. (Oba et al., 2004) found that CG6178 can adenylate fatty acids but fails to 
form the adenylate of D-luciferin. This could reflect a lack of binding by D-
luciferin, or the inability of CG6178 to catalyze the formation of the respective 
AMP ester. To clarify the basis for this defect, we measured light emission from 
CycLuc2 in the presence of D-luciferin. We found that D-luciferin is a competitive 
inhibitor of CycLuc2-mediated light emission with a Ki value of 25.7 ± 4.5 μM 
(Table 3.1). Surprisingly, the Km for CycLuc2 with CG6178 is 13.8 ± 1.9 μM, 
similar to that of D-luciferin, and much higher than the submicromolar Km of 
CycLuc2 with firefly luciferase (Harwood et al., 2011). Thus, CG6178 binds both 
D-luciferin and CycLuc2 with similar midmicromolar affinity but is unable to 
subsequently adenylate D-luciferin to form LH2-AMP. Consistent with the role of 
CG6178 as a long-chain fatty acyl-CoA synthetase, the long-chain fatty acids 
palmitic acid, oleic acid, and linolenic acid were all competitive inhibitors of light 
emission with Ki values of 2–4 μM (Table 3.1). The medium-chain caprylic 
(octanoic) acid was a weaker inhibitor (13 μM), and the short-chain acetic acid 
had a calculated Ki value of >1 mM (Table 3.1).  
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Table 3.1. D-luciferin and long-chain fatty acids competitively inhibit light 
output from CycLuc2-treated CG6178 
 
Purified CG6178 and CycLuc2 at concentrations ranging from 0.122 to 125 μM 
was treated with either no inhibitor; 25, 50, or 100 μM of D-luciferin or acetic acid; 
15, 30, or 50 μM of caprylic acid; or 1, 5, or 15 μM of palmitic, oleic, or linolenic 
acids. The assays were performed in triplicate and each curve was fit to the 
Michaelis–Menten equation by nonlinear regression (GraphPad 6.0) to determine 
apparent Km and Vmax values. All Ki values were calculated using the equation 
Km(app) = Km(1 + [I]/Ki) for each inhibitor concentration and are represented as the 
mean ± SD. 
 
 
Light emission from firefly luciferase in vitro is typically characterized by a 
“burst” phase, where a high initial rate of photon emission is achieved in the first 
few seconds, followed by a reduction in the rate of photon flux in a subsequent 
“glow” phase of much longer duration (Fraga, 2008). The basis for this behavior 
has not been fully elucidated, but it is generally thought to be due to rapid 
formation of the excited-state oxyluciferin, followed by slow dissociation of the 
products after initial photon emission (Fraga, 2008). CG6178 lacks this 
characteristic burst phase but proceeds directly to the glow phase (Figure 3.6), 
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suggesting that the maximal rate of light emission is slower than the dissociation 
rate of the products and, unsurprisingly, slower than firefly luciferase. Light 
emission is dependent on the presence of ATP, because only a very weak signal 
is observed without it, probably owing to residual levels in the protein prep of 
CG6178 (Figure 3.7). Total integrated light output over two minutes for 100 μM 
CycLuc2 with CG6178 was 0.11% of 100 μM D-luciferin with firefly luciferase, 
and 2.5% of 100 μM CycLuc2 with firefly luciferase. When integrating the signal 
emitted during the second minute (e.g., after the luciferase burst), the relative 
emission from CycLuc2 with CG6178 increased to 0.14% of firefly luciferase with 
D-luciferin and only 6.7-fold less than luciferase with CycLuc2 (Figure 3.6).  
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Figure 3.6. Burst kinetics profiles of D-luciferin, CycLuc2, and their 
respective adenylates. Purified FLuc, CG6178, or enzyme buffer with or without 
BSA was rapidly injected into (A) LH2, LH2-AMP or (B) CycLuc2, CycLuc2-AMP 
(100 μM final). Light emission was recorded every 0.2 s for 1 s pre-injection and 
120 s post-injection. 
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Figure 3.7. Burst kinetics profiles of CG6178 and CycLuc2 or CycLuc2-AMP 
with and without ATP. Purified CG6178 (40 nM final) was rapidly injected into 
CycLuc2, CycLuc2-AMP (100 μM final) with or without 2 mM ATP final added to 
the buffer. Light emission was recorded every 0.2 s for 1 s pre-injection and 120 
s post-injection. 
 
 
We next synthesized the adenylates of D-luciferin and CycLuc2 (LH2-AMP 
and CycLuc2-AMP) to determine the effect of bypassing adenylation on the rate 
of photon flux from CG6178. Treatment of CG6178 with CycLuc2-AMP led to 
rapid and robust light emission at a rate that was 4.5-fold higher than CycLuc2 
alone (Figure 3.6). This suggests that adenylation of CycLuc2 is the rate-limiting 
step in the formation of the excited-state oxyluciferin (Hastings et al., 1953). 
Consistent with this observation, bypassing the prohibitive adenylation step for D-
luciferin by supplying LH2-AMP also allowed measurable light emission, albeit at 
a slower rate than CycLuc2. Both adenylates also displayed weak but 
measurable background bioluminescence in the presence of a high concentration 
(7,500 nM) of BSA (Viviani and Ohmiya, 2006), but CycLuc2-AMP emission 
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increased 2,100-fold upon the addition of catalytic quantities of CG6178 (40 nM), 
whereas LH2-AMP emission increased 40-fold (Figure 3.6). 
In principle, the presence of a latent luciferase in fruit flies means that 
these insects could be rendered bioluminescent if treated with CycLuc2. 
However, we were unable to detect bioluminescence from fruit flies fed food 
containing 100 μM CycLuc2. We therefore asked whether bioluminescence could 
be detected from the endogenous expression of CG6178 in Drosophila 
Schneider 2 (S2) cells (Chintapalli et al., 2007), where compound access and cell 
number can both be readily controlled. Both live and lysed Drosophila S2 cells 
do, in fact, elicit a bioluminescent glow when treated with CycLuc2 (Figure 3.8 
and Figure 3.9). Photon flux was linear with S2 cell number down to a detection 
limit of 5,000 cells at an average of 0.3 photons per second per cell (Figure 
3.10). No photon flux over background was observed when S2 cells were treated 
with D-luciferin (Figure 3.8).  
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Figure 3.8. CG6178 bioluminescence is detected in both live S2 cells and 
live transfected CHO cells. (A) Plate image of 3.0 × 105 live S2 and CHO cells 
treated with (1) no substrate or with 100 μM of (2) D-luciferin, (3) CycLuc2, (4) 6ʹ-
NH2LH2, (5) 6ʹ-MeNHLH2, (6) 6ʹ-Me2NLH2, or (7) CycLuc1. (B) Quantified flux 
from live S2 and CHO cells. (C) Plate images of ∼8.0 × 103 live CHO cells 
transiently transfected with FLuc or CG6178 after treatment as above. (D) 
Quantified flux from transfected CHO cells. All assays were performed in 
triplicate, represented as the mean ± SEM, and compared by t test. ns, not 
statistically significant; *** P <0.001, **** P < 0.0001. 
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Figure 3.9. CG6178 light emission is detectable in both lysed Schneider 2 
(S2) cells and lysed transiently transfected CHO cells. (A) Light emission 
from 3.0 × 105 lysed S2 or CHO cells. (B) Light emission from ∼7.6 × 104 lysed 
transfected CHO cells. All assays were performed in triplicate, represented as 
the mean ± SEM, and compared using the unpaired t test. ns, not statistically 
significant; * P < 0.05, **** P < 0.0001. 
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Figure 3.10. Bioluminescence from live Drosophila S2 cells treated with 
CycLuc2 correlates linearly with the number of cells present. Light emission 
from live S2 cells treated with 100 μM CycLuc2 shows a linear correlation 
between photon flux and cell number. The assay was performed in triplicate, is 
represented as the mean ± SEM, and was fit by linear regression (GraphPad 6.0) 
(R2 = 0.9913). 
 
Mammalian CHO cells did not emit light after treatment with any of the 
tested luciferins. However, transfection of CHO cells with CG6178 rendered them 
highly bioluminescent in the presence of CycLuc2. Overexpression from a CMV 
promoter rather than the endogenous Drosophila dHNF4 promoter (Palanker et 
al., 2009) yielded bioluminescence of much greater intensity (∼800 photons per 
second per cell; Figure 3.8 and Figure 3.9). The luciferase activity exhibited the 
same selectivity for CycLuc2 as purified CG6178 and live S2 cells, and treatment 
of transfected CHO cells with D-luciferin did not result in light emission (Figure 
3.8). Photon flux from live CG6178-transfected CHO cells treated with 100 μM 
CycLuc2 was 63% of that from firefly luciferase-transfected CHO cells treated 
with 100 μM D-luciferin (Figure 3.8). 
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Discussion 
It has long been surmised that beetle luciferases evolved from ACSLs. 
Here we have shown that an ACSL from a non-bioluminescent insect species 
outside the order of beetles is in fact a latent luciferase, capable of catalyzing 
light emission from a small molecule substrate. Bioluminescence can be 
selectively detected with the synthetic luciferin CycLuc2 in vitro and in live 
Drosophila S2 cells and CG6178-transfected mammalian CHO cells. D-luciferin 
is an inhibitor of CG6178 but is not a substrate for CG6178. Interestingly, both 
CG6178 and firefly luciferase are competitively inhibited by many medium- and 
long-chain fatty acids (C8–C20), but not all of these are good substrates for 
adenylation (e.g., palmitate) (Matsuki et al., 1999; Oba et al., 2005). This 
suggests that subtle conformational differences can affect whether or not the 
carboxylate is able to react with ATP in the binding pocket to form the AMP ester. 
We therefore postulate that the unique rigid and asymmetric ring structure of 
CycLuc2 acts as a handle to help properly align the substrate within the CG6178 
pocket, allowing adenylation to occur where it fails with D-luciferin.  
According to our model, CG6178 possesses latent luciferase activity 
because its natural substrate promiscuity (Glasner et al., 2006; Khersonsky and 
Tawfik, 2010; Oba et al., 2005; O’Brien and Herschlag, 1999) allows the 
adenylation of CycLuc2, thereby enabling the intrinsic chemistry accessible to 
this adenylated intermediate to proceed within the protected confines of the 
enzyme pocket. Unlike fatty acids, CycLuc2 possesses a chromophore, and once 
81 
 
activated to CycLuc2-AMP it can be oxidized to emit light. Although there is no 
known role for oxygen in the natural catalytic function of ACSLs, oxygen is 
ubiquitous and has ready access to hydrophobic pockets in proteins (Baron et 
al., 2009). Because of the spin-forbidden interaction of triplet oxygen with singlet-
state molecules, oxygen is generally unreactive in the absence of an activating 
cofactor such as a transition metal or flavin, so its presence in protein active sites 
is usually unnoticed and inconsequential. One exception is the reduction of 
oxygen to superoxide by carbanions (Abell and Schloss, 1991; Fetzner and 
Steiner, 2010; Russell and Bemis, 1966). Although alternative explanations for 
the mechanism of firefly luciferase have been offered (Sundlov et al., 2012), we 
propose that formation of the luciferin-AMP ester within the enzyme allows 
access to a resonance-stabilized carbanion that can reduce molecular dioxygen 
to superoxide by single-electron transfer and then react by subsequent 
recombination of the radical pair after spin inversion to form a peroxide (Figure 
3.11). The formation of a carbanion intermediate may be further facilitated in the 
enzyme by coordination of the substrate carbonyl oxygen to a conserved lysine 
residue (K443 in FLuc), which has been shown to be important for the oxidative 
reaction of LH2-AMP with firefly luciferase (Branchini et al., 2005b; Sundlov et al., 
2012) and is found in all beetle luciferases and many ACSLs, including CG6178 
(Figure 3.2). Access to the luciferyl-AMP chemical intermediate thus opens up 
new chemical reactivity space that is directed by both the substrate and the 
enzyme.  
82 
 
 
 
Figure 3.11. Proposed mechanisms of LH2-AMP oxidation. (A) The classical 
mechanism (Fraga, 2008) proposes direct reaction of a carbanion with oxygen, 
which is spin-forbidden. (B) A recently proposed alternative (Sundlov et al., 2012) 
suggests that oxygen acts to abstract a hydrogen from the C4 of the luciferin 
substrate to form a radical, which then recombines with the hydroperoxy radical 
to form a peroxide. However, oxygen abstraction of a hydrogen is disfavored by 
40–50 kcal/mol (Fossey et al., 1995). (C) We propose that a carbanion at C4 
reduces triplet oxygen by single-electron transfer to form superoxide and a C4 
radical, a mechanism with precedence in both chemistry (Russell and Bemis, 
1966) and enzymology (Abell and Schloss, 1991; Fetzner and Steiner, 2010). 
Recombination of these radicals after spin-flip forms a peroxide that 
subsequently reacts by the canonical mechanism (Fraga, 2008).  
 
The interplay between enzyme-directed substrate activation and the 
substrate-directed chemistry that ensues has significant implications for evolution 
and for the design of new enzymatic activities. In this case, a new overall 
catalytic function – light emission – is revealed simply upon the addition of a 
xenobiotic substrate. The selectivity of CG6178 for CycLuc2 over D-luciferin 
could potentially be exploited for the design of new substrate-selective 
luciferases (Harwood et al., 2011), perhaps by combining features of both beetle 
luciferases and ACSLs. Furthermore, although we did not observe 
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bioluminescence from the mammalian ACSLs in CHO cells, which have lower 
homology to firefly luciferase, mammalian ACS enzymes are known to adenylate 
xenobiotics such as ibuprofen (Tracy et al., 1993; Watkins and Ellis, 2012). We 
therefore expect that probing the intersection between the luminogenic chemistry 
of small-molecule luciferin analogs (Branchini et al., 1989; Conley et al., 2012; 
Iwano et al., 2013; McCutcheon et al., 2012; Reddy et al., 2010; Takakura et al., 
2010; Woodroofe et al., 2008, 2012) and the activation chemistry of existing 
adenylating enzymes (Watkins and Ellis, 2012) will reveal that latent luciferase 
activity is more common than previously thought.  
 
 
Materials and Methods 
Collaborators 
Gadarla Randheer Reddy of the Miller Lab: Synthesis of all synthetic luciferins  
 
General 
Chemicals for synthesis were obtained from Aldrich unless otherwise 
noted. D-luciferin was obtained from Anaspec and 6ʹ-aminoluciferin was obtained 
from Marker Gene Technologies, Inc. CycLuc1, CycLuc2, 6ʹ-MeNHLH2, and 6ʹ-
Me2NLH2 were synthesized as previously described (Reddy et al., 2010). Protein 
concentrations were determined using Coomassie Plus (Thermo Scientific). 
Immobilized glutathione (Thermo Scientific) was used for GST-tagged protein 
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purification. Unless otherwise stated, all protein purification steps were performed 
at 4 °C. Data were plotted and analyzed with GraphPad Prism 6.0. High-
resolution mass spectral data were recorded on a Waters QTOF Premier 
spectrometer (University of Massachusetts Medical School Proteomics and Mass 
Spectrometry Facility). Small molecule absorbance was measured using a Cary 
50 Bio UV-Visible spectrophotometer. Burst kinetics assays were performed on a 
Turner Biosystems 20/20n luminometer and reported as relative light units (RLU). 
Unless otherwise noted, all other bioluminescence assays were performed on a 
Xenogen IVIS-100. Data acquisition and analysis were performed with Living 
Image software and reported as radiance [photons per second per square 
centimeter per steradian (p/s/cm2/sr)] or total flux [photons per second (p/s)] for 
each region of interest corresponding to each well of the 96-well plate. All RP-
HPLC was performed on an Agilent 1100 using a C18 column (Waters Atlantis 
4.6 × 250 mm) at a flow rate of 1.0 mL/min using solvent A (0.1% formic acid in 
H2O) and solvent B (0.1% formic acid in CH3CN).  
 
Protein expression and purification 
The Drosophila protein CG6178 was PCR-amplified from the Drosophila 
Gene Collection cDNA library (GM05240) (Stapleton et al., 2002) and cloned into 
the BamHI–NotI sites of pGEX6P-1. CG6178 and firefly luciferase were 
expressed and purified as GST-fusion proteins from the vector pGEX6P-1 as 
previously described (Harwood et al., 2011). PreScission Protease (GE 
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Healthcare) cleavage of the GST-fusion was used to elute the untagged protein 
(Harwood et al., 2011). 
 
Substrate dose–response assays with purified protein 
Luminescence assays were initiated by adding 30 μL of 40 nM purified 
enzyme in enzyme buffer [20 mM Tris (pH 7.4), 0.1 mM EDTA, 1 mM (tris-(2-
carboxyethyl) phosphine) (TCEP), and 0.8 mg/mL BSA] to 30 μL of 2x substrate 
in substrate buffer [20 mM Tris (pH 7.6), 0.1 mM EDTA, 8 mM MgSO4, and 4 mM 
ATP] in a black 96-well plate (Costar 3915). Imaging was performed 1 min after 
enzyme addition, with final substrate concentrations ranging from 0.122 to 125 
μM using the IVIS-100 as described above. 
 
Bioluminescence emission scans 
Each purified enzyme in enzyme buffer was rapidly injected into a cuvette 
containing substrate in substrate buffer to a final enzyme concentration of 100 
nM for luciferase and 1,000 nM for CG6178 and a final substrate concentration of 
200 μM. The emission from 400 to 800 nm was recorded in a SPEX FluoroMax-3 
fluorimeter with closed excitation slits 10 s after injection. Data are normalized to 
the peak emission intensity and reported as normalized emission.  
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Burst kinetics assays 
Using a Turner Biosystems 20/20n luminometer, 40 μL of purified enzyme 
in injection buffer [25 mM Tris (pH 7.7), 0.125 mM EDTA, 5mM MgSO4, 2.5 mM 
ATP, 0.625 mg/mL BSA, and 0.625 mM TCEP] was rapidly injected into a clear 
Eppendorf tube containing 10 μL substrate in 10 mM sodium acetate (pH 4.5) to 
final enzyme concentrations of 0.4 nM for luciferase and 40 nM for CG6178, a 
final substrate concentration of 100 μM for all substrates, and a final pH of 7.4. 
Measurements were taken every 0.2 s for 1 s pre-injection and 120 s post-
injection. Data acquisition was performed with SIS for 20/20n v1.9.0 software. 
Data are reported as RLU integrated for each 0.2 s interval. Because photon flux 
for luciferase is linear with luciferase concentration over the 0.4–40 nM range, 
data for luciferase were multiplied by 100 to correct for the concentration 
difference for comparison with CG6178. To correct for the wavelength sensitivity 
of the PMT in the 20/20n, the emission intensities were also measured using the 
IVIS-100 as described above. Data from the IVIS and from the 20/20n at the 60 
second time point were normalized to the WT + LH2 value. The correction factor 
of CycLuc2 was calculated by dividing the normalized IVIS data by the 
normalized 20/20n data. All 20/20n data were then multiplied by this correction 
factor (underreported by 3.6-fold).  
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Cell culture 
Drosophila S2 cells were grown at ambient temperature and were cultured 
in Schneider’s Drosophila Medium (Gibco) supplemented with 10% FBS and 100 
U/mL penicillin/streptomycin (P/S). CHO-K1 cells were grown in a CO2 incubator 
at 37 °C with 5% CO2 and were cultured in F-12K Nutrient Mixture (Gibco) 
supplemented with 10% FBS and 100 U/mL P/S. 
 
Live cell luminescence assays 
S2 cells were washed with HBSS, scraped from the tissue culture dish, 
and suspended in Schneider’s medium. CHO cells were washed with HBSS, 
trypsinized, and suspended in F-12K medium. Both were centrifuged at 25 x g for 
10 min to pellet the cells. Each was suspended in HBSS at a concentration of 
6,000 cells per microliter and 50 μL per well was plated in 96-well black tissue 
culture-treated plates (3916; Costar). Luminescence assays were initiated by 
adding 50 μL of 2x substrate in HBSS at a final concentration of 100 μM. Imaging 
was performed 1 min after addition of substrate using the IVIS-100 as described 
above. 
 
Lysed cell luminescence assays 
S2 cells were washed with HBSS, scraped from the tissue culture dish, 
and suspended in Schneider’s medium. CHO cells were washed with HBSS, 
trypsinized, and suspended in F-12K medium. Both were centrifuged at 25 x g for 
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10 min to pellet the cells. Each was suspended in 1x Passive Lysis Buffer 
(Promega) at a concentration of 6,000 cells per microliter. Luminescence assays 
were initiated by adding 50 μL of 2x substrate in lysed cell substrate buffer [20 
mM Tris (pH 7.4), 0.1 mM EDTA, 8 mM MgSO4, 4mM ATP, 1 mg/mL BSA, and 
1mM TCEP] to 50 μL of lysate in a black 96-well plate (3915; Costar) with a final 
substrate concentration of 100 μM. Imaging was performed 1 min after addition 
of substrate using the IVIS-100 as described above. 
 
Transfections 
CG6178 and firefly luciferase were cloned into the BamHI and NotI sites of 
pcDNA 3.1 and transfected into CHO-K1 cells for live and lysed cell experiments. 
Transient transfections were performed using Lipofectamine 2000 on cells plated 
at 60–75% confluency in 96-well black tissue culture treated plates (3916; 
Costar) for live cell assays or six-well plates for lysed cell assays. For live cells, 
0.075 µg DNA per well was transfected; for lysed cells, 2.25 µg DNA per well 
was transfected. Assays were performed in triplicate 24 h after transfection. 
 
Transfected CHO cell luminescence assays 
Transfected CHO cells were washed with HBSS. For live cell imaging, the 
cells in 96-well plates were incubated with 60 μL of 100 μM substrate in HBSS 
and imaging was performed 3 min after addition of substrate. Cells grown in six-
well plates were first lysed for 20 min at room temperature with Passive Lysis 
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Buffer (1 mL per well). Luminescence assays were initiated by adding 30 μL of 
lysate to 30 μL of 2x substrate in lysed cell substrate buffer in a black 96-well 
plate (3915; Costar). Imaging was performed 1 min after addition of lysate, at a 
final substrate concentration of 100 μM using the IVIS-100 as described above. 
 
D-luciferyl-adenylate synthesis 
The synthesis of D-LH2-AMP was similar to a previously described method 
(Branchini et al., 2002). Under an argon atmosphere, a solution of 100 mg (0.49 
mmol) of dicyclohexylcarbodiimide in 0.8 mL dry DMSO was added to a solution 
of D-LH2 (4.5 mg, 0.16 mmol) and adenosine-5ʹ-monophosphate (15 mg, 0.043 
mmol) in dry DMSO. The reaction mixture was mixed at room temperature for 10 
min and 5 mL acetone was added to quench the reaction. The resulting white 
precipitate was collected by centrifugation, washed twice with 3 mL cold acetone, 
and extracted into 10 mM sodium acetate, pH 4.5, containing 40 mM sodium 
chloride (2 x 0.75 mL). D-LH2-AMP was isolated from the pooled extracts by RP-
HPLC (0–5 min, 15% B; 5–40 min, linear gradient to 40% B). D-LH2-AMP eluted 
at 14.8 min. The concentration in eluent was determined spectrophotometrically 
using D-LH2 as a reference [UV LH2 (H2O:CH3CN, 75:25, vol/vol) λmax 330 nm (ε 
= 16,800)] and the product was aliquoted, lyophilized to a solid, and stored at 
−20 °C. High-resolution MS-electrospray ionization (HRMS-ESI) [M-H]− 
calculated for C21H19N7O9PS2 was 608.0444; the value found was 608.0424. 
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CycLuc2-adenylate synthesis 
Under an argon atmosphere, a solution of 59 mg (0.0.29 mmol) of 
dicyclohexylcarbodiimide in 0.47mL dry DMSO was added to a solution of 
CycLuc2 (3.0 mg, 0.009 mmol) and adenosine-5′-monophosphate (8.8 mg, 0.025 
mmol) in dry DMSO. The reaction mixture was mixed at room temperature for 10 
min and 3 mL acetone was added to quench the reaction. The resulting white 
precipitate was collected by centrifugation, washed twice with 2 mL cold acetone, 
and extracted into 10 mM sodium acetate, pH 4.5, containing 40 mM sodium 
chloride (2 × 0.45 mL). CycLuc2-AMP was isolated from the pooled extracts by 
RP-HPLC (0–5 min, 25% B; 5–40 min, linear gradient to 50% B). CycLuc2-AMP 
eluted at 11.8 min. The concentration in eluent was determined 
spectrophotometrically using CycLuc2 as a reference [UV CycLuc2 
(H2O:CH3CN, 70:30, vol/vol) λmax 396 nm (ε = 8,600)] and the product was 
aliquoted and lyophilized to a solid and stored at −20 °C. HRMS-ESI [M-H]− 
calculated for C24H24N8O8PS2 was 647.0899; the value found was 647.0896. 
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CHAPTER IV: 
Insect fatty acyl-CoA synthetases exhibit unique latent luciferase activity 
with synthetic luciferin analogs 
 
 
 
Summary 
Long-chain fatty acyl-CoA synthetases (ACSLs) are homologs of firefly 
luciferase. Recently, we found that an ACSL from Drosophila melanogaster, 
CG6178, is a latent luciferase that emits light with the synthetic luciferin CycLuc2 
but not with the natural beetle luciferase substrate D-luciferin. Here we examine 
firefly luciferase, CG6178, and two additional ACSLs with a substrate palette of 
22 synthetic luciferins. We find that the latent luciferase activity of CG6178 
extends beyond CycLuc2. Furthermore, an ACSL from the non-luminescent 
beetle Agrypnus binodulus is a second latent luciferase with different substrate 
specificity than CG6178, while an ACSL from the luminescent beetle Pyrophorus 
angustus lacks any luciferase activity despite a higher homology to luciferase. 
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Introduction 
 Firefly luciferase (from Photinus pyralis) and fatty acyl-CoA synthetases 
(ACSLs) are both members of the acyl-adenylate/thioester-forming enzyme 
superfamily (Chang et al., 1997). These enzymes share the ability to catalyze the 
formation of fatty acyl-CoA products from free fatty acids (Oba et al., 2003) 
(Figure 4.1). However, luciferase also has the ability to catalyze bioluminescent 
light emission from its native substrate D-luciferin (Figure 4.1). Very weak activity 
has been shown from an ACSL with D-luciferin (Viviani et al., 2013), but not from 
any ACSL outside the order of beetles. We recently reported that the ACSL 
CG6178 from Drosophila melanogaster is able to act on the synthetic luciferin 
analog CycLuc2 and catalyze light emission (Mofford et al., 2014a). Therefore, it 
is possible to reveal latent luciferase activity from an ACSL if supplied with an 
appropriate synthetic substrate. 
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Figure 4.1. Fatty acyl-CoA synthetases and firefly luciferase catalyze 
similar, two-step reactions. (A) Fatty acyl-CoA synthetases catalyze the 
formation of an activated adenylate of a free fatty acid followed by displacement 
of the adenylate by CoASH to form the acyl-CoA product. (B) Firefly luciferase 
catalyzes the formation of an activated adenylate of D-luciferin followed by 
oxidation to an excited state oxyluciferin that is responsible for light emission. 
Oxidation can also produce the off-pathway “dark product” dehydroluciferyl 
adenylate that inhibits luciferase and does not emit light. 
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Oba et al. have characterized several luciferase-like enzymes from 
various insects, showing them to be ACSLs (Oba et al., 2004, 2008, 2010). The 
Agrypnus binodulus Luciferase Like protein (AbLL) from a non-luminous 
Japanese click beetle, possesses high sequence identity to firefly luciferase 
(46%, Figure 4.2) and to other beetle luciferases (e.g. Pyrophorus 
plagiophthalmus luciferase, 55%) (Oba et al., 2008). However, no bioluminescent 
light is produced upon treatment with D-luciferin. The Pyrophorus angustus 
Luciferase Like protein (PaLL) from the luminous Panamanian click beetle also 
possesses high sequence identity to firefly luciferase (46%, Figure 4.2) and even 
higher identity to its own dorsal and ventral luciferases (dPaLuc and vPaLuc, 
58% each) but does not emit light with D-luciferin (Oba et al., 2010). Both of 
these ACSLs possess higher identity to firefly luciferase than the latent luciferase 
CG6178 (39%) and the actual beetle luciferase from P. plagiophthalmus (48%). 
Due to their high homology to multiple luciferases and their fatty acyl-CoA 
synthetase activity, we hypothesized that these enzymes would also possess 
latent luciferase activity and tested both against our panel of synthetic luciferin 
analogs. 
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Figure 4.2. Primary sequence alignment of firefly luciferase and three fatty 
acyl-CoA synthetases. Primary sequences are displayed as a Clustal format 
alignment by Mafft (Katoh et al., 2002). Motifs 1-3 are conserved between 
members of the acyl-adenylate superfamily. Residues within 5 Å of the luciferin 
binding pocket are marked above with #. Luciferase K443 is involved in oxidation 
or thioesterification of the substrate and is marked below with *. Luciferase K529 
is involved in adenylation of the substrate and is marked below with +. 
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Results 
We have reported the synthesis and characterization of an expanded 
panel of synthetic luciferin analogs based on the general structure of CycLuc1 
and CycLuc2 (Mofford et al., 2014b; Reddy et al., 2010) (Figure 4.3). 
Additionally, luciferins with a simplified aromatic core and extended π-
conjugation have been reported (Iwano et al., 2013) and we have utilized a 
similar core structure to develop several additional π-conjugated substrates using 
our CycLuc modifications (Figure 4.3). 
 
 
 
Figure 4.3. Chemical structures of luciferin substrates. 
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Upon screening CG6178 with our expanded panel of synthetic luciferins, 
we identified several additional substrates that support light emission (Figure 4.4 
and Figure 4.5). CycLuc2 remains the optimal substrate at high dosage (250 µM, 
Figure 4.4). Several other dialkylated luciferins (CycLuc4, 8, and 12) also 
support light emission. In fact, CycLuc12 produces the highest total flux under 
lower dose conditions (3.91 µM, Figure 4.5). While they are not dialkylated, 
CycLuc7 and 11 are also able to act as substrates. AbLL also possesses latent 
luciferase activity, but with a substrate selectivity that is markedly different than 
CG6178 (Figure 4.4 and Figure 4.5). Like CG6178, AbLL is able to utilize 
CycLuc2, 7, 11 and 12, but prefers CycLuc7 over CycLuc2. AbLL also accepts 
the short cinnamyl-type substrates Me2NPh-1n-Cys and C8Ph-1n-Cys that are 
inactive with CG6178. Curiously, AbLL is unable to use C2Ph-1n-Cys differing 
from C8Ph-1n-Cys by a single methylene.  AbLL also emits weaker overall light 
compared to CG6178, even though it has increased sequence identity to firefly 
luciferase. PaLL has equal sequence identity to luciferase as AbLL, but was 
inactive with all tested substrates (Figure 4.4 and Figure 4.5). 
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Figure 4.4. ACSL activity upon treatment with 250 µM of the indicated 
luciferin analog. The indicated ACSL (20nM final) was treated with the indicated 
luciferin analog (250 µM final). The assay was performed in triplicate and is 
represented as the mean ± SEM. 
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Figure 4.5. ACSL activity upon treatment with 3.91 µM of the indicated 
luciferin analog. The indicated ACSL (20nM final) was treated with the indicated 
luciferin analog (3.91 µM final). The assay was performed in triplicate and is 
represented as the mean ± SEM. 
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Since the first enzymatic step of catalysis is adenylation, we examined the 
effects of the ATP reagent on light emission, and found that ATP purity affects 
the maximal rate of flux from both CG6178 and AbLL. Enzymatic Vmax using ATP 
from Sigma was reduced compared to using ATP from MP Biomedicals; CG6178 
was particularly sensitive (ΔVmax = 13-fold reduction with CycLuc2) (Figure 4.6, 
Figure 4.7, and Figure 4.8). We hypothesize that there is a small amount of 
contaminating pyrophosphate present in the ATP from Sigma that is responsible 
for this reduction. Addition of pyrophosphate to MP Bio’s ATP results in a similar 
level of light to Sigma’s ATP (Figure 4.9). Moreover, pre-treatment of Sigma’s 
ATP with pyrophosphatase produced an increase in signal similar to that 
achieved with MP Bio’s ATP (Figure 4.9). The noncompetitive inhibition by 
pyrophosphate (Ki 0.87 µM ± 0.32 µM) lowers the effective enzyme 
concentration, while having no effect on the Km of the luciferin substrate (Figure 
4.6 and Figure 4.7).  
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Figure 4.6. CG6178 activity is reduced by using impure ATP. (A) Dose-
response curves of CG6178 and the indicated luciferin analog using ATP 
purchased from either Sigma or MP Biomedicals. (B) Dose-response curves from 
(A) normalized to total flux at 125 µM substrate. The assays were performed in 
triplicate and are represented as the mean ± SEM. Curves were fit to the 
Substrate Inhibition equation [Y=Vmax*X/(Km + X*(1+X/Ki))] by nonlinear 
regression. 
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Figure 4.7. AbLL activity is reduced by using impure ATP. (A) Dose-
response curves of AbLL and the indicated luciferin analog using ATP purchased 
from either Sigma or MP Biomedicals. (B) Dose-response curves from (A) 
normalized to total flux at 125 µM substrate. The assays were performed in 
triplicate and are represented as the mean ± SEM. CycLuc1, 2, and 7 curves 
were fit to the Michaelis–Menten equation by nonlinear regression. Other curves 
were fit to the Substrate Inhibition equation [Y=Vmax*X/(Km + X*(1+X/Ki))] by 
nonlinear regression. 
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Figure 4.8. Firefly luciferase activity is minimally affected by ATP purity. 
Dose-response curves of FLuc and the indicated luciferin analog using ATP 
purchased from either Sigma or MP Biomedicals. The assays were performed in 
triplicate and are represented as the mean ± SEM. Curves were fit to the 
Michaelis–Menten equation by nonlinear regression. 
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Figure 4.9. PPi Affects Light Emission from FLuc and CG6178. (A) Dose-
response curves of FLuc light emission with D-luciferin using ATP purchased 
from either MP Biomedicals or Sigma. Left Panel: MP Bio ATP is supplemented 
with increasing concentrations of pyrophosphate (PPi). Right Panel: Each ATP 
with or without pre-treatment with pyrophosphatase (PPase). (B) Dose-response 
curves of CG6178 light emission with CycLuc2 using ATP purchased from either 
MP Biomedicals or Sigma. Left Panel: MP Bio ATP is supplemented with 
increasing concentrations of pyrophosphate (PPi). Right Panel: Each ATP with or 
without pre-treatment with pyrophosphatase (PPase). The assays were 
performed in triplicate and are represented as the mean ± SEM. FLuc curves 
were fit to the Michaelis–Menten equation by nonlinear regression. CG6178 
curves were fit to the Substrate Inhibition equation [Y=Vmax*X/(Km + X*(1+X/Ki))] 
by nonlinear regression. Note: Assays were performed with 2 mM ATP final. 
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Interestingly, the contaminating pyrophosphate has a very different effect 
on firefly luciferase (Figure 4.8). It slightly increases the Vmax of firefly luciferase 
with D-luciferin, likely because it can react with the enzyme-bound potent 
inhibitor dehydroluciferyl adenylate (Figure 4.1) to release dehydroluciferin and 
ATP. A similar effect has been observed upon the addition of CoASH, which is 
hypothesized to release the dehydroluciferyl adenylate inhibitor as the CoA ester 
(Fraga et al., 2005). However, upon treatment with high pyrophosphate dose 
(200 µM, 10% ATP concentration), luciferase light emission is inhibited as well 
(Figure 4.9). 
Reactions between the synthetic luciferins and firefly luciferase were less 
sensitive to ATP purity (Figure 4.8). Previous work in the lab has also 
established that the addition of CoASH has little effect on aminoluciferins (Reddy 
et al., 2010). The chemical structures of these substrates may make them less 
likely to form the dehydroluciferyl adenylate, so the addition of pyrophosphate or 
CoASH has no discernible effect. Alternatively, the high-affinity synthetic 
luciferins may be capable of forming dehydroluciferin inhibitors that are so potent 
that pyrophosphate-mediated conversion of dehydroluciferyl adenylates to 
dehydroluciferin and ATP does not meaningfully reduce inhibition. Another 
possibility is that pyrophosphate cannot form dehydroluciferins and ATP from the 
dehydroluciferyl adenylates of the aminoluciferins considered here. 
Additionally, neither CG6178 nor AbLL behave as expected with traditional 
Michaelis-Menten kinetics (Figure 4.6 and Figure 4.7). Both display the 
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predicted increase in emission with increasing dosage at low substrate 
concentrations. However, both then show a decrease in total flux at or near the 
highest substrate concentrations tested. We hypothesize that the decrease is 
due to substrate inhibition, where the enzyme is actually inhibited by its own 
substrate (Reed et al., 2010). Accounting for substrate inhibition by fitting the 
data with the equation Y=Vmax*X/(Km + X*(1+X/Ki)) still results in a good fit. We 
propose that there could be a secondary allosteric binding site for the luciferin, 
where at high concentration the luciferin also acts as a noncompetitive inhibitor, 
forcing the enzyme into a conformation that is unable to catalyze light emission. 
Indeed, it is the more hydrophobic substrates such as CycLuc11 and 12 where 
this effect is most pronounced and these substrates would be most apt to bind a 
small hydrophobic pocket and disrupt catalysis. 
Upon rapid injection of enzyme to substrate, firefly luciferase produces a 
burst of light followed by an immediate decay to a lower level steady state 
(Fraga, 2008). These are known as the “burst phase” and “glow phase” 
respectively. This decay is thought to be a result of product inhibition by either 
the light-emitting oxyluciferin and AMP products, or the “dark” dehydroluciferyl 
adenylate side-product. The decay is more pronounced with the tighter binding 
synthetic luciferins than with D-luciferin (Figure 4.10).  
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Figure 4.10. Burst kinetics of each ACSL with the indicated luciferin analog. 
Purified enzyme (100 nM final) was rapidly injected into substrate (250 μM final). 
Light emission was recorded every 0.5 s for 1 s pre-injection and 120 s post-
injection. Background luminescent signal in the absence of enzyme is shown for 
reference (in gray). The assays were performed in triplicate, are represented as 
the mean ± SEM, and are presented on the same log scale. 
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CG6178 and AbLL each display distinct and alternative profiles to 
luciferase. For example, CG6178 does not exhibit a burst phase, proceeding 
directly to the glow phase within the first few seconds post-injection (Figure 4.10 
and Figure 4.11). AbLL does not reach a steady state level of light emission, 
continuing to increase even two minutes after injection (Figure 4.10 and Figure 
4.11). These distinct profiles suggest that there are altered mechanisms of 
catalysis between the three enzymes. 
 
 
 
Figure 4.11. CycLuc2 burst kinetics with ACSLs. Purified enzyme (100 nM 
final) was rapidly injected into substrate (250 μM final). Light emission was 
recorded every 0.5 s for 1 s pre-injection and 120 s post-injection. The assays 
were performed in triplicate, are represented as the mean ± SEM, and are 
presented on an appropriate linear scale. 
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Discussion 
CG6178 is an ACSL from the fruit fly and the first latent luciferase 
described. Although CycLuc2 remains the best substrate identified at high 
substrate concentration, other rigid aminoluciferins can also serve as light-
emitting substrates (e.g. CycLuc4, 8, and 12). AbLL is another latent luciferase 
that exhibits different substrate specificity, and even emitting light with luciferin 
analogs that are inactive with CG6178 (i.e. Me2NPh-1n-Cys and C8Ph-1n-Cys). 
On the other hand, PaLL has no luciferase activity with any of the tested luciferin 
analogs. These results stand in stark contrast to firefly luciferase, which is 
remarkably tolerant to substrate modification and will emit light with D-luciferin 
and all 21 synthetic luciferin analogs.  
Unexpectedly, homology to a beetle luciferase was not a good predictor of 
latent luciferase activity among the three ACSLs tested. PaLL is an ACSL from 
the luminous beetle P. angustus that is 58% identical to its own luciferases, 
vPaLuc and dPaLuc, and 46% identical to firefly luciferase; yet it exhibited no 
luciferase activity with any of the tested substrates. AbLL, an ACSL from the non-
luminous beetle A. binodulus, is 55% identical to P. plagiophthalmus click beetle 
luciferase and shares higher identity to firefly luciferase than CG6178 (46% vs. 
39%), yet is a weaker latent luciferase. These results then beg the question: what 
are the defining features that can predict latent luciferase activity?  
In order for luciferase to catalyze light emission, it must be able to 
efficiently couple the adenylation and oxidation of each luciferin substrate. 
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Luciferase possesses two conserved lysine residues (K529 and K443) that are 
responsible for adenylation and oxidation respectively (Branchini et al., 2005b). 
Both are conserved in the three ACSLs, as they are necessary for adenylation 
and thioesterification of their natural fatty acid substrates (Figure 4.2). Luciferase 
undergoes a conformational change between the two catalytic steps in order to 
position the correct lysine in the active site (Sundlov et al., 2012). Therefore, the 
position of each lysine during catalysis and the ability of luciferase to undergo the 
conformational changes between catalytic steps all connect to finally catalyze 
light emission. 
CG6178 fails to emit light with D-luciferin because it is unable to form its 
adenylate (Oba et al., 2004). Although, D-luciferin can bind in the active site of 
CG6178 and act as an inhibitor of CycLuc2-mediated light emission (Mofford et 
al., 2014a). Ergo, D-luciferin is probably not positioned properly relative to the 
first lysine (K527, CG6178 numbering) and/or ATP for that catalytic step. 
However, if supplied with pre-adenylated D-luciferin, CG6178 is able to oxidize 
that intermediate and emit light, meaning K441 is aligned correctly (Mofford et al., 
2014a). The cyclic dialkylated modifications of CycLuc2, 4, 8, and 12 must alter 
the binding orientation relative to K527 (and/or ATP) to allow adenylation to 
occur. Additionally, CG6178 does not display the typical burst phase of firefly 
luciferase, but proceeds directly to the glow phase. This shows the absence of 
product inhibition and suggests that product dissociation is not the rate limiting 
step in catalysis. CG6178 may undergo a slower conformational change between 
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catalytic steps relative to firefly luciferase. Moreover, the presence of 
contaminating pyrophosphate from the Sigma ATP results in a significant 
decrease in the maximal rate of light emitted. Perhaps the excess pyrophosphate 
is forcing the luciferyl adenylate to undergo the reverse reaction and release the 
luciferin and ATP, instead of proceeding to the oxidation step. If the 
conformational change between steps is slower, that may give pyrophosphate 
enough time to react before oxidation can occur. 
AbLL displays weaker total photon flux relative to CG6178, with notably 
different substrate selectivity. The differences in substrate preference are likely 
caused by variations in the substrate binding pocket. Changes in the residues 
that line the pocket will alter the binding orientations of each luciferin relative to 
the two catalytic lysines and the ATP co-substrate, allowing AbLL to only utilize a 
subset of the panel. By studying the shape of the AbLL (and CG6178) binding 
pocket, it may be possible to engineer a luciferase to adopt the same substrate 
specificity while exhibiting the higher total photon flux of firefly luciferase. 
The weaker level of light emission from AbLL may be explained by the 
slow burst kinetics observed. AbLL may not couple the adenylation and oxidation 
steps of catalysis as efficiently as the other enzymes so it may take longer for the 
total population of enzyme to reach a steady state. Using pre-adenylated luciferin 
it should be possible to determine which catalytic steps are responsible for the 
decrease. For example, if the slow burst is due to a slow adenylation rate, using 
pre-adenylated luciferin will compensate and increase the burst rate. If the slow 
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burst is due to oxidation, using pre-adenylated luciferin will have no effect. If the 
slow burst is due to a combination of both steps, using pre-adenylated luciferin 
should slightly increase the burst rate. Then, once we determine which catalytic 
step(s) are less efficient, we can compare AbLL to CG6178 and luciferase, using 
both sequence alignment and structural studies. Hopefully the differences and 
similarities between the enzymes will link back to the differences in catalysis, and 
the characteristics of a luciferase will start to take shape. 
Finally, PaLL does not support light emission from any of the tested 
luciferin analogs, despite having 58% sequence identity to the two luciferases 
found in P. angustus and 46% identity to firefly luciferase. This enzyme may be 
the best ACSL we have tested to determine the features necessary for latent 
luciferase activity. First, we can test luciferin binding by screening for inhibition of 
fatty acyl-CoA synthesis. If the luciferin is able to bind to the active site, then it 
should also be a competitive inhibitor of the enzyme’s native function. Second, if 
the luciferin can bind, we can bypass the adenylation step using pre-adenylated 
luciferin. As with determining the slow burst of AbLL, using pre-adenylated 
luciferin can dissect which catalytic step(s) are deficient with PaLL. Then, once 
we have determined where PaLL falls short, we can compare it to the other 
ACSLs to identify the differences and map them back to those defects. 
So what are the defining features of a beetle luciferase? The enzyme 
must: 1) bind a luciferin in an orientation conducive to adenylation; 2) adenylate 
the carboxylate; 3) undergo a conformational change to align the second lysine in 
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the active site, and 4) oxidize the luciferyl adenylate to an excited-state 
oxyluciferin. As for how to predict which ACSLs will have luciferase activity, that 
remains unclear. Structural studies of these ACSLs may aid in dissecting the 
differences in emission efficiency (e.g., by comparing PaLL to the others). 
Additionally, many of the residues that line the luciferin binding pocket of firefly 
luciferase are not well conserved amongst ACSLs. Some of these residues have 
already been identified as important for emission with D-luciferin. For example, 
S347 in firefly luciferase is critical for catalysis with D-luciferin, as the S347A 
mutation has detrimental effects on both Km and Vmax. Perhaps testing more 
ACSLs will allow for recognition of conserved residues that are critical for light 
emission with all luciferins and will help to identify other ACSLs with latent 
luciferase activity. 
In summary, we have identified a second latent luciferase (AbLL) among 
insect ACSLs with a different substrate fingerprint than CG6178. This 
demonstrates that nascent luciferase activity in an ACSL is not limited to the fruit 
fly. However, we see that luciferase activity is also not universal to all insect 
ACSLs (e.g. PaLL). These results suggest that ACSLs can be a source of 
genetic diversity and structural insights for the construction of substrate-selective 
luciferases, especially if the defining characteristics of latent luciferase activity 
can be unveiled. 
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Materials and Methods 
Collaborators 
Gadarla Randheer Reddy of the Miller Lab:  
Synthesis of all benzothiazole core synthetic luciferins  
Kiran Reddy of the Miller Lab: 
 Synthesis of all phenyl core extended-conjugation synthetic luciferins 
 
General 
Chemicals were purchased from Aldrich, Matrix Scientific, Oakwood, or 
TCI. ATP was purchased from both MP Biomedicals and Sigma. D-luciferin was 
obtained from Anaspec and 6ʹ-NH2LH2 was obtained from Marker Gene 
Technologies Inc. CycLuc1, CycLuc2, 6ʹ-MeNHLH2, and 6ʹ-Me2NLH2 were 
synthesized as previously described (Reddy et al., 2010). CycLuc3-12 were 
synthesized as previously described (Mofford et al., 2014b). Other luciferins were 
prepared within the Miller lab. Data were plotted with GraphPad Prism 6.0. 
 
Plasmid constructs 
The DNA sequences for long-chain fatty acyl-CoA synthetases CG6178, 
AbLL, and PaLL were codon optimized for mammalian expression, synthesized 
by GenScript, and cloned into the BamHI–NotI sites of pGEX6P-1. WT luc2 
luciferase was used in pGEX6P-1 as previously described (Mofford et al., 
2014b). 
115 
 
Enzyme expression and purification 
Luciferases, fatty acyl-CoA synthetases, and chimeras were expressed 
and purified as GST-fusion proteins from the pGEX6P-1 vector as previously 
described (Mofford et al., 2014b). Briefly, JM109 cells were grown at 37 °C until 
the OD600 reached 0.5-1, induced with 0.1 mM IPTG, and incubated with 
shaking at 20 °C overnight. Cells were pelleted at 5000 RPM, then flash frozen in 
liquid nitrogen. The E. coli pellets from 1 L of culture were thawed on ice, 
resuspended in 25 mL lysis buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% 
Tween 20) containing 1 mM phenylmethylsulfonyl fluoride, and disrupted by 
sonification (Branson Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the 
resulting cell lysate was clarified by centrifugation at 35,000 RPM for 60 min at 4 
°C. The supernatant was batch-bound to immobilized glutathione (Thermo 
Scientific) for 1 hr at 4 °C, and the beads were washed with lysis buffer 
containing 10 mM DTT, followed by wash buffer (50 mM Tris [pH 8.1], 250 mM 
NaCl, and 10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 
150 mM NaCl, 1 mM TCEP). Twenty units of PreScission Protease (GE 
Healthcare) were added, and incubation continued overnight at 4 °C to cleave 
the GST-fusion and elute the untagged enzyme. Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). 
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Purified protein luminescence assays 
Luminescence assays were initiated by adding 30 μL of purified luciferase 
in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 
mg/mL BSA) to 30 μL 2x substrate in substrate buffer (20 mM Tris [pH 7.4], 0.1 
mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 3915). 
Imaging was performed one minute after enzyme addition using a Xenogen IVIS-
100 at a final enzyme concentration of 20 nM and final substrate concentrations 
ranging from 0.122 to 250 μM. Data acquisition and analysis was performed with 
Living Image® software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate. 
 
ATP evaluation assays using pyrophosphate and pyrophosphatase 
D-Luciferin and CycLuc2 were prepared at concentrations from 1,000 μM 
to 0.488 μM in evaluation buffer (20 mM Tris [pH 7.4] and 0.1 mM EDTA). ATP 
from either MP Biomedicals or Sigma was prepared at 16 mM in evaluation 
buffer with 32 mM MgSO4. Pyrophosphate was prepared at 1.6 mM, 160 μM, and 
16 μM in evaluation buffer. Pyrophosphatase (NEB) was prepared at 4 units/mL 
in enzyme buffer. Luciferase and CG6178 were prepared at 80 nM in enzyme 
buffer. In a black 96-well plate (Costar 3915), 25 μL luciferin, 12.5 μL ATP, and 
12.5 μL pyrophosphate or evaluation buffer were added. Enzyme buffer (25 μL) 
was added, proceeding directly to luminescence, or pyrophosphatase (25 μL) 
was added and held at ambient temperature for 45 minutes. Luminescence was 
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then initiated by adding 25 μL of luciferase or CG6178. Imaging was performed 
one minute after luciferase/CG6178 addition at a final concentrations of 250 μM 
to 0.122 μM luciferin; 2 mM ATP; 0 μM, 2 μM, 20 μM, or 200 μM pyrophosphate; 
0 or 0.1 units/well pyrophosphatase; and 20 nM luciferase/CG6178. 
 
Burst kinetics assays 
Using a Promega GloMax-Multi Detection System, 50 μL of purified 
enzyme in enzyme buffer was rapidly injected into a white 96-well plate (Costar 
3912) containing 50 μL of 2x substrate in substrate buffer to a final enzyme 
concentration of 100 nM and a final luciferin substrate concentration of 250 μM. 
Measurements were taken every 0.5 s for 1 s pre-injection and 120 s post-
injection. Data are reported as Relative Light Units (RLU). 
 
 
 
 
  
118 
 
CHAPTER V: 
Chimeric Firefly Luciferase / Fatty Acyl-CoA Synthetase Enzymes Improve 
Substrate Selectivity 
 
 
 
 
Summary 
Firefly luciferase and its homologs, the long-chain fatty acyl-CoA 
synthetases (ACSLs), are each comprised of two domains: a substrate binding 
N-terminal domain and a catalytic C-terminal domain. Here we show that 
swapping the C-terminal domain of an ACSL onto the N-terminal domain of 
luciferase is tolerated and can confer selectivity toward synthetic luciferin 
substrates. Thus, the development of luciferase/ACSL chimeric enzymes 
represents an alternative strategy to modulate luciferase function and increase 
the utility of bioluminescence based imaging reagents. 
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Introduction 
Firefly luciferase is the enzyme responsible for the brilliant light emitted by 
the firefly Photinus pyralis. Luciferase catalyzes a two-step reaction consisting of 
adenylation and oxidation of its native substrate D-luciferin (Fraga, 2008) (Figure 
5.1). Luciferase is comprised of a large N-terminal domain (residues 1-436) and 
a small C-terminal domain (residues 440-550) joined by a short hinge region of 
437ArgLeuLys439 (Sundlov et al., 2012). D-Luciferin and ATP both bind in the N-
terminal domain. However, the C-terminal domain contains two catalytic lysine 
residues (K443 and K529) responsible for facilitating the oxidation and 
adenylation of D-luciferin, respectively (Figure 5.2) (Branchini et al., 2005b; 
Sundlov et al., 2012). At rest, luciferase is in a conformation conducive to 
adenylation, with K529 positioned in the active site. After adenylation, the C-
terminal domain undergoes a ~140° rotation to align K443 in the active site for 
subsequent oxidation (Sundlov et al., 2012).  
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Figure 5.1. Parallels between luciferase and fatty acyl-CoA synthetase 
mechanisms. (A) Firefly luciferase catalyzes adenylation and subsequent 
oxidation of its native substrate, D-luciferin, to form an excited state oxyluciferin 
molecule that is responsible for light emission. Oxidation can also produce the 
off-pathway “dark product” dehydroluciferyl adenylate that does not emit light. (B) 
Long-chain fatty acyl-CoA synthetases catalyze adenylation and subsequent 
thioesterification of long-chain fatty acids, such as arachidonic acid, to form the 
fatty acyl-CoA product. 
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Figure 5.2. Amino acid alignment of firefly luciferase and two fatty acyl-CoA 
synthetases, CG6178 and AbLL. Primary sequences are displayed as a Clustal 
format alignment by Mafft (Katoh et al., 2002). Motifs 1-3 are conserved between 
members of the acyl-adenylate superfamily. Residues within 5 Å of the luciferin 
binding pocket are marked above with #. K443, marked below with *, is involved 
in oxidation or thioesterification of the substrate. K529, marked below with +, is 
involved in adenylation of the substrate. <---NC---> marks the interface between 
the N- and C-termini. Red bars mark the splice sites for the active site chimeras. 
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In addition to catalyzing light emission, luciferase has also been shown to 
act as a long-chain fatty acyl-CoA synthetase (ACSL) and catalyze the synthesis 
of fatty acyl-CoAs from free fatty acids (Oba et al., 2003) (Figure 5.1). Fatty acyl-
CoA synthesis involves a two-step mechanism beginning with the adenylation of 
the fatty acid, followed by thioesterification to form the final acyl-CoA product. 
This second step is in contrast to the oxidation of D-luciferyl adenylate during 
light emission. Dedicated ACSLs share high homology to luciferase and are 
hypothesized to be luciferase’s evolutionary predecessor (McElroy et al., 1967; 
Oba et al., 2006a; Viviani et al., 2013). Like luciferase, ACSLs are comprised of 
two domains: a large N-terminal and a small C-terminal domain (Gulick et al., 
2003; Reger et al., 2008). Similarly, fatty acid and ATP binding occur in the N-
terminal domain, while the C-terminal domain provides the two conserved lysine 
residues for adenylation, followed by thioesterification (Figure 5.2).  
Our lab has developed a panel of synthetic luciferin analogs (Mofford et 
al., 2014b; Reddy et al., 2010) (Figure 5.3) and recently reported that the ACSL 
CG6178 from Drosophila melanogaster possesses latent luciferase activity when 
supplied with a suitable synthetic substrate (Mofford et al., 2014a). We have 
since identified a second ACSL, AbLL, from a non-luminous click beetle 
Agrypnus binodulus (Oba et al., 2008) that also possesses luciferase activity but 
with different substrate specificity than CG6178. Both of these ACSLs share high 
sequence identity to firefly luciferase (Figure 5.2), yet neither emit light upon 
treatment with D-luciferin (Mofford et al., 2014a; Oba et al., 2008).  
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Figure 5.3. Chemical structures of all luciferin analogs. (A) Acyclic and (B) 
Cyclic luciferin analogs use the traditional benzothiazole-thiazoline core of D-
luciferin with either acyclic or cyclic modifications at the 6ʹ position respectively 
(Mofford et al., 2014b; Reddy et al., 2010). (C) “Non-traditional core” luciferin 
analogs use chromophores not limited to the benzothiazole-thiazoline core of D-
luciferin. Me2NPh-1n-Cys and Me2NPh-2n-Cys were originally reported by Iwano 
et al. (Iwano et al., 2013). 
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While these findings show luciferase homologs possess latent luciferase 
activity, both CG6178 and AbLL lack the signal intensity needed for practical 
bioluminescent sensors. We therefore hypothesized that chimeric enzymes 
between luciferase and an ACSL would provide the substrate selectivity of the 
ACSL, but generate higher rates of light emission that are desirable for use as a 
reporter. Here we evaluate the bioluminescent activity and substrate selectivity of 
chimeric luciferase/ACSL enzymes. 
 
Results 
In order to generate a luciferase with improved selectivity, we first sought 
to create chimeras of luciferase and CG6178 that swap the residues predicted to 
line the luciferin binding pocket. We chose our initial splice sites at highly 
conserved areas in the primary sequence (Figure 5.2 red bars) based on the 
hypothesis that the secondary and tertiary enzyme folds would also be 
conserved in those areas and the chimeras would still fold correctly. Using 
Gibson Assembly (Gibson et al., 2009), we generated the FLuc/CG/FLuc 
chimera containing residues 1-208 of luciferase, 210-341 of CG6178 and 343-
550 of luciferase. For comparison, we also made the reverse CG/FLuc/CG 
chimera. Unfortunately, our design hypothesis was incorrect and these enzymes 
were inactive as luciferases (Figure 5.4). Moreover, both were poorly expressed 
and impure, probably reflecting stability issues due to poor conservation of inter-
domain contacts (Figure 5.4). Potentially, a better choice of splice sites and/or 
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compensatory mutation to conserve inter-domain contacts could allow for 
successful application of this strategy. 
 
 
Figure 5.4. Luciferase/CG6178 active site chimeras are non-functional 
luciferases. (A) SDS-PAGE gel of FLuc/CG/FLuc and CG/FLuc/CG chimeras. 
(B) FLuc/CG/FLuc and (C) CG/FLuc/CG (20 nM final) treated with 250 µM of the 
indicated luciferin analog. The assay was performed in triplicate and is 
represented as the mean ± SEM. 
 
Alternatively, instead of generating chimeras within the N-terminal domain 
of luciferase and disturbing any inter-domain contacts, we chose to exploit the 
two-domain architecture of these enzymes. Since the N-terminal and C-terminal 
domains are separate, they should be able to fold independently and result in a 
functional enzyme. By placing our splice site at the junction of the two domains 
(R437 luciferase numbering, Figure 5.2), we created the luciferase/CG6178 and 
luciferase/AbLL chimeras: FLuc/CG, FLuc/Ab, CG/FLuc, and Ab/FLuc. 
Gratifyingly, all four of these enzymes expressed cleanly and at normal yields 
(Figure 5.5). 
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Figure 5.5. Luciferase/ACSL C-terminal chimeras are well expressed. (A) 
SDS-PAGE gel of luciferase/CG6178 and luciferase/AbLL C-terminal fusions. (B) 
SDS-PAGE gel of WT and mutant luciferase C-terminal fusions. 
 
Although the CG/FLuc and Ab/FLuc C-terminal fusions did function as 
luciferases, they lowered the already weak light emitted from WT CG6178 and 
AbLL and were thus not investigated further (Figure 5.6). However, FLuc/CG 
and FLuc/Ab did retain high luciferase activity. As reported by Oba et al. (Oba et 
al., 2006b), we found that the FLuc/CG fusion is less active toward D-luciferin 
than WT luciferase (Figure 5.7 and Figure 5.8). Nonetheless, the maximal 
sustained photon flux one minute after substrate introduction was equivalent or 
even exceeding WT with many of the synthetic luciferins, especially those that 
are not limited to the traditional benzothiazole-thiazoline core structure of D-
luciferin (Figure 5.7, Figure 5.8, Figure 5.9, and Figure 5.10). Even more 
surprisingly, the C-terminal fusion with AbLL (FLuc/Ab) drastically lowered 
activity with D-luciferin but greatly improved maximum activity with several 
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synthetic luciferins (e.g., 6ʹ-iBuMeNLH2, CycLuc4, and CycLuc11) (Figure 5.7, 
Figure 5.8, Figure 5.9, and Figure 5.10). Many synthetic luciferins display high 
affinity for WT luciferase and the C-terminal fusions, and their corresponding 
oxyluciferin products become potent inhibitors of subsequent rounds of catalysis. 
Since these data are acquired one minute after introduction of substrate to 
enzyme, there is substantial product inhibition observed. Therefore, the 
measured photon flux does not always obey Michaelis-Menten kinetics (Figure 
5.8, Figure 5.9, and Figure 5.10). Interestingly, the chimeras improve the photon 
flux from these substrates without sacrificing their high affinity. For example, 
CycLuc4 appears to have reached Vmax at all concentrations tested, and with all 
three enzymes (Figure 5.9). However, FLuc/Ab displays increased photon flux 
relative to the other two. Other luciferase mutants we have observed typically 
increase the maximal rate of light emitted with a given substrate by lowering the 
affinity and reducing product inhibition (Harwood et al., 2011; Mofford et al., 
2014b). This does not appear to be the case with the C-terminal fusions. 
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Figure 5.6. CG6178/Luciferase and AbLL/Luciferase C-Terminal Chimeras 
have lower photon flux compared to their WT counterparts. (A) WT CG6178 
vs. CG6178/FLuc and (B) WT AbLL vs. AbLL/FLuc treated with 250 µM of the 
indicated luciferin analog. Data are normalized to the parent enzyme signal. The 
assay was performed in triplicate and is represented as the mean ± SEM.  
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Figure 5.7. Normalized photon flux from WT luciferase and each WT 
chimera. Purified luciferase (10 nM) was treated with 250 µM of the indicated 
luciferin analog. Data are normalized to the signal from WT luciferase. The assay 
was performed in triplicate and is represented as the mean ± SEM. 
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Figure 5.8. Dose-response curves of WT luciferase and WT chimeras with 
acyclic luciferins. Purified luciferase (10 nM) was treated with 0.122 to 250 µM 
of the indicated luciferin analog. The assay was performed in triplicate and is 
represented as the mean ± SEM. Data were fit to the Michaelis-Menten equation 
by nonlinear regression, though many high affinity substrates do not fit this 
analysis well. 
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Figure 5.9. Dose-response curves of WT luciferase and WT chimeras with 
cyclic luciferins. Purified luciferase (10 nM) was treated with 0.122 to 250 µM of 
the indicated luciferin analog. The assay was performed in triplicate and is 
represented as the mean ± SEM. Data were fit to the Michaelis-Menten equation 
by nonlinear regression, though many high affinity substrates do not fit this 
analysis well. 
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Figure 5.10. Dose-response curves of WT luciferase and WT chimeras with 
non-traditional core luciferins. Purified luciferase (10 nM) was treated with 
0.122 to 250 µM of the indicated luciferin analog. The assay was performed in 
triplicate and is represented as the mean ± SEM. Data were fit to the Michaelis-
Menten equation by nonlinear regression, though many high affinity substrates 
do not fit this analysis well. 
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Following our success with the WT luciferase fusions, we generated C-
terminal fusions with the N-terminal domains of the luciferase mutants R218K 
and R218K+L286M+S347A (RK/CG, RK/Ab, and Triple/Ab). Both of these 
mutant luciferases have been shown to increase the maximal rate of photon flux 
for many high-affinity synthetic substrates, albeit with a decreased substrate 
affinity compared to WT (Mofford et al., 2014b). Moreover, both mutant 
luciferases can achieve a higher maximal photon flux with synthetic luciferins 
than either WT luciferase or the ACSL C-terminal fusions described above 
(Mofford et al., 2014b), making their respective chimeras interesting targets for 
synergistic improvement. 
For the most part, the beneficial effect of C-terminal fusions did not readily 
translate to the mutant luciferases. The R218K fusions did show improved light 
emission with a small subset of the synthetic substrates. For example, RK/Ab 
showed improved flux with 6ʹ-iBuMeNLH2 and CycLuc11 (Figure 5.11). However, 
this did not extend to the other substrates, nor was the effect as substantial as 
that observed with the FLuc/Ab fusion. The RK/CG fusion was able to improve 
flux from the “non-traditional core” luciferins, but was markedly worse than 
R218K with almost all of the traditional core substrates. The triple mutant-AbLL 
fusion (Triple/Ab) was worse with every substrate compared to the parent 
luciferase (Figure 5.12). The triple mutant-CG6178 fusion was not evaluated. 
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Figure 5.11. Normalized photon flux from R218K luciferase and each R218K 
chimera. Purified luciferase (10 nM) was treated with 250 µM of the indicated 
luciferin analog. Data are normalized to the signal from WT luciferase. The assay 
was performed in triplicate and is represented as the mean ± SEM. 
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Figure 5.12. Normalized photon flux from R218K+L286M+S347A luciferase 
and each triple mutant chimera. Purified luciferase (10 nM) was treated with 
250 µM of the indicated luciferin analog. Data are normalized to the signal from 
WT luciferase. The assay was performed in triplicate and is represented as the 
mean ± SEM. 
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To better determine the reason for the change in light emission with the 
chimeras, we measured the burst kinetics of each enzyme/substrate pair. Upon 
rapid injection of enzyme to substrate, luciferase displays an almost immediate 
burst of light during a “burst phase” (Fraga, 2008), followed by a decrease in total 
flux to a lower level during the subsequent “glow phase”. The decrease is caused 
by slow dissociation of either the oxyluciferin and AMP light-emitting products, or 
the “dark” dehydroluciferyl adenylate side-product (Figure 5.1). This product 
inhibition limits the subsequent rounds of catalysis. The burst phase peak at 
saturating substrate concentration represents the maximal rate of light emission 
that the luciferase can achieve (Branchini et al., 2014). Therefore, we can use 
each burst profile to compare the relative maximal rates and levels of product 
inhibition between the parent luciferase and each chimera. 
The FLuc/CG fusion results in little change in the peak emission rate 
during the burst phase compared to WT luciferase (Figure 5.13, Figure 5.14, 
and Figure 5.15). However, several traditional core substrates show increased 
product inhibition resulting in a lower level of sustained light emission during the 
glow phase (e.g. 6ʹ-NH2LH2, 6ʹ-MeNHLH2, CycLuc2, and CycLuc10). Conversely, 
many of the “non-traditional core” substrates actually displayed less product 
inhibition, resulting in improved flux during the glow phase (e.g. Me2NPh-2n-Cys 
and C2Ph-1n-Cys). 
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Figure 5.13. Burst kinetics profiles of WT luciferase and WT chimeras with 
acyclic luciferins. Purified luciferase (100 nM final) was rapidly injected into the 
indicated luciferin analog (250 µM final). Light emission was recorded every 0.5 s 
for 1 s pre-injection and 120 s post-injection. The assay was performed in 
triplicate and is represented as the mean ± SEM. 
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Figure 5.14. Burst kinetics profiles of WT luciferase and WT chimeras with 
cyclic luciferins. Purified luciferase (100 nM final) was rapidly injected into the 
indicated luciferin analog (250 µM final). Light emission was recorded every 0.5 s 
for 1 s pre-injection and 120 s post-injection. The assay was performed in 
triplicate and is represented as the mean ± SEM. 
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Figure 5.15. Burst kinetics profiles of WT luciferase and WT chimeras with 
non-traditional core luciferins. Purified luciferase (100 nM final) was rapidly 
injected into the indicated luciferin analog (250 µM final). Light emission was 
recorded every 0.5 s for 1 s pre-injection and 120 s post-injection. The assay was 
performed in triplicate and is represented as the mean ± SEM. 
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Like FLuc/CG, the RK/CG chimera produced similar peak burst rates 
relative to the parent R218K luciferase, but also displays increased product 
inhibition (Figure 5.16). This translates to almost all of the traditional core 
luciferins producing weaker total flux with the chimera than with R218K. 
However, as with FLuc/CG, product inhibition with RK/CG is lessened with the 
“non-traditional core” luciferins, resulting in an increase in sustained light output 
during the glow phase (e.g. Me2NPh-2n-Cys). 
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Figure 5.16. Burst kinetics profiles of R218K and triple mutant luciferases 
and their chimeras with select luciferins. Purified R218K luciferase or chimera 
(A) or R218K+L286M+S347A luciferase or chimera (B) [100 nM final] was rapidly 
injected into the indicated luciferin analog (250 µM final). Light emission was 
recorded every 0.5 s for 1 s pre-injection and 120 s post-injection. The assay was 
performed in triplicate and is represented as the mean ± SEM. 
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In contrast to the CG6178 fusions, all three AbLL chimeras displayed a 
drastic reduction in the peak rate of light emission. Interestingly, FLuc/Ab follows 
the decreased burst with almost no product inhibition, resulting in an increase in 
sustained light emitted during the glow phase, especially with 6ʹ-iBuMeNLH2, 
CycLuc4, and CycLuc11 (Figure 5.13, Figure 5.14, and Figure 5.15). On the 
other hand, RK/Ab and Triple/Ab both follow the decrease in the peak burst rate 
with equivalent or even increased product inhibition compared to their respective 
parent luciferases. Thus, RK/Ab produces weaker sustained light emission with 
all substrates except 6ʹ-iBuMeNLH2 and CycLuc11 and Triple/Ab emits weaker 
sustained light emission with all substrates. (Figure 5.16). 
 
Discussion 
The C-terminal domain of firefly luciferase provides two catalytic residues 
into the active site: lysine 529 is essential for AMP-ester formation, and after 
domain rotation, lysine 443 plays a critical role in the subsequent 
thioesterification or oxidation. Replacement of the C-terminal domain of firefly 
luciferase with that of CG6178 or AbLL is well tolerated. Despite the lack of direct 
interaction between the C-terminal domain and the substrate bound to the N-
terminal domain, we find that C-terminal domain swapping can have profound 
effects on substrate utilization. These results complement Branchini et al.’s 
recent finding that a C-terminal chimera of two luciferases can improve the 
overall activity of firefly luciferase toward D-luciferin (Branchini et al., 2014).  
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The observed differences to light emission by the chimeras may reflect 
changes in any or all of the key phases of catalysis. First, subtle differences in 
the alignment of the two lysines with respect to the luciferin substrate at either or 
both catalytic steps can manifest as changes in the rate of adenylation and/or 
oxidation. Next, the ability of the chimeric enzymes to undergo the necessary 
conformational change between the catalytic steps or the ability of the 
oxyluciferin, AMP, or dehydroluciferyl adenylate products to dissociate can 
impact the overall rate of light emission. Finally, changes to the quantum yield, 
the ability of the luciferin to access an excited-state oxyluciferin, or the ratio of 
oxyluciferin to dehydroluciferyl adenylate could be responsible for changes in the 
amount of light observed. 
The FLuc/CG and RK/CG chimeras generally result in comparable peak 
emission rate during the burst phase of catalysis compared to WT and R218K 
luciferases respectively. This suggests that the orientation of the two lysines is 
well conserved, the first conformational change of the C-terminal domain is 
unaffected, and the quantum yield is maintained. The variation in light emitted 
appears to be caused by an increase in product inhibition. A minor allosteric 
contact of the new domain could disrupt the second conformational change back 
to the adenylation state, causing the products to bind more tightly and stay bound 
longer than in the parent luciferases. Alternatively, a small increase in the 
formation of dehydroluciferyl adenylate could cause increased product inhibition. 
The dehydroluciferyl adenylate of D-luciferin is a more potent inhibitor of 
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luciferase (Ki = 3.8 ± 0.7 nM) than its oxyluciferin (Ki = 0.50 ± 0.03 µM) (Ribeiro 
and Esteves da Silva, 2008), a feature that most likely translates to each 
synthetic luciferin. Therefore a small increase in dehydroluciferyl adenylate that 
does not significantly impact the burst height may still accumulate over time to 
lower the observed level of light during the glow phase. Interestingly, the domain 
swap has the opposite effect on the “non-traditional core” luciferins than on the 
traditional substrates. The extended conjugation in these substrates may push 
the more bulky aromatic rings away from their normal contacts and shift their 
binding orientations, removing the potential for increased product affinity. The 
alternative core structures may also favor a reduction in dehydroluciferyl 
adenylate formation. Thus, the potentially subtle differences the luciferin 
orientation within the binding pocket can have a profound effect on the total light 
observed. 
Conversely, all three AbLL fusions result in a dramatic decrease in the 
peak emission rate during the burst phase compared to their respective parent 
luciferases. The FLuc/Ab chimera displays little to no product inhibition, resulting 
in significantly increased total flux during the glow phase with several luciferin 
analogs (e.g., 6ʹ-iBuMeNLH2, CycLuc4, CycLuc11). However, the burst height is 
so reduced with the “non-traditional core” luciferins that all of these substrates 
produce a lower level of light during the glow phase. Both the RK/Ab and 
Triple/Ab chimeras retain equal or even increased product inhibition compared to 
their respective parent luciferases, resulting in an even lower level of sustained 
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light during the glow phase. The RK/Ab fusion produced lower sustained light 
from all substrates except 6ʹ-iBuMeNLH2 and CycLuc11, while the Triple/Ab 
fusion produced lower sustained light from all substrates. Thus, swapping the C-
terminus combined with the changes brought on by these mutations are neither 
additive nor synergistic.  
The decrease in burst intensity from the AbLL fusions is indicative of a 
decrease in the overall catalytic rate of the enzymes. The effects of FLuc/Ab and 
RK/Ab are not as consistent between substrates as those of FLuc/CG and 
RK/CG, suggesting that the orientation of one or both lysines within the active 
site has been affected. The varying luciferin structures likely result in alterations 
to their respective orientations in the binding pocket and some are more apt to 
tolerate the new positions of these lysines than others. Also, the rate of each 
conformational change between the two domains after each catalytic step may 
have been impacted/slowed down. A slower first conformational change would 
result in a slower substrate oxidation rate, and may translate to a slower 
reversion back to the resting state, thus lowering the overall rate of catalysis and 
decreasing product inhibition by providing the products more time to dissociate. 
Alternatively, the quantum yield and/or ability of the luciferin to access the excited 
state may be affected. 
It should be possible to determine which of these parameters have 
impacted the photon flux from the AbLL fusions. First, using pre-adenylated 
luciferin, we can evaluate whether the lower burst rate is due to one or both of 
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the catalytic steps. For example, if the decreased burst is due to a slower 
adenylation rate, using pre-adenylated luciferin will compensate and the chimera 
should burst like WT. If the decrease is due to a slower oxidation rate, then using 
pre-adenylated luciferin will result in no change to the burst profile. If the 
decreased burst is due to a defect in both catalytic steps, using pre-adenylated 
luciferin will result in a partial increase in the burst rate. Second, we can 
determine the relative quantum yields of the light emitting reaction for each 
enzyme/substrate pair using the method described by Branchini et al (Branchini 
et al., 2014). Finally, we can directly measure the ratio of the oxyluciferin and 
dehydroluciferyl adenylate products by HPLC. By running all of these 
experiments, we can narrow down the causes of the changes in light emission by 
the chimera. However, at this time, we have not investigated the effects of pre-
adenylated luciferin or relative quantum yield using the chimeric luciferases. 
 
Conclusion 
Here we demonstrate that C-terminal fusions between firefly luciferase 
and ACSLs are well tolerated and result in functional luciferases. Remarkably, 
despite the lack of direct interactions between the substrates and the C-terminal 
domain, these chimeras improve photon flux with multiple synthetic luciferins and 
increase substrate specificity compared to WT luciferase. While both ACSLs 
(CG6178 and AbLL) used here possess latent luciferase activity, the substrate 
specificity engendered by their respective C-terminal domains in the chimeras 
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differs from that of the full ACSL. Neither of the WT luciferase fusions result in as 
dramatic of an effect as the active site mutations R218K or 
R218K+L286M+S347A. However, the chimeras do not lower the affinity of the 
substrates as severely as these mutants do. Thus, C-terminal fusions between 
luciferase and ACSLs represent an alternative strategy to direct mutation that 
can modulate luciferase function and develop new and improved bioluminescent 
reporters. 
 
Materials and Methods 
Collaborators 
Gadarla Randheer Reddy of the Miller Lab:  
Synthesis of all benzothiazole core synthetic luciferins  
Kiran Reddy of the Miller Lab: 
 Synthesis of all “non-traditional core” synthetic luciferins 
 
General 
Chemicals were purchased from Aldrich, Matrix Scientific, Oakwood, or 
TCI. D-luciferin was obtained from Anaspec and 6ʹ-NH2LH2 was obtained from 
Marker Gene Technologies Inc. CycLuc1, CycLuc2, 6ʹ-MeNHLH2, and 6ʹ-
Me2NLH2 were synthesized as previously described (Reddy et al., 2010). 
CycLuc3-12 were synthesized as previously described (Mofford et al., 2014b). 
148 
 
Other acyclic luciferins and “non-traditional core” luciferins were prepared within 
the Miller lab. Data were plotted with GraphPad Prism 6.0. 
 
Plasmid constructs 
The DNA sequences for long-chain fatty acyl-CoA synthetases CG6178 
(Figure 5.17) and AbLL (Figure 5.18) were codon optimized for mammalian 
expression, synthesized by GenScript, and cloned into the BamHI–NotI sites of 
pGEX6P-1. WT luc2 luciferase (Figure 5.19) and codon optimized R218K and 
triple mutant R218K/L286M/S347A were used as previously described (Mofford 
et al., 2014b).  Plasmid constructs containing the chimeric enzymes were 
generated using Gibson Assembly (NEB). Fragments of each cDNA 
corresponding to the desired region of each enzyme were PCR amplified and 
purified via agarose gel purification. PCR primers were designed to give 
overlapping ends of complementary DNA with the adjacent fragment of DNA for 
that chimera, per Gibson Assembly instructions (Figure 5.20). Each DNA 
fragment and pGEX6P-1 plasmid digested with BamHI and NotI were incubated 
with Gibson Assembly master mix per the manufacturer’s instructions to generate 
the final combined constructs (Figure 5.21 and Figure 5.22). 
 
  
149 
 
Codon Optimized CG6178 
 
Primary Amino Acid Sequence: 
MTSKLLPGNIVYGGPVTERQAQDSRSLGQYILDKYKSFGDRTVLVDAVNG 
VEYSASFMHKSIVRLAYILQKLGVKQNDVVGLSSENSVNFALAMFAGLAV 
GATVAPLNVTYSDREVDHAINLSKPKIIFASKITIDRVAKVASKNKFVKG 
IIALSGTSKKFKNIYDLKELMEDEKFKTQPDFTSPAANKDEDVSLIVCSS 
GTTGLPKGVQLTQMNLLATLDSQIQPTVIPMEEVTLLTVIPWFHAFGCLT 
LITTACVGARLVYLPKFEEKLFLSAIEKYRVMMAFMVPPLMVFLAKHPIV 
DKYDLSSLMVLLCGAAPLSRETEDQIKERIGVPFIRQGYGLSESTLSVLV 
QNDEFCKPGSVGVLKVGIYAKVIDPDTGKLLGANERGELCFKGDGIMKGY 
IGDTKSTQTAIKDGWLHTGDIGYYDDDFEFFIVDRIKELIKYKGYQVPPA 
EIEALLLTNDKIKDAAVIGKPDEEAGELPLAFVVKQANVQLTENEVIQFV 
NDNASPAKRLRGGVIFVDEIPKNPSGKILRRILREMLKKQKIAV- 
 
Codon Sequence: 
ATGACTTCAAAGCTGCTGCCAGGAAACATCGTGTATGGAGGACCCGTCAC 
AGAGAGACAGGCTCAGGACTCAAGATCACTGGGACAGTACATCCTGGATA 
AGTATAAAAGCTTTGGCGATCGCACCGTGCTGGTGGACGCAGTGAACGGG 
GTCGAGTACTCCGCCTCTTTCATGCACAAGTCCATTGTGCGACTGGCTTA 
TATCCTGCAGAAGCTGGGGGTGAAACAGAATGACGTGGTCGGACTGAGCT 
CCGAGAACTCTGTGAATTTCGCCCTGGCTATGTTTGCAGGACTGGCCGTG 
GGCGCTACAGTCGCACCTCTGAACGTGACTTACAGTGATAGAGAAGTGGA 
CCATGCCATCAATCTGTCTAAGCCAAAGATCATCTTCGCTAGTAAGATCA 
CAATTGACCGCGTGGCCAAAGTCGCTTCTAAGAACAAATTCGTGAAGGGC 
ATCATTGCCCTGAGCGGGACTAGCAAGAAGTTCAAGAATATCTACGATCT 
GAAAGAGCTGATGGAGGACGAAAAGTTCAAAACTCAGCCAGATTTTACCT 
CACCCGCCGCTAACAAGGATGAAGACGTGAGCCTGATCGTCTGCTCTAGT 
GGCACCACAGGGCTGCCAAAAGGCGTGCAGCTGACCCAGATGAATCTGCT 
GGCTACACTGGACAGCCAGATTCAGCCCACCGTGATCCCTATGGAGGAAG 
TGACCCTGCTGACAGTCATTCCCTGGTTCCACGCCTTTGGATGCCTGACA 
CTGATCACTACCGCTTGTGTGGGCGCAAGACTGGTCTACCTGCCTAAGTT 
CGAGGAAAAACTGTTTCTGAGCGCTATTGAGAAGTATAGAGTGATGATGG 
CATTCATGGTGCCCCCTCTGATGGTCTTTCTGGCCAAGCATCCCATCGTG 
GATAAATACGACCTGTCAAGCCTGATGGTGCTGCTGTGTGGAGCAGCACC 
ACTGTCCAGGGAGACTGAAGATCAGATCAAGGAGCGAATTGGAGTGCCTT 
TTATCCGGCAGGGATACGGCCTGAGTGAGTCAACCCTGTCCGTGCTGGTC 
CAGAACGACGAGTTCTGCAAGCCAGGATCTGTGGGCGTCCTGAAGGTCGG 
CATCTACGCAAAAGTCATCGATCCCGACACAGGGAAACTGCTGGGAGCCA 
ATGAGCGGGGGGAACTGTGTTTTAAGGGGGATGGAATTATGAAAGGGTAC 
ATCGGAGACACTAAGTCCACACAGACTGCCATCAAGGATGGCTGGCTGCA 
CACCGGCGACATCGGGTACTATGACGATGACTTCGAGTTCTTTATCGTGG 
ATAGAATTAAGGAACTGATCAAGTACAAAGGCTATCAGGTGCCACCCGCC 
GAGATTGAAGCTCTGCTGCTGACAAACGATAAGATCAAGGACGCTGCAGT 
GATCGGAAAGCCTGACGAGGAAGCAGGCGAGCTGCCACTGGCCTTCGTGG 
TCAAACAGGCTAACGTGCAGCTGACTGAGAATGAAGTGATCCAGTTTGTC 
AACGATAATGCAAGTCCTGCAAAGAGGCTGCGAGGAGGCGTGATCTTCGT 
GGACGAGATCCCTAAGAATCCATCAGGCAAAATTCTGCGGAGAATCCTGC 
GGGAAATGCTGAAGAAACAGAAGATCGCCGTGTAA 
 
Figure 5.17. Codon optimized CG6178 amino acid and codon sequence. 
Forward PCR primer sequences for the N- and C-terminal domains are 
highlighted in yellow. Reverse primer sequences are highlighted in purple. 
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Codon Optimized AbLL 
 
Primary Amino Acid Sequence: 
MSKESNIVYGPVGAAPVLESTAGKQLFDSLKRHGHLPQAIIDYQTKQSIS 
YKNLFEATCKLAHSLEEYGLKQNDVIAICSENNLNFYKPVCAALYCGIVI 
APLNDSYSEGEYVNALNISEPKLIFCSKKCLPRLVGLKARCSFIKGFVVI 
DSTEDINGNECLPNFILRNSDPNFDIEKYEPRVFNSNEQVAAILLSSGTT 
GFPKGVMLTHKNFSILFAHANDPVSGTQRIPGTTVLSILPYFHGFGFITN 
ISYIKSGIRVVMLQRFEPEAFLRAIEEYEVRSTITVPPILIFLAKSPIVD 
KYNLSSLKEIICGAAPSGREIVEAVVKRLKVSGIRYGYGLTECGLAICTT 
PPNNFKIGSSGVVVPFMAVKIRDVESGKTLKPTQIGEICVKGDMLMKGYA 
GNEKATKEMIDEDGWLHTGDIGYFDKDGHIYIVDRIKELIKYKGFQVPPA 
ELEALLLHHPCVKDAAVIGIPDELAGELPAAFIVKQHGKEVTEKEIVDYI 
AKQVSSAKHLRGGVRFIPDIPRTAAGKIQRNLLRNMIAKKKIAV- 
 
Codon Sequence: 
ATGTCCAAGGAGAGTAATATCGTCTATGGTCCAGTCGGCGCAGCCCCCGT 
CCTCGAAAGTACAGCAGGGAAACAGCTCTTTGATTCTCTGAAGAGACACG 
GCCATCTCCCTCAGGCTATCATTGACTACCAGACCAAGCAGAGTATCTCA 
TATAAAAACCTGTTCGAGGCCACATGCAAGCTGGCTCACAGCCTCGAGGA 
ATACGGACTGAAACAGAACGACGTGATCGCCATCTGTTCCGAAAACAATC 
TGAACTTCTACAAGCCAGTCTGCGCCGCTCTGTATTGTGGGATCGTGATT 
GCCCCCCTCAATGATAGCTACTCCGAGGGTGAATATGTGAACGCTCTGAA 
TATTTCAGAGCCCAAGCTCATCTTCTGCAGCAAGAAATGTCTCCCTCGAC 
TGGTGGGGCTCAAGGCCAGGTGCAGCTTCATCAAGGGTTTTGTGGTCATC 
GACTCTACCGAGGATATTAACGGCAATGAATGTCTGCCCAACTTCATCCT 
CAGGAACTCTGACCCTAACTTCGATATCGAGAAGTACGAACCAAGAGTCT 
TCAACAGCAATGAGCAGGTGGCAGCCATCCTGCTCAGCTCCGGGACCACA 
GGTTTTCCAAAGGGCGTGATGCTGACTCACAAAAACTTCAGTATCCTCTT 
TGCCCATGCTAATGACCCAGTCTCAGGCACCCAGAGAATCCCCGGAACTA 
CCGTGCTGAGCATTCTCCCATACTTCCACGGGTTCGGTTTTATCACCAAC 
ATCTCTTACATCAAGAGTGGCATCCGGGTGGTCATGCTGCAGCGCTTCGA 
GCCCGAAGCATTTCTGCGCGCCATCGAGGAATACGAGGTCCGAAGCACCA 
TTACAGTGCCCCCTATCCTGATTTTCCTCGCCAAGTCCCCCATCGTGGAT 
AAGTACAATCTGTCTAGTCTCAAGGAAATCATTTGCGGGGCTGCACCTTC 
TGGTCGGGAGATCGTCGAAGCAGTGGTCAAGAGACTGAAAGTGAGTGGCA 
TCCGGTACGGCTATGGACTGACAGAGTGCGGACTCGCTATCTGTACAACT 
CCACCCAACAATTTCAAGATTGGCTCAAGCGGAGTGGTCGTGCCTTTTAT 
GGCCGTCAAAATCCGCGACGTGGAGTCCGGCAAGACTCTGAAACCAACCC 
AGATTGGGGAAATCTGCGTGAAGGGCGACATGCTGATGAAAGGGTACGCC 
GGTAACGAGAAGGCCACAAAAGAGATGATCGACGAAGATGGATGGCTGCA 
CACTGGCGACATTGGATACTTCGACAAGGATGGGCATATCTATATTGTGG 
ATAGGATCAAGGAGCTGATCAAGTATAAAGGGTTTCAGGTGCCTCCAGCT 
GAGCTGGAAGCACTGCTCCTGCACCATCCTTGTGTCAAGGACGCCGCTGT 
GATCGGCATTCCTGATGAGCTGGCCGGAGAACTCCCAGCAGCCTTCATCG 
TGAAGCAGCACGGAAAAGAGGTCACAGAGAAGGAAATTGTGGACTACATC 
GCTAAGCAGGTCTCCTCTGCAAAACATCTGAGGGGCGGCGTGAGGTTCAT 
CCCCGATATCCCTCGCACTGCTGCAGGGAAGATTCAGCGAAACCTCCTCC 
GAAACATGATTGCTAAAAAGAAGATCGCCGTGTGA 
 
Figure 5.18. Codon optimized AbLL amino acid and codon sequence. 
Forward PCR primer sequences for the N- and C-terminal domains are bold. 
Reverse primer sequences are highlighted in green. 
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WT luc2 Luciferase 
 
Primary Amino Acid Sequence: 
MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVD 
ITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGV 
AVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKII 
IMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSG 
STGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMF 
TTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTL 
IDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAIL 
ITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSG 
YVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVA 
PAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHGKTMTEKEIVD 
YVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAKKGGKIAV- 
 
Codon Sequence: 
ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACT 
CGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACG 
CCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGAC 
ATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTAT 
GAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGA 
ATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTG 
GCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAG 
CATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGC 
AAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATC 
ATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTT 
CGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCG 
AGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGC 
AGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGT 
CCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCG 
ACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTC 
ACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCG 
CTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAAT 
CTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTC 
ATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGC 
GCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTAC 
CAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTG 
ATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCC 
CTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTG 
TGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGC 
TACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTG 
GCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCA 
TCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCC 
CCAGCCGAACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGC 
CGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAG 
TCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGAC 
TATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGT 
GTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCA 
AGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA 
 
Figure 5.19. WT luc2 luciferase amino acid and codon sequence. Forward 
PCR primer sequences for the N- and C-terminal domains are highlighted in 
blue. Reverse primer sequences are highlighted in red. 
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Figure 5.20. PCR primer design for chimeric constructs. (A) Representative 
construct for FLuc/CG chimera in pGEX6P-1 expression plasmid. PCR primers 
contain overlapping regions of the desired cDNA and the adjacent DNA. (B) PCR 
products of the representative FLuc/CG chimera. Note: The 3ʹ end of the 
luciferase fragment is identical to the 5ʹ end of the CG6178 fragment (marked by 
red-box/yellow-box). The 5ʹ end of the luciferase fragment is identical to the 
pGEX6P-1 BamHI cut site and the 3ʹ end is identical to the pGEX6P-1 NotI cut 
site (marked by black boxes). These overlapping identical areas are required for 
Gibson Assembly. (C) FLuc/CG and FLuc/Ab chimera PCR primers. Primer set 1 
is for the N-terminal domain and primer set 2 is for the C-terminal domain. 
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FLuc/CG Chimera Final Sequence 
 
Primary Amino Acid Sequence: 
MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVD 
ITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGV 
AVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKII 
IMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSG 
STGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMF 
TTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTL 
IDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAIL 
ITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSG 
YVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRIKELIKYKGYQVP 
PAEIEALLLTNDKIKDAAVIGKPDEEAGELPLAFVVKQANVQLTENEVIQ 
FVNDNASPAKRLRGGVIFVDEIPKNPSGKILRRILREMLKKQKIAV- 
 
Codon Sequence: 
ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACT 
CGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACG 
CCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGAC 
ATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTAT 
GAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGA 
ATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTG 
GCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAG 
CATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGC 
AAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATC 
ATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTT 
CGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCG 
AGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGC 
AGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGT 
CCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCG 
ACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTC 
ACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCG 
CTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAAT 
CTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTC 
ATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGC 
GCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTAC 
CAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTG 
ATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCC 
CTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTG 
TGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGC 
TACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTG 
GCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCA 
TCGTGGACCGGATTAAGGAACTGATCAAGTACAAAGGCTATCAGGTGCCA 
CCCGCCGAGATTGAAGCTCTGCTGCTGACAAACGATAAGATCAAGGACGC 
TGCAGTGATCGGAAAGCCTGACGAGGAAGCAGGCGAGCTGCCACTGGCCT 
TCGTGGTCAAACAGGCTAACGTGCAGCTGACTGAGAATGAAGTGATCCAG 
TTTGTCAACGATAATGCAAGTCCTGCAAAGAGGCTGCGAGGAGGCGTGAT 
CTTCGTGGACGAGATCCCTAAGAATCCATCAGGCAAAATTCTGCGGAGAA 
TCCTGCGGGAAATGCTGAAGAAACAGAAGATCGCCGTGTAA 
 
Figure 5.21. FLuc/CG chimera amino acid and codon sequence. The 
CG6178 C-terminal domain is highlighted in blue. Colored sequences reflect the 
Gibson Assembly primers from above. 
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FLuc/Ab Chimera Final Sequence 
 
Primary Amino Acid Sequence: 
MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVD 
ITYAEYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGV 
AVAPANDIYNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKII 
IMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSG 
STGLPKGVALPHRTACVRFSHARDPIFGNQIIPDTAILSVVPFHHGFGMF 
TTLGYLICGFRVVLMYRFEEELFLRSLQDYKIQSALLVPTLFSFFAKSTL 
IDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLPGIRQGYGLTETTSAIL 
ITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLGVNQRGELCVRGPMIMSG 
YVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRIKELIKYKGFQVP 
PAELEALLLHHPCVKDAAVIGIPDELAGELPAAFIVKQHGKEVTEKEIVD 
YIAKQVSSAKHLRGGVRFIPDIPRTAAGKIQRNLLRNMIAKKKIAV- 
 
Codon Sequence: 
ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACT 
CGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCTACG 
CCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGAC 
ATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTAT 
GAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGA 
ATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTG 
GCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAG 
CATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCAAGAAAGGGCTGC 
AAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATC 
ATCATGGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTT 
CGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCG 
AGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGC 
AGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGT 
CCGATTCAGTCATGCCCGCGACCCCATCTTCGGCAACCAGATCATCCCCG 
ACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTC 
ACCACGCTGGGCTACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCG 
CTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAAT 
CTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTC 
ATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGC 
GCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCTTCCACCTAC 
CAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTG 
ATCACCCCCGAAGGGGACGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCC 
CTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTG 
TGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGC 
TACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTG 
GCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCA 
TCGTGGACCGGATCAAGGAGCTGATCAAGTATAAAGGGTTTCAGGTGCCT 
CCAGCTGAGCTGGAAGCACTGCTCCTGCACCATCCTTGTGTCAAGGACGC 
CGCTGTGATCGGCATTCCTGATGAGCTGGCCGGAGAACTCCCAGCAGCCT 
TCATCGTGAAGCAGCACGGAAAAGAGGTCACAGAGAAGGAAATTGTGGAC 
TACATCGCTAAGCAGGTCTCCTCTGCAAAACATCTGAGGGGCGGCGTGAG 
GTTCATCCCCGATATCCCTCGCACTGCTGCAGGGAAGATTCAGCGAAACC 
TCCTCCAAACATGATTGCTAAAAAGAAGATCGCCGTGTGA 
 
Figure 5.22. FLuc/Ab chimera amino acid and codon sequence. The AbLL C-
terminal domain is highlighted in green. Colored sequences reflect the Gibson 
Assembly primers from above. 
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Enzyme expression and purification 
Luciferases, fatty acyl-CoA synthetases, and chimeras were expressed 
and purified as GST-fusion proteins from the pGEX6P-1 vector as previously 
described (Mofford et al., 2014b). Briefly, JM109 cells were grown at 37 °C until 
the OD600 reached 0.5-1, induced with 0.1 mM IPTG, and incubated with 
shaking at 20 °C overnight. Cells were pelleted at 5000 RPM, then flash frozen in 
liquid nitrogen. The E. coli pellets from 1 L of culture were thawed on ice, 
resuspended in 25 mL lysis buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% 
Tween 20) containing 1 mM phenylmethylsulfonyl fluoride, and disrupted by 
sonification (Branson Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the 
resulting cell lysate was clarified by centrifugation at 35,000 RPM for 60 min at 4 
°C. The supernatant was batch-bound to immobilized glutathione (Thermo 
Scientific) for 1 hr at 4 °C, and the beads were washed with lysis buffer 
containing 10 mM DTT, followed by wash buffer (50 mM Tris [pH 8.1], 250 mM 
NaCl, and 10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 
150 mM NaCl, 1 mM TCEP). Twenty units of PreScission Protease (GE 
Healthcare) were added, and incubation continued overnight at 4 °C to cleave 
the GST-fusion and elute the untagged enzyme. Protein concentrations were 
determined using Coomassie Plus (Thermo Scientific). 
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Purified protein luminescence assays 
Luminescence assays were initiated by adding 30 μL of purified luciferase 
in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM TCEP, and 0.8 
mg/mL BSA) to 30 μL 2x substrate in substrate buffer (20 mM Tris [pH 7.4], 0.1 
mM EDTA, 8 mM MgSO4, and 4 mM ATP) in a black 96-well plate (Costar 3915). 
Imaging was performed one minute after enzyme addition using a Xenogen IVIS-
100 at a final enzyme concentration of 10 nM and final substrate concentrations 
ranging from 0.122 to 250 μM. Data acquisition and analysis was performed with 
Living Image® software. Data are reported as total flux (p/s) for each ROI 
corresponding to each well of the 96-well plate. 
 
Burst kinetics assays 
Using a Promega GloMax-Multi Detection System, 50 μL of purified 
enzyme in enzyme buffer was rapidly injected into a white 96-well plate (Costar 
3912) containing 50 μL of 2x substrate in substrate buffer to a final enzyme 
concentration of 100 nM and a final luciferin substrate concentration of 250 μM. 
Measurements were taken every 0.5 s for 1 s pre-injection and 120 s post-
injection. Data are reported as Relative Light Units (RLU). 
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CHAPTER VI: 
Luciferin Amides Enable in Vivo Bioluminescence Detection of 
Endogenous Fatty Acid Amide Hydrolase Activity 
Mofford, D.M. et. al. (2015) JACS. 137(27), 8684–8687. 
 
 
Summary  
Firefly luciferase is homologous to fatty acyl-CoA synthetases. We 
hypothesized that the firefly luciferase substrate D-luciferin and its analogs are 
fatty acid mimics that are ideally suited to probe the chemistry of enzymes that 
release fatty acid products. Here, we synthesized luciferin amides and found that 
these molecules are hydrolyzed to substrates for firefly luciferase by the enzyme 
fatty acid amide hydrolase (FAAH). In the presence of luciferase, these 
molecules enable highly sensitive and selective bioluminescent detection of 
FAAH activity in vitro, in live cells, and in vivo. The potency and tissue distribution 
of FAAH inhibitors can be imaged in live mice, and luciferin amides serve as 
exemplary reagents for greatly improved bioluminescence imaging in FAAH-
expressing tissues such as the brain. 
158 
 
Introduction  
Firefly luciferase is best known for its light emission chemistry with D-
luciferin, but it is also a long-chain fatty acyl-CoA synthetase (ACSL) that can 
bind fatty acid substrates such as arachidonic acid (Oba et al., 2003) (Figure 
6.1). Conversely, we have recently shown that an ACSL from the fruit fly 
Drosophila melanogaster is a latent luciferase that can emit light with a synthetic 
luciferin (Mofford et al., 2014a). In both cases, adenylation of a carboxylic acid is 
the first step in catalysis. Furthermore, both enzymes can bind fatty acids ranging 
from octanoic acid to arachidonic acid, suggesting that D-luciferin and 
aminoluciferin analogs (Adams and Miller, 2014; Mofford et al., 2014b; Reddy et 
al., 2010) are acting as fatty acid mimics. Based in part on this observation, we 
hypothesized that luciferins are ideally suited to probe the chemistry of enzymes 
that release fatty acid products.  
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Figure 6.1. Enzyme mechanisms and luciferin structures. (A) Firefly 
luciferase catalyzes light emission from D-luciferin. (B) Firefly luciferase is also a 
fatty acyl-CoA synthetase. (C) FAAH cleaves anandamide to arachidonic acid. 
(D) Luciferin amides could allow bioluminescence imaging of FAAH activity. 
 
Fatty acid amide hydrolase (FAAH) is a serine hydrolase that limits the 
lifetime and sphere of action of fatty acid amide second messengers by 
hydrolysis to their corresponding fatty acids (Blankman and Cravatt, 2013; 
Cravatt et al., 1996) (Figure 6.1). Most notably, arachidonoyl ethanolamine 
(anandamide) is a locally generated agonist for the cannabinoid receptor CB1. 
Inhibition of FAAH prolongs the action of anandamide and is therefore an 
attractive drug target for the treatment of pain, anxiety, and cannabinoid 
dependence (Blankman and Cravatt, 2013). Many FAAH inhibitors are being 
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developed as potential therapeutics, and there is great interest in detecting FAAH 
activity in vivo (Shoup et al., 2014). Current techniques to assay FAAH inhibitors 
in mice primarily require sacrificing the mouse, homogenizing the tissues, adding 
radioactive lipid substrates, and HPLC analysis of the products (Long et al., 
2011). This places large demands on time and quantities of mice required to 
evaluate inhibitors and furthermore cannot give longitudinal data from the same 
animal. Some inroads have been made with PET imaging probes for FAAH, but 
these are specialized and expensive tools with low throughput and signal-to-
noise that lack the specificity for whole-body imaging (Shoup et al., 2014).  
FAAH readily accepts a wide range of saturated and unsaturated fatty acid 
amides in addition to anandamide (Boger et al., 2000; Cravatt et al., 1996) and 
has been shown to hydrolyze ethanolamides, primary amides, and methyl 
amides (Boger et al., 2000; Cravatt et al., 1996; Patricelli and Cravatt, 1999). We 
therefore hypothesized that FAAH could hydrolyze luciferin amides to their 
respective carboxylates, resulting in the formation of a luminogenic luciferase 
substrate (Figure 6.1). Here we show that luciferin amides allow exquisitely 
selective and sensitive imaging of endogenous FAAH activity in live cells and in 
live mice. FAAH is both necessary and sufficient for bioluminescence to occur 
and is the only enzyme activating these probes. The performance of FAAH 
inhibitors can be imaged in live mice, and inhibitors that cross the blood-brain 
barrier can be readily distinguished from those that cannot. Moreover, the 
amount of luciferin amide probe needed to perform this imaging is >1,000-fold 
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lower than typical D-luciferin imaging conditions but nonetheless improves overall 
signal from the brain. Thus, luciferin amides also excel at delivering luciferins into 
FAAH-expressing cells and tissues.  
 
Results and Discussion 
To test our initial hypothesis, we synthesized four luciferin amides (Figure 
6.1) by the condensation of electrophilic nitriles (Mofford et al., 2014b; Reddy et 
al., 2010) with a D-cysteine amide (see Supporting Information). Without a free 
carboxylate, these luciferin analogs are not light-emitting substrates for purified 
firefly luciferase (Figure 6.2 and Figure 6.3). Pretreatment of the luciferin amides 
with recombinant rat FAAH (Mileni et al., 2008) restores luminescent activity and 
could be specifically blocked by incubation with FAAH inhibitors such as PF3845 
(Ahn et al., 2009) (Figure 6.2 and Figure 6.3). The presence of FAAH or FAAH 
inhibitors has no effect on light emitted from the parent luciferins (Figure 6.2 and 
Figure 6.3). Thus, luciferin amides can be used to detect FAAH activity and 
inhibition in vitro. 
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Figure 6.2. FAAH inhibitor structures and in vitro FAAH inhibitor screen. (A) 
FAAH inhibitor structures. (B) Photon flux from the indicated luciferin analog (10 
μM) normalized to emission in the presence of FAAH with no FAAH inhibitor. The 
assay was performed in triplicate and is represented as the mean ± SEM.  
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Figure 6.3. Luciferin amides report on rat FAAH activity in vitro. (A) Photon 
flux from the indicated luciferin analog (10 μM) in the absence of FAAH or 
presence of FAAH with and without a FAAH inhibitor. (B) Direct comparison of 
each luciferin amide after treatment with rFAAH without inhibitor from (A). (C) 
Dependence of photon flux on the concentration of rFAAH after 30 min 
incubation with the indicated luciferin amide at pH 7.4, ambient temperature. All 
assays were performed in triplicate and are represented as the mean ± SEM. 
 
We next sought to determine whether luciferin amides were specific to 
FAAH and sensitive enough to enable the detection of FAAH activity in live cells. 
Chinese hamster ovary (CHO) cells are known to express FAAH (Okamoto et al., 
2005), an integral membrane protein (Blankman and Cravatt, 2013), but at levels 
insufficient to detect with fluorescence-based assays (Ramarao et al., 2005). In 
contrast, treatment of luciferase-expressing CHO cells with luciferin amides 
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resulted in robust bioluminescence (Figure 6.4A and Figure 6.5). Potentially, in 
the complex environment of the cell, luciferin amides could be cleaved by 
proteases or other serine hydrolases. However, treatment with PF3845, which 
specifically inhibits FAAH but no other serine hydrolases (Ahn et al., 2009), 
blocked emission from luciferin amides but had no effect on luciferase activity in 
the presence of the parent luciferin (Figure 6.4A). Furthermore, inhibitors of 
other serine hydrolases had no effect, and we evaluated the potency of a wide 
range of FAAH inhibitors in the natural context of live cell membranes (Figure 
6.6 and Figure 6.7). Lacking an ionized carboxylate, the luciferin amides also 
served as excellent luciferin delivery vehicles in these FAAH expressing cells, 
yielding higher bioluminescence signals than their parent luciferins at 
concentrations <100 μM (Figure 6.5). CycLuc1 methyl amide achieved higher 
maximal photon flux than CycLuc1 amide, presumably because uncleaved 
CycLuc1 amide can ultimately inhibit luciferase, while CycLuc1 methyl amide 
cannot (Figure 6.5 and Figure 6.8). 
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Figure 6.4. Luciferin amides report on FAAH activity in live mammalian 
cells. (A) Relative photon flux from live luciferase-expressing CHO cells treated 
with the indicated luciferins and luciferin amides (125 μM) in the absence (black 
bars) or presence (red bars) of the FAAH inhibitor PF3845. The data are 
normalized to the uninhibited sample for each luciferin (black bars). (B) Relative 
flux from live luciferase-expressing HeLa cells treated with the same set of 
substrates after transfection with empty pcDNA3.1 vector (black bars), 
pcDNA3.1-hFAAH (blue bars), or pcDNA3.1-hFAAH and treatment with the 
FAAH inhibitor PF3845 (red bars). The data are normalized to the uninhibited 
hFAAH transfected sample for each luciferin (blue bars). All assays were 
performed in triplicate and are represented as the mean ± SEM. 
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Figure 6.5. Luciferin amides report on FAAH activity in live cells and 
improve signal over parent luciferins. (A) Live CHO cells transfected with 
luciferase were incubated with 1 μM PF3845 for five minutes and then imaged 
with varying concentrations of the indicated luciferin analog. (B) Live HeLa cells 
co-transfected with either luciferase and human FAAH or luciferase and empty 
vector were incubated with 1 μM PF3845 for five minutes and then imaged with 
varying concentrations of the indicated luciferin analog. The assay was 
performed in triplicate and is represented as the mean ± SEM. Curves were fit to 
the Michaelis–Menten equation by nonlinear regression. 
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Figure 6.6. Luciferin amides report on inhibitor potency in live cells. (A) Live 
CHO cells transfected with luciferase were incubated with varying concentrations 
of FAAH inhibitor for five minutes and then imaged with CycLuc1 methyl amide 
(10 μM). (B) Live HeLa cells co-transfected with luciferase and human FAAH 
were incubated with varying concentrations of FAAH inhibitor for five minutes and 
then imaged with CycLuc1 methyl amide (10 μM). The assays were performed in 
triplicate and are represented as the mean ± SEM. Data was fit by nonlinear 
regression to log(inhibitor) vs. response (three parameters) to determine relative 
IC50 values. CHO cell IC50 values: PF3845, 12 nM; URB597, 2.7 nM; URB937, 16 
nM. HeLa cell IC50 values: PF3845, 86 nM; URB597, 31 nM; URB937, 57 nM. 
 
168 
 
 
Figure 6.7. Luciferin amides report on FAAH activity in live CHO cells. Live 
CHO cells transfected with luciferase were incubated with 1 μM of the indicated 
serine hydrolase inhibitor for five minutes and then imaged with the indicated 
luciferin analog (10 μM). All assays were performed in triplicate and are 
represented as the mean ± SEM. FAAH inhibitors: PF3845, PF750, PF622, 
URB597, URB937, OL135, and AZ513; MAGL inhibitors: JZL184 and KML29; 
ABHD6 inhibitor: WWL70 (Bandiera et al., 2014). 
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Figure 6.8. Luciferin primary amides can inhibit luciferase in vitro. (A) 
Purified firefly luciferase treated with 7.81 μM D-luciferin alone or in the presence 
of 10 μM or 25 μM D-luciferin amide. (B) Purified luciferase treated with 7.81 μM 
CycLuc1 alone or in the presence of 10 μM or 25 μM of CycLuc1 amide, 
CycLuc1 methyl amide, or CycLuc1 ethyl ester. The assay was performed in 
triplicate and is represented as the mean ± SEM. Each amide was compared to 
luciferin only by t-test. ns: not statistically significant; *** P <0.001. 
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HeLa cells do not express FAAH (Day et al., 2001; Dickason-Chesterfield 
et al., 2006), and luciferin amides do not yield bioluminescence in luciferase-
expressing HeLa cells (Figure 6.4B). Transfection of HeLa cells with human 
FAAH enabled bioluminescence with luciferin amides (Figure 6.4B and Figure 
6.5). Specific inhibition of the transfected FAAH with PF3845 blocked 
bioluminescence (Figure 6.4B) and the potency of FAAH inhibitors could be 
evaluated in these FAAH-transfected live cells (Figure 6.6). FAAH has been 
shown to cleave some fatty acid esters (Patricelli and Cravatt, 1999), and we find 
that it indeed also contributes to the cleavage of CycLuc1 ethyl ester (Figure 
6.9). However, unlike CycLuc1 amides, the ethyl ester of CycLuc1 is not 
exclusively cleaved by FAAH and is hydrolyzed to CycLuc1 in both CHO and 
HeLa cells (Figure 6.9). 
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Figure 6.9. CycLuc1 ethyl ester supports bioluminescence from both live 
CHO and HeLa cells. (A) Live CHO cells transfected with luciferase were 
incubated with 1 μM PF3845 for five minutes and then imaged with varying 
concentrations of either CycLuc1 or CycLuc1 ethyl ester. (B) Live HeLa cells co-
transfected with either luciferase and human FAAH or luciferase and empty 
vector were incubated with 1 μM PF3845 for five minutes and then imaged with 
varying concentrations of either CycLuc1 or CycLuc1 ethyl ester. The assay was 
performed in triplicate and is represented as the mean ± SEM. Curves were fit to 
the Michaelis–Menten equation by nonlinear regression. 
 
In mice, FAAH is highly expressed in the brain (Long et al., 2011). We 
thus expected that luciferin amides would result in strong brain bioluminescence 
in luciferase-expressing mice if able to access this tissue. We used adeno-
associated virus 9 (AAV9) to express luciferase only in the brain striatum (Evans 
et al., 2014). The amides are less water-soluble than the parent carboxylates, 
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necessitating a lower imaging dose. Nonetheless, CycLuc1 amide yielded 
dramatically higher photon flux in these mice than the parent luciferin CycLuc1 or 
the conventional substrate D-luciferin (Figure 6.10). A 400-fold lower dose of 
CycLuc1 amide was markedly superior to the standard imaging dose of D-
luciferin (Figure 6.10). Even 1,000-fold lower doses yielded higher brain 
bioluminescence than D-luciferin (Figure 6.11). 
 
 
 
Figure 6.10. Bioluminescence from mice that express luciferase in specific 
tissues after treatment with luciferins and luciferin amides. CycLuc1 amide 
compared to D-Luciferin for bioluminescence imaging in live mice expressing 
luciferase in (A) the brain or (B) the heart and leg muscles. Quantification is 
represented as the mean ± SEM for n = 3 mice. 
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Figure 6.11. CycLuc1 amide increases total photon flux from the brain at 
1,000-fold lower dose than D-luciferin. Mice striatally injected with AAV9-CMV-
luc2 were treated with 0.4 μmol/kg CycLuc1 amide or 400 μmol/kg D-luciferin. 
Quantification was normalized to D-luciferin signal for each mouse and is 
represented as the mean ± SEM for n=3 mice. 
 
Pretreatment with PF3845 (Figure 6.2), which has been demonstrated to 
inhibit only FAAH in mice (Ahn et al., 2009), completely blocked brain 
bioluminescence when using luciferin amides (Figure 6.12). Tail-vein injection of 
AAV9-CMV-luc2 primarily transduces heart (Inagaki et al., 2006) and leg muscles 
(Figure 6.10), tissues where FAAH activity has been reported to be absent (Long 
et al., 2011). In these mice, luciferin amides yielded dramatically lower photon 
flux than could be achieved with their parent luciferins (Figure 6.10). By contrast, 
CycLuc1 ethyl ester was on par with equal doses of the parent luciferin in the 
heart and leg muscles, but ineffective in the brain (Figure 6.10). These 
differences likely reflect the location of the liberating enzymatic activity and 
biodistribution of the more hydrophobic ester. 
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Figure 6.12. Inhibition of FAAH by PF3845 results in loss of signal from 
CycLuc1 amide in the brain. Mice striatally injected with AAV9-CMV-luc2 were 
imaged with CycLuc1 amide alone or after pre-treatment with 10 mg/kg PF3845. 
Quantification is represented as the mean ± SEM for n=3 mice and was 
compared by t-test. ** P <0.01. 
 
To visualize FAAH activity throughout the mouse, we next turned to 
transgenic mice that express luciferase in all tissues (Cao et al., 2004). When D-
luciferin or CycLuc1 is introduced into these mice, the weakest light emission is 
from the head, and bioluminescence is dominated by superficial tissues (Figure 
6.13 and Figure 6.14). In marked contrast, injection of CycLuc1 amide revealed 
the strongest bioluminescence signals from the brain and kidneys (Figure 6.13), 
tissues known to have high FAAH activity (Long et al., 2011). Ventral 
bioluminescence was less well-defined, which may reflect rapid transit of 
released luciferin out of FAAH-expressing tissues such as the liver (Figure 6.14). 
Pretreatment of mice with PF3845 completely blocked bioluminescence from 
luciferin amides in the brain and in all peripheral tissues (Figure 6.13, Figure 
6.15, and Figure 6.16) but had no effect on bioluminescence from the parent 
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luciferins (Figure 6.17). The aminoluciferin amides (Figure 6.1) readily sense 
FAAH activity in vivo (Figure 6.14), and can be imaged at extremely low doses 
(as low as 8 nmol/kg; Figure 6.18). Although D-luciferin amide senses FAAH 
activity in vitro and in live cells, it works poorly in live mice and cannot sense 
FAAH activity in the brain (Figure 6.14). This is consistent with our contention 
that the improved biodistribution properties of aminoluciferins and low Km values 
render them superior for use as luminogenic sensors in vivo (Adams and Miller, 
2014). Interestingly, CycLuc1 methyl amide did not exhibit an advantage over 
CycLuc1 amide in the mouse (Figure 6.14). Presumably, inhibition of luciferase 
by uncleaved luciferin primary amides is not an issue at the substrate 
concentrations achieved in vivo. 
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Figure 6.13. Luciferin amides report on FAAH activity in live mice that 
ubiquitously express luciferase. (A) Bioluminescence imaging with CycLuc1 or 
CycLuc1 amide in ubiquitously expressing transgenic luciferase mice treated with 
vehicle only or the indicated FAAH inhibitor. (B) Total flux from the brain and 
kidneys quantitated as a function of inhibitor concentration and normalized to the 
vehicle-only signal, represented as the mean ± SEM for n = 3 mice. Data were fit 
by nonlinear regression to determine relative IC50 values in the brain (PF3845, 
0.14 mg/kg; URB597, 0.40 mg/kg; URB937, ND) and kidneys (PF3845, 0.03 
mg/kg; URB597, 0.07 mg/kg; URB937, 0.33 mg/kg). 
 
177 
 
 
Figure 6.14. Bioluminescence from mice that ubiquitously express 
luciferase after treatment with luciferins and luciferin amides. (A) Dorsal 
view of FVB-Tg(CAG-luc) mice injected with the indicated substrate. (B) Ventral 
view of mice in (A). 
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Figure 6.15. Ventral view of ubiquitously-expressing luciferase mice treated 
with CycLuc1 amide. Mice were pre-treated with vehicle only (18:1:1 
PBS:Kolliphor:ethanol), or the indicated FAAH inhibitors. Quantification was 
normalized to the average vehicle-only signal and is represented as the mean ± 
SEM for n=3 mice. Data was fit by nonlinear regression to determine relative 
ventral IC50 values (PF3845: 0.08 mg/kg, URB597: 0.06 mg/kg, URB937: 0.46 
mg/kg). 
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Figure 6.16. Mice ubiquitously-expressing luciferase treated with high 
inhibitor dose. Mice were pre-treated with vehicle only (18:1:1 
PBS:Kolliphor:ethanol), or the indicated FAAH inhibitors and imaged with 
CycLuc1 amide. 
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Figure 6.17. FAAH inhibitors do not affect parent luciferins. (A) Dorsal view 
of live FVB-Tg(CAG-luc) mice, injected with the indicated inhibitor and treated 
with CycLuc1. (B) Ventral view of mice in (A). Quantification is represented as 
the mean ± SEM for n=3 mice. Each inhibitor was compared to vehicle only by t-
test. No statistically significant difference was found for any inhibitor. 
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Figure 6.18. CycLuc1 amide can be imaged at doses as low as 8 nmol/kg 
and signal is not saturated at 1 μmol/kg. (A) Dorsal view of FVB-Tg(CAG-luc) 
mice injected with the indicated concentration of CycLuc1 amide. (B) Ventral 
view of mice in (A). Quantification is represented as n=1 mouse per substrate 
dose. 
 
182 
 
Finally, we sought to determine whether luciferin amides could be used to 
evaluate the tissue distribution of prospective FAAH inhibitors, which can have 
important effects on their efficacy (Clapper et al., 2010). URB937 is a brain-
impermeable FAAH inhibitor that differs from the global FAAH inhibitor URB597 
by a single hydroxyl group (Clapper et al., 2010) (Figure 6.2). Bioluminescence 
imaging with CycLuc1 amide confirmed that URB597 inhibits FAAH activity in 
both peripheral and brain tissues (Figure 6.13, Figure 6.15, and Figure 6.16), 
whereas no inhibition of FAAH activity is detected in the brains of URB937-
treated mice (Figure 6.13).  
Many bioluminescent sensors have been described based on “caged” pro-
luciferins that can release a luciferin upon the action of an enzyme or reactive 
small molecule (Adams and Miller, 2014; Van de Bittner et al., 2013). The labile 
moiety is distinct from the luciferin and often separated by a self-immolative linker 
(Carl et al., 1981). A limitation of this approach is that the luciferin itself is not 
contributing to specific recognition or selectivity; the best one can hope for is that 
its presence is innocuous. Our approach embraces the inherent fatty acid 
mimetic properties of luciferin analogs to create sensors for enzymes that release 
fatty acids. The power of this approach is borne out in the exquisite specificity 
and sensitivity of luciferin amides for FAAH even in vivo, simply by replacing an 
oxygen atom with nitrogen (Figure 6.1). Furthermore, we find that luminogenic 
sensors based on high-affinity, cell-permeable aminoluciferins perform better in 
mice than those based on D-luciferin. As the number of structurally distinct 
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luciferin analogs grows (Adams and Miller, 2014; Mofford et al., 2014b), we 
anticipate there will be additional opportunities to build sensors based on the 
inherent properties of the luciferin itself. 
In summary, we have found that luciferin amides are highly sensitive and 
selective reporters of FAAH activity. These sensors readily translate from in vitro 
assays to live cells to in vivo imaging to report on the activity of a single enzyme 
in its natural context. The bioluminescence approach described herein reveals 
otherwise invisible endogenous enzymatic activity in live cells and mice and more 
broadly allows imaging of the biodistribution consequences of subtle 
modifications to a prospective therapeutic inhibitor in vivo (e.g., ability to cross 
the blood-brain barrier). Further refinement and modification of the structure of 
the luciferin (Adams and Miller, 2014; Mofford et al., 2014b) and the scissile bond 
could potentially allow extension of this bioluminescence detection approach to 
other enzymes (Bandiera et al., 2014; Long and Cravatt, 2011). Finally, luciferin 
amides are excellent reagents for increasing the sensitivity of bioluminescence 
imaging in FAAH-expressing cells and tissues, such as the brain, and allow 
orders of magnitude lower imaging doses than the natural luciferase substrate. 
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Materials and Methods 
Collaborators 
Gadarla Randheer Reddy of the Miller Lab: Synthesis of all synthetic luciferins 
Kiran Reddy of the Miller Lab: Synthesis of all luciferin amides 
Spencer Adams of the Miller Lab:  
Training and assistance with mouse imaging. Tail-vein injection of AAV. 
 
General 
Chemicals for synthesis were obtained from Aldrich. D-luciferin was 
obtained from Anaspec for in vitro work and from Gold Bio for mouse work. 
Serine hydrolase inhibitors were purchased from Cayman. CycLuc1 was 
synthesized as previously described (Reddy et al., 2010). Protein concentrations 
were determined using Coomassie Plus (Thermo Scientific). Immobilized 
glutathione (Thermo Scientific) was used for glutathione S-transferase (GST)-
tagged protein purification. Kolliphor® EL was obtained from Sigma Life Sciences 
(Stock # C5135) Data were plotted and analyzed with GraphPad Prism 6.0. High 
resolution mass spectral data were recorded on a Waters QTOF Premier 
spectrometer (University of Massachusetts Medical School Proteomics and Mass 
Spectrometry Facility). Bioluminescence assays were performed on a Xenogen 
IVIS-100 system in the Small Animal Imaging facility. Data acquisition and 
analysis were performed with Living Image® software. Data are reported as total 
flux (p/s) for each region of interest (ROI). For in vitro and cellular assays, the 
185 
 
ROIs correspond to each well of a 96-well plate. For in vivo assays, the ROIs 
correspond to the indicated region of a mouse. 
 
Plasmid constructs 
Human and rat FAAH genes (hFAAH and rFAAH) were purchased from 
the Mammalian Gene Collection of Thermo Fisher Scientific (clone IDs: hFAAH 
5728192, rFAAH 7370226). Residues 30-579 of the rFAAH gene were PCR-
amplified and cloned into the EcoRI and NotI sites of pGEX6P-1, resulting in 
removal of the N-terminal transmembrane domain (Mileni et al., 2008). Full 
length hFAAH was PCR-amplified and cloned into the KpnI and NotI sites of 
pcDNA3.1 to yield pcDNA3.1-hFAAH. 
 
Protein expression and purification 
Rat FAAH (30-579) and firefly luciferase were expressed as GST-fusion 
proteins using the pGEX6P-1 vector in the E. coli strain JM109. Cells were grown 
at 37 °C until the OD600 reached 0.5-1, induced with 0.1 mM IPTG, and 
incubated at 20°C overnight. Cells were pelleted at 5,000 RPM in a Sorvall 2C3C 
Plus centrifuge (H600A rotor) at 4 °C for 15 min, then flash frozen in liquid 
nitrogen. E. coli pellets from 1 L of culture were thawed on ice, resuspended in 
25 mL lysis buffer (50 mM Tris [pH 7.4], 500 mM NaCl, and 0.5% Tween 20) 
containing 1 mM phenylmethylsulfonyl fluoride, and disrupted by sonification 
(Branson Sonifier). Dithiothreitol (DTT) was added at 10 mM, and the resulting 
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cell lysate was clarified by centrifugation at 35,000 RPM in a Beckman 50.2 Ti 
rotor for 60 min at 4 °C. The supernatant was batch-bound to immobilized 
glutathione for 1 hr at 4 °C, and the beads were washed with lysis buffer 
containing 10 mM DTT, followed by wash buffer (50 mM Tris [pH 8.1], 250 mM 
NaCl, and 10 mM DTT) and storage buffer (50 mM Tris [pH 7.4], 0.1 mM EDTA, 
150 mM NaCl, 1 mM TCEP). Twenty units of PreScission Protease (GE 
Healthcare) were added, and incubated overnight at 4 °C to cleave the GST-
fusion and elute the untagged protein into storage buffer. 
 
Purified protein rFAAH activity assays 
FAAH inhibitors were prepared at 4 μM in substrate buffer (20 mM Tris 
[pH 7.4], 0.1 mM EDTA, 8 mM MgSO4, and 4 mM ATP). Luciferins and luciferin 
amides were prepared at 40 μM in substrate buffer. Luciferase and rFAAH were 
prepared at 400 nM in enzyme buffer (20 mM Tris [pH 7.4], 0.1 mM EDTA, 1 mM 
TCEP, and 0.8 mg/mL BSA). In a black 96-well plate (Costar 3915), 25 μL FAAH 
inhibitor or substrate buffer was added to three wells each. rFAAH (25 μL) or 
enzyme buffer was added to the inhibitor and incubated at ambient temperature 
for 5 minutes. Luciferin or luciferin amide (25 μL) was then added to each well 
and incubated at ambient temperature for 20 minutes. Luminescence was then 
initiated by adding 25 μL of luciferase. Imaging was performed one minute after 
luciferase addition and integrated for 2-20s at a final concentration of 1 μM FAAH 
inhibitor, 10 μM luciferin, 100 nM rFAAH, and 100 nM luciferase. 
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Purified rFAAH dose-response assays 
Purified rFAAH was prepared at concentrations ranging from 8 μM to 3.91 
nM in enzyme buffer. Luciferin amides were prepared at 20 μM in substrate 
buffer. Luciferase was prepared at 400 nM in enzyme buffer. In a black 96-well 
plate (Costar 3915), 50 μL of each luciferin amide was added per well. rFAAH 
(25 μL) was then added to the amide and incubated at ambient temperature for 
30 minutes. Luminescence was then initiated by adding 25 μL of luciferase. 
Imaging was performed one minute after luciferase addition for 2-20s at a final 
concentration of 2,000 nM to 0.977 nM rFAAH, 10 μM luciferin amide, and 100 
nM luciferase. 
 
Luciferin amide inhibitor assays with purified luciferase 
Luciferin amides were prepared at 40 μM or 100 μM in substrate buffer. 
Luciferins were prepared at concentrations from 1,000 μM to 0.488 μM in 
substrate buffer. Luciferase was prepared at 200 nM in enzyme buffer. In a black 
96-well plate (Costar 3915), 25 μL luciferin amide or substrate buffer was added 
to three rows each. Luciferin (25 μL) was added to the luciferin amide. 
Luminescence was then initiated by adding 50 μL of luciferase. Imaging was 
performed one minute after luciferase addition for 2-20s at a final concentration 
of 0 μM, 10 μM, or 25 μM luciferin amide, 250 μM to 0.122 μM luciferin, and 100 
nM luciferase. 
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Cell culture 
Chinese hamster ovary (CHO) cells and HeLa cells were grown in a CO2 
incubator at 37°C with 5% CO2 and were cultured in F-12K Nutrient Mixture 
(GIBCO) and Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO), 
respectively. Both media were supplemented with 10% fetal bovine serum and 
100 U/mL penicillin/streptomycin. 
 
Transfections 
CHO cells were transfected with codon-optimized firefly luciferase (luc2) 
as previously described (Mofford et al., 2014b). HeLa cells were transfected with 
pcDNA3.1-luc2 plasmid (Mofford et al., 2014b) and either pcDNA3.1- hFAAH or 
empty pcDNA3.1 vector. Transient transfections were performed at RT using 
Lipofectamine 2000 on cells plated at 60%–75% confluency in 96-well black 
tissue culture treated plates (Costar 3916). For CHO cells, 0.075 μg DNA/well of 
pcDNA3.1-luc2 was transfected; for HeLa cells, 0.0375 μg DNA/well each of 
pcDNA3.1-luc2 and either pcDNA3.1- hFAAH or empty pcDNA3.1 was 
transfected. Assays were performed in triplicate 24 hrs after transfection. 
 
Live cell FAAH activity assays 
Transfected cells were washed with HBSS. For substrate dose-response 
curves, the cells in 96-well plates were incubated with 50 μL of 2 μM FAAH 
inhibitor in HBSS or HBSS only at ambient temperature for 5 minutes. Then, 50 
μL of 2x substrate was added to each well to achieve final substrate 
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concentrations ranging from 125 μM to 0.061 μM. For inhibitor dose-response 
curves, the cells in 96-well plates were incubated with 50 μL of 2x FAAH inhibitor 
in HBSS at ambient temperature for 5 minutes (final inhibitor concentrations 
ranging from 10 μM to 0.21 pM). Then, 50 μL of 2x substrate was added to each 
well to a final luciferin concentration of 10 μM. Imaging was performed three 
minutes after addition of substrate. 
 
Mice 
All of the experiments involving mice were conducted in accordance with 
the Institutional Animal Care and Use Committee of The University of 
Massachusetts Medical School (docket #A-2474-14). Female FVB mice and 
luciferase-expressing transgenic mice (FVB-Tg(CAG-luc,-
GFP)L2G85Chco/FathJ) were purchased from Jackson Laboratories (Bar 
Harbor, ME). Striatal injection of AAV9-CMV-luc2 into FVB mice was performed 
as previously described (Evans et al., 2014). 
 
Tail-vein injection of AAV 
FVB mice were injected in the lateral tail vein with 1x1011 particles of 
AAV9-CMV-luc2 luciferase (Evans et al., 2014) suspended in sterile filtered PBS 
at a final volume of 200 μL. The mice were held under a heat lamp to warm the 
tail for better visualization of the lateral tail vein due to vasodilation and then 
placed into a Tailveiner (Braintree Scientific, Braintree, MA). The tails were 
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cleaned with a 70% isopropyl alcohol wipe and injection was performed using a 
27.5 gauge needle. Once the needle was withdrawn, the tail was compressed 
with sterile gauze to ensure complete homeostasis. The mice were monitored 
afterwards for recovery of normal behavior before returning to their colony. 
Imaging was performed weeks to months after AAV injection. 
 
Substrate and FAAH inhibitor preparation for mouse injection 
All FAAH inhibitors were prepared by direct dissolution into 18:1:1 
PBS:Kolliphor:ethanol and sterile filtering through a 0.22 μm syringe filter. Each 
inhibitor was injected intraperitoneally (i.p.) at 5 μL/g mouse. Inhibitors were 
prepared at 2 mg/mL, 0.2 mg/mL, 0.02 mg/mL, and 0.002 mg/mL to achieve final 
concentrations of 10 mg/kg, 1 mg/kg, 0.1 mg/kg, and 0.01 mg/kg respectively. 
Due to limited solubility, URB597 was prepared at 0.4 mg/mL and injected at 10 
μL/g to achieve a dose of 4 mg/kg. D-luciferin (100 mM) and CycLuc1 (5 mM) 
were prepared by direct dissolution into PBS and were sterile filtered through a 
0.22 μm syringe filter. All other luciferins were prepared by diluting a 50 mM 
DMSO stock into PBS and sterile filtering through a 0.22 μm syringe filter. 
CycLuc1 ethyl ester was not soluble in PBS and was therefore prepared by 
diluting the 50 mM DMSO stock into 18:1:1 PBS:Kolliphor:ethanol. Each 
substrate was injected i.p. at 4 μL/g mouse. Substrates were prepared at 100 
mM (D-Luciferin), 5 mM (CycLuc1), 250 μM (substrates for AAV mice), and 100 
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μM (substrates for FVB-Tg[CAG-luc] mice) to achieve final concentrations of 400 
μmol/kg, 20 μmol/kg, 1 μmol/kg, and 0.4 μmol/kg respectively. 
 
Bioluminescence imaging of mice 
Each mouse was weighed to determine substrate and/or FAAH inhibitor 
dosing and anesthetized using 2.5% isoflurane in 1 L/min oxygen. FAAH 
inhibitors were injected i.p. at 5 μL/g mouse 30 minutes prior to luciferin injection. 
Luciferin substrate was injected i.p. at 4 μL/g mouse and mice were imaged 
dorsally at 10 minutes and ventrally at 13 minutes. 
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CHAPTER VII: 
Luciferin Amides and Imaging in the Brain Discussion 
AKA: “Luciferins Behave Like Drugs” 
Mofford, D.M., and Miller, S.C. (2015). ACS Chem. Neurosci. 6(8), 1273–1275. 
 
 
 
 
Summary 
The light emission chemistry of firefly luciferase can be harnessed to 
reveal otherwise invisible biological processes occurring in the brains of live 
animals. Though powerful, the need for the luciferase substrate D-luciferin to 
traverse the blood-brain barrier poses limitations on the sensitivity and 
interpretation of these experiments. In this Viewpoint, we discuss bioluminescent 
imaging probes for the enzyme fatty acid amide hydrolase (FAAH) and the 
broader implications for optical imaging and drug delivery in the brain. 
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Viewpoint 
Luciferins do not treat disease, but in many ways these exogenous 
molecules act like drugs. Instead of a eliciting a therapeutic response, luciferins 
emit light when they encounter their target (luciferase). If you want to light up the 
brain in a luciferase-expressing mouse, you essentially have a drug delivery 
problem: how to get across the blood-brain barrier. Generally, this means you 
want a molecule that is small (<500 MW), lipophilic enough to readily diffuse 
across cell membranes, and preferably not a substrate for the armada of efflux 
pumps poised at the border, ready to send your molecule packing. D-Luciferin, 
the substrate for firefly luciferase, gets a gold star for small size, but everything 
else has room for improvement.  
Fireflies produce light by the oxidation of D-luciferin to an excited-state 
molecule (Figure 7.1). Recent work has shown that the enzyme firefly luciferase 
will accept many substrate analogues, allowing tuning of the molecular properties 
of the luciferin (Adams and Miller, 2014; Mofford et al., 2015). These synthetic 
luciferins are not necessarily “better” than the natural substrate. Indeed, if firefly 
luciferase is provided with a saturating concentration of luciferin in a test tube, 
the rate of photon emission is higher with the natural substrate D-luciferin than 
with any synthetic luciferin analogue yet made (Adams and Miller, 2014). 
However, in vivo, and particularly in the brain, the access of D-luciferin is limited. 
Saturating levels of D-luciferin are not achieved after intraperitoneal (IP) injection 
into live mice (Aswendt et al., 2013). Under these conditions, luciferin analogues 
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with higher cell permeability and lower Km values for luciferase can perform 
better than the natural substrate, and do so at substantially lower imaging doses 
(Adams and Miller, 2014; Mofford et al., 2015). 
 
 
 
Figure 7.1. Enzyme catalyzed reactions. (A) Firefly luciferase oxidizes its 
substrate D-luciferin to emit light. This chemistry requires a free carboxylate. (B) 
FAAH hydrolyzes anandamide and many other fatty acid amides. (C) Luciferin 
amides can be hydrolyzed by FAAH to unmask substrates for luciferase (Mofford 
et al., 2015). 
 
A complete picture of all the factors that restrict D-luciferin access to the 
brain has not yet emerged. In general, small lipophilic compounds can penetrate 
the blood-brain barrier (BBB), while large and/or hydrophilic compounds are 
excluded. D-Luciferin is small (<300 MW), but relatively polar. Its ability to access 
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the brain by simple diffusion is therefore expected to be modest. Furthermore, 
there are many efflux pumps (aka “drug resistance pumps”) that actively remove 
molecules from the brain. These include ABCG2, Pgp (ABCB1), MRP1 (ABCC1), 
and MRP4 (ABCC4) (Adams and Miller, 2014; Cheung et al., 2015). D-Luciferin 
was thought to be a substrate only for ABCG2 (Adams and Miller, 2014; Cheung 
et al., 2015). However, it has recently been reported to be a substrate for MRP4 
as well (Cheung et al., 2015). The relevance of this finding for access to the brain 
has not yet been established.  
It is important to be mindful of the role that the blood-brain barrier plays in 
restricting the access of the luciferin substrate. Some experimental techniques or 
disease states can disrupt the BBB. For example, injection of luciferase-
expressing cells into the brain will disrupt the BBB, and immediate imaging of 
those injected cells is therefore unlikely to reflect an intact BBB. (Aswendt et al., 
2013) And as recently demonstrated by Ayzenberg et al., (Ayzenberg et al., 
2015) neuro-inflammation also has the potential to disrupt the BBB. The 
bioluminescent signal from D-luciferin may increase simply due to improved 
substrate access to brain tissue, and be confused with an increase in gene 
expression (Ayzenberg et al., 2015). Similarly, the growth of brain tumors that 
disrupt the BBB may also affect the interpretation of the resulting imaging data. 
Potentially, the use of luciferins that are less sensitive to BBB disruption could 
help avoid these issues. 
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Synthetic luciferin substrates with higher lipophilicity and lower Km values 
for luciferase can improve imaging in the brain (Adams and Miller, 2014; Mofford 
et al., 2015) (Figure 7.2). These substrates are expected to more readily diffuse 
across cell membranes, and due to their lower Km values less substrate is 
needed to saturate the luciferase. Changes to the luciferin structure may also 
affect efflux pump activity, but itis not yet clear if or how the efflux of synthetic 
luciferins from the brain differs from D-luciferin. All substrates for firefly luciferase 
require a free carboxylate. At physiological pH, the presence of an ionized 
carboxylate on the luciferin is thus another factor that limits its cell permeability 
and ability to cross the blood-brain barrier. This is where things get really 
interesting. Fatty acid amide hydrolase (FAAH) is the enzyme responsible for the 
hydrolysis of anandamide, an endogenous ligand for the cannabinoid receptor 
CB1 (Figure 7.1). We synthesized luciferin amides designed to be substrates for 
FAAH, a promising drug target for the treatment of pain and anxiety (Mofford et 
al., 2015). Cleavage of luciferin amides by FAAH liberates a luciferin substrate, 
allowing sensitive and specific bioluminescence detection of FAAH activity in the 
brain and periphery (Mofford et al., 2015). This was all by design- but what was 
surprising was that luciferin amides improve brain bioluminescence in live mice 
over both D-luciferin and their parent luciferins (Mofford et al., 2015) (Figure 7.2). 
Far less substrate is needed for imaging, and the photon flux is increased. 
Luciferin amides are acting as luciferin “pro-drugs”. 
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Figure 7.2. Bioluminescence imaging in luciferase-expressing mice. (A) 
Adeno-associated virus (AAV)9 was used to express luciferase only in the 
striatum of the brain. Photon flux from the same mouse was compared using the 
indicated luciferin analogue and dose (i.p. injection). (B) The same set of luciferin 
analogues was compared at equal dose in a transgenic mouse that ubiquitously 
expresses luciferase. 
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When imaging in mice that express luciferase in all tissues, 
bioluminescence is dominated by superficial tissues- wherever the luciferin goes, 
you will see light. A caveat of imaging in these mice is that emission from deep 
tissues that are harder to access is often obscured. This is particularly true in the 
head, where photon flux from the nose, eyes, ears, and tissue overlying the brain 
overshadows emission from the brain itself (Figure 7.2). Remarkably, it is the 
brain that yields the highest bioluminescence signal when these same mice are 
treated with luciferin amides (Mofford et al., 2015) (Figure 7.2). This reflects both 
the ability of luciferin amides to traverse the blood-brain barrier, and the high 
selectivity for cleavage to the light-emitting luciferin by FAAH.  
Ask your average medicinal chemist how to improve the cellular delivery 
of a carboxylic acid, and they will say: make an ester. Esters are more lipophilic, 
and upon entry into cells are anticipated to be hydrolyzed to the carboxylic acid 
by “esterase activity” (where the specific enzyme or enzymes performing this 
activity are often unknown). Although luciferin esters can be hydrolyzed to their 
respective luciferins in cells and in mice, they have not been very effective at 
delivering luciferins into the brain (Mofford et al., 2015) (Figure 7.2). In part, this 
may be because “esterase activity” is everywhere. On the other hand, luciferin 
amides are exemplary at delivering synthetic luciferins into the brain, where 
endogenous FAAH activity liberates the parent luciferin (Mofford et al., 2015). 
Potentially, FAAH could be more generally exploited in a “pro-drug” strategy to 
specifically unmask a broader range of carboxylic acids in the brain. Somewhat 
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ironically, we find that FAAH is also responsible for some of the generic “esterase 
activity” toward luciferin esters, at least in tissue culture cells (Mofford et al., 
2015). 
Many optical imaging probes are too large or polar to efficiently enter the 
brain. Excitingly, bioluminescence imaging combines the specificity of a 
genetically encoded luciferase reporter with the versatility of a small yet highly 
tunable “drug-like” luciferin emitter, offering a wealth of opportunities to shed light 
on the inner workings of the brain, and also show how to get there. 
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CHAPTER VIII: 
Discussion 
 
 
Animals capable of glowing in the dark have fascinated people throughout 
history (Harvey, 1957). There are fish that make the oceans shimmer (Haddock 
et al., 2010), fungi that make the forests glow (Purtov et al., 2015), and beetles 
that light up the sky (Viviani, 2002). Our fascination with this phenomenon has 
led scientists on a long journey to determine why and how these creatures glow. 
The study of how an organism can emit light by bioluminescence is not only 
intriguing from an academic perspective, it has proven to be a useful tool to study 
numerous biological processes. 
Bioluminescence imaging has become an invaluable resource for non-
invasively reporting on biological functions, with the North American firefly, 
Photinus pyralis, providing the preferred reporter system (Welsh and Noguchi, 
2012). The firefly luciferase enzyme is genetically encodable, stable in live cells 
and organisms (Welsh and Noguchi, 2012), and catalyzes light emission with a 
high quantum yield (Ando et al., 2008). Its substrate, D-luciferin, is small, stable, 
and easily synthesized (McCutcheon et al., 2015). Together, they can report on 
otherwise invisible events such as gene expression, enzyme activity, or 
protein/protein interactions by production of a readily detected photon of light 
(Badr and Tannous, 2011; Fan and Wood, 2007; Prescher and Contag, 2010). 
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Despite its numerous advantages, firefly bioluminescence is 
fundamentally limited by the photophysical properties of its substrate, D-luciferin. 
This molecule is relatively polar, has a modest affinity for firefly luciferase, and 
emits yellow-green light after catalysis by firefly luciferase (Fraga, 2008). All of 
these are areas that are less than optimal, especially for in vivo imaging. To 
overcome these shortcomings, in CHAPTER II, I discuss the development of 
synthetic luciferin analogs based on the core structure of D-luciferin (Mofford et 
al., 2014b; Reddy et al., 2010). These luciferins were designed to display red-
shifted light emission, bringing the wavelength to a region where light is more 
able to penetrate through tissue (Mobley and Vo-Dinh, 2003; Weissleder and 
Ntziachristos, 2003). They also have increased affinity for luciferase (Harwood et 
al., 2011; Mofford et al., 2014b), so less substrate is required to saturate the 
enzyme; a particularly beneficial feature for use in live cells or animals where the 
cell membrane will limit access to the luciferase. Moreover, our modifications to 
the luciferin structure increase their hydrophobicity and lipophilicity, which should 
increase their cell permeability. Finally, D-luciferin is the only naturally occurring 
substrate for firefly luciferase and all other beetle luciferases. We hypothesized 
that structural differences between the synthetic luciferins described here could 
potentially be exploited to create selective luciferases, enabling discrimination 
between substrates for use without interference between signals. 
Although the synthetic luciferins discussed in CHAPTER II may sound like 
the solution to all of the limitations of firefly bioluminescence, they are not without 
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their own flaws. The increased affinity for luciferase translates to an increase in 
product inhibition, and a decrease in the intensity of sustained light emitted in 
vitro (Harwood et al., 2011; Mofford et al., 2014b; Reddy et al., 2010). To date, 
no example of a synthetic substrate has actually improved on what is achievable 
with firefly luciferase and saturating conditions of D-luciferin (Table 8.1). 
 
Table 8.1. Optimal enzyme/substrate pairs under various conditions. 
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Previous work in the lab identified several point mutations as beneficial for 
use with aminoluciferins (Harwood et al., 2011). For example, the R218K 
mutation generally improves the maximal photon flux from all of the 
aminoluciferins described in this chapter by reducing their affinity and limiting 
product inhibition. However, since all of the synthetic luciferins show increased 
photon flux, and D-luciferin remains a substrate with R218K, this single mutation 
is not sufficient to discriminate between substrates. We therefore combined 
R218K with the L286M and S347A mutations to create a triple mutant luciferase 
that not only increases the maximal rate of sustained light emission from several 
synthetic substrates, but displays unprecedented selectivity for our substrates 
over D-luciferin (Table 8.1). Photon flux from D-luciferin is reduced by 10,000-
fold compared to WT, while photon flux from the preferred substrate, CycLuc7, 
increases 450-fold. We hypothesize that the combination of these three 
mutations functions in part by lowering the affinity of all luciferins, shifting the 
affinity for the synthetic substrates to the mid-micromolar range, while shifting the 
affinity for D-luciferin into the millimolar range.  
Both mutant luciferases lower the binding affinity of each substrate and 
help relieve product inhibition, resulting in an increased rate of photon emission 
in vitro. However, if the reduction in substrate affinity is too great and the 
luciferase is used under limiting substrate conditions (i.e., in live cells and 
organisms), the amount of substrate required for effective catalysis may not be 
attainable. The R218K mutant does not appear to have this problem, producing 
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the highest photon flux of any luciferase/luciferin combination tested here from 
cells overlaid with high substrate dose (250 µM with CycLuc2), or low dose (1.95 
µM with CycLuc12) (Table 8.1). Conversely, while the triple mutant luciferase 
exceeds the photon flux of WT with any luciferin upon treatment with high dose of 
CycLuc2, CycLuc7, and CycLuc11, the loss of affinity by the combination of all 
three mutations results in all substrates emitting lower photon flux than WT and 
D-luciferin at low substrate dose. Therefore, it is unlikely that the concentration of 
substrate needed for efficient catalysis will be achievable in live mice. For use 
under the limiting substrate conditions of live cells and organisms, I propose that 
there is a “Goldilocks zone” of substrate affinity, where the luciferin does not bind 
too tightly, reducing the photon flux via product inhibition, but also does not bind 
too weakly, necessitating the need for high substrate concentration for light 
emission. A Km of approximately 1 µM seems to be optimal, especially when 
paired with the increased cell permeability of the synthetic luciferins (e.g., 
CycLuc12 is preferred in live cells at low substrate dose with both WT [Km = 0.3 
µM] and R218K [Km = 1.7 µM]). 
While the development of the triple mutant luciferase provides a proof-of-
concept towards new, orthogonal bioluminescent systems, additional 
optimization is still required. As discussed in CHAPTER I, WT luciferase is 
remarkably promiscuous and functions with all of the synthetic substrates that we 
(and others) have developed. Although the triple mutant luciferase is inactive 
toward D-luciferin, CycLuc7 still emits with the WT luciferase. Moreover, the loss 
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of affinity of the triple mutant toward its substrates limits its usefulness in vivo. 
However, there are continually new luciferin analogs being produced bearing 
increasingly varied chemical structures (Branchini et al., 1989; Conley et al., 
2012; Iwano et al., 2013; McCutcheon et al., 2012; Woodroofe et al., 2012). As 
the number of structurally distinct synthetic luciferins grows, there will be 
increased opportunity to exploit those differences in the development of 
orthogonal bioluminescent enzyme/substrate pairs.  
The identification of a mutant luciferase that was more active toward 
substrates other than D-luciferin prompted us to look for other “luciferase-like” 
enzymes that do not emit light with D-luciferin. Long-chain fatty acyl-CoA 
synthetases (ACSLs) have been characterized based on their similarities to 
luciferase in an effort to identify additional bioluminescent enzymes (Oba et al., 
2004, 2006a, 2008, 2010), but only very weak light emission has ever been 
observed with D-luciferin (Viviani et al., 2013). We hypothesized that 
bioluminescence is possible with these enzymes, but that D-luciferin is either 
unable to bind, or is binding in an orientation not conducive to catalysis. Perhaps, 
if supplied with an appropriate synthetic substrate, an ACSL could exhibit 
luciferase activity.  
In CHAPTER III, I discuss the identification and characterization of the first 
latent luciferase discovered: CG6178 from Drosophila melanogaster (Mofford et 
al., 2014a). Furthermore, in CHAPTER IV, I report that another ACSL, AbLL from 
the non-luminous click beetle Agrypnus binodulus, also possesses luciferase 
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activity. Neither CG6178 nor AbLL display the same level of substrate 
promiscuity as firefly luciferase, only recognizing a subset of the synthetic 
luciferins tested. Interestingly, while neither enzyme catalyzes light emission with 
D-luciferin, their respective substrate specificities are distinct. For example, 
CG6178 catalyzes light emission within a similar class of substrates (i.e., cyclic 
dialkylated aminoluciferins similar to CycLuc2). Conversely, AbLL accepts 
substrates of varying structure and discriminates between substrates with 
relatively minor structural differences. AbLL recognizes two short cinnamyl-type 
substrates: the acyclic dimethylamine Me2NPh-1n-Cys and the dialkylated 
tetrahydroquinoline C8Ph-1n-Cys, but is inactive toward the dialkylated indoline 
C2Ph-1n-Cys. Structural analysis of the AbLL binding pocket may determine how 
this level of recognition is accomplished. Moreover, structural studies of both 
latent luciferases may aid in the development of luciferases with improved 
substrate selectivity as discussed above. Neither CG6178 nor AbLL display the 
necessary photon flux for use as a bioluminescent reporter. However, we predict 
that structural analysis will make it possible to uncouple substrate specificity from 
signal intensity, allowing for the development of additional orthogonal luciferase 
reporters. 
We were quite surprised to find that homology to luciferase is a poor 
predictor of luciferase activity. CG6178 possesses 39% identity to firefly 
luciferase, while AbLL possesses 46% identity; yet, AbLL emits weaker photon 
flux than CG6178. A third ACSL, PaLL from the luminous Panamanian click 
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beetle Pyrophorus angustus, also possesses 46% identity to luciferase, yet does 
not exhibit luciferase activity with any luciferin analog (CHAPTER IV). Perhaps 
conservation of primary amino acid sequence does not translate to conserved 
tertiary structure. There could be slight differences in each enzyme’s final fold 
that dictate the presence or absence of luciferase activity. Conversely, there 
could be residues that are necessary for catalysis that have not become 
apparent from the limited number of ACSLs screened. For example, a putative 
binding site for oxygen has not been identified in luciferase (Branchini et al., 
1998). If such a site exists, it may not be present in PaLL. However, we are still in 
the early stages of investigating luciferase activity in ACSLs. As more enzymes 
are screened, and as detailed structural studies are performed, patterns that can 
predict luciferase activity may still emerge. 
Mammalian ACSLs are less homologous to firefly luciferase than insect 
ACSLs. In fact, it is thought that mammalian and insect ACSLs evolved 
independently (Oba et al., 2005). Therefore, while endogenous expression of 
CG6178 was sufficient to support light emission from live Drosophila S2 cells 
treated with CycLuc2, it was not surprising to find that CHO cells did not emit 
light when treated with any luciferin analog (CHAPTER III). Still, I predict that a 
suitable synthetic luciferin will elicit bioluminescence from a mammalian enzyme 
as well. Mammalian-specific luciferins may be quite distinct from our current 
analogs. As long as that luciferin contains a chromophore and a free carboxylate, 
binds to the enzyme in the correct orientation for adenylation and oxidation, and 
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oxygen can access the active site, bioluminescence should occur. If this can be 
achieved, it will not only show further commonality to light emission by 
bioluminescence, it would also present a useful source of diversity for the 
generation of new orthogonal pairs, as discussed above. 
The identification of multiple ACSLs with latent luciferase activity prompted 
us to look more closely at the light emitting chemistry (CHAPTER III). The 
canonical mechanism is for oxygen to react with the intermediate luciferyl 
adenylate. However, since oxygen exists in a triplet-state, with two unpaired 
electrons occupying degenerate orbitals, it is “spin-forbidden” to react with 
singlet-state molecules such as the luciferyl adenylate (Min et al., 2011). We 
therefore proposed that the formation of a resonance stabilized carbanion at the 
C4 position of the luciferyl adenylate reduces molecular dioxygen by single 
electron transfer to form superoxide and a C4 radical (Fetzner and Steiner, 2010; 
Russell and Bemis, 1966). Reaction between those two radicals is no longer 
forbidden and they can recombine after a spin-flip to form a peroxide that can 
react via the canonical mechanism. This seemed to us to be the only 
thermodynamically-viable model. In fact, since we proposed this route, Branchini 
et al. have shown experimental support for reduction of molecular dioxygen by 
single electron transfer in a luciferin model system (Branchini et al., 2015). They 
report the formation of a superoxide anion, a feature consistent with our model 
but not the classical model. Thus, the oxidation chemistry did not need to evolve 
from an ACSL; the inherent reactivity of a carbanion with oxygen is sufficient. In 
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order for an enzyme to catalyze light emission, it must adenylate the luciferin, 
promote formation of the intermediate carbanion, and allow oxygen into the 
active site. The inherent carbanion reactivity, combined with the properties of the 
luciferin, will result in photon emission. Therefore, nascent enzymatic activity can 
be as much dependent on the properties of the substrate as on the actual 
enzyme.  
In an effort to harness the substrate specificity of ACSLs with latent 
luciferase activity, while improving the photon intensity, in CHAPTER V I develop 
and characterize luciferase/ACSL chimeric enzymes. Firefly luciferase and 
ACSLs are divided into two domains: a large N-terminal substrate-binding 
domain, and a small C-terminal catalytic domain containing two lysine residues 
responsible for adenylation and oxidation/thioesterification. Here we find that 
replacing the C-terminal domain of firefly luciferase with that of either CG6178 or 
AbLL is not only permitted, but results in improved selectivity for synthetic 
luciferins over D-luciferin. While the luciferin binding pocket within the N-terminal 
domain should remain mostly unchanged in the C-terminal fusions, the 
orientation of those two lysines from each C-terminal domain may vary and thus 
impact overall catalysis. For example, the FLuc/CG fusion behaves very similarly 
to WT luciferase, while the FLuc/Ab fusion does not. Firefly luciferase displays 
burst kinetics as discussed in CHAPTER I, while AbLL slowly increases its 
photon flux even after two minutes, as shown in CHAPTER IV. The FLuc/Ab 
chimera displays an intermediate profile with a peak rate of light emission after 
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several seconds and little to no product inhibition. These findings suggest that 
rather than modular roles for the two domains, it is the interaction of both that 
contribute to the overall function of the enzyme.  
One possible explanation for the intermediate activity of the FLuc/Ab 
chimera is that the AbLL C-terminal domain does not efficiently undergo the 
necessary conformational change between adenylation and oxidation. There 
could be residues that line the interface between it and the N-terminal domain 
that hinder its movement. For example, there is a loop that extends from the C-
terminal domain of firefly luciferase into the N-terminal domain and positions 
K529 in the active site for adenylation (Figure 8.1). While K529 is conserved 
between ACSLs, the remaining residues of the loop are not. If the loop of an 
ACSL binds more tightly to the N-terminal domain of luciferase, it may hinder the 
conformational change between the adenylation and oxidation steps and lower 
the rate of catalysis. 
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Figure 8.1. The loop in firefly luciferase that positions K529 is not well 
conserved in ACSLs. The loop (green) that extends from the C-terminal domain 
(blue) to the N-terminal domain (red) of luciferase to position K529 (yellow) for 
adenylation of the luciferin (cyan). The primary sequence of the loop residues is 
not conserved between ACSLs (insert). [Figure from PDB 4G36 (Sundlov et al., 
2012)]. 
 
Additionally, we find that mutations that improved luciferase photon flux 
with synthetic luciferins did not readily translate to use with the C-terminal ACSL 
fusions. Neither the R218K point mutation nor the triple mutant synergized with 
the CG6178 and AbLL fusions as well as WT luciferase. These mutations were 
identified by saturating mutagenesis at specific sites in the luciferase active site. 
By re-screening using the chimera background instead of WT luciferase, it is 
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possible that there will be alternative mutations that will better cooperate with the 
new domain. Conceivably, the combination of direct mutation with chimeric 
enzymes may prove to be more beneficial than either one alone. 
Apart from simply understanding and optimizing firefly bioluminescence, 
the aim of my work was to increase the applications of bioluminescence 
throughout biology. In CHAPTER VI, I sought to expand the bioluminescence 
toolkit by developing a sensor for fatty acid amide hydrolase (FAAH) (Mofford et 
al., 2015). FAAH is responsible for hydrolyzing fatty acid amide second 
messengers to their respective fatty acids (Cravatt et al., 1996). Based on the 
hypothesis that luciferase evolved from a fatty acyl-CoA synthetase (Day et al., 
2009), and our discovery of two ACSLs that are able to catalyze light emission 
with a synthetic luciferin, we propose that D-luciferin and its analogs are 
essentially fatty acid mimics. We therefore hypothesized that a luciferin amide 
would mimic the native fatty acid amide substrates for FAAH and be hydrolyzed 
to release a proper luciferin. As expected, luciferin amides do not produce light 
as they are unable to be adenylated and thus are not substrates for luciferase. 
They are, however, extremely specific substrates for FAAH, readily translating 
from in vitro assays, to live cells, and finally to live mice (Table 8.1). 
As discussed in CHAPTER II, we propose that the improved cell 
permeability and increased enzyme affinity of synthetic luciferins make them 
superior to D-luciferin for use in live cells and organisms. Consistent with this 
proposal, using the amide of our synthetic luciferin CycLuc1 allowed us to report 
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on FAAH activity in the brains of live mice, whereas the amide of D-luciferin was 
insufficient. FAAH may not be able to hydrolyze sufficient quantity of D-luciferin 
amide to overcome the higher Km of D-luciferin. Moreover, the luciferin amide 
modification ameliorated cell permeability to a greater extent. In the brains of live 
mice, CycLuc1 amide increases photon flux over D-luciferin, even at 1,000-fold 
lower substrate dose. It is likely that the lack of an ionized carboxylate on the 
amides increases their cell permeability, while the membrane bound FAAH 
results in rapid hydrolysis. Therefore, as discussed in CHAPTER VII, luciferin 
amides are also ideal luciferin delivery vehicles for cells and tissues that express 
FAAH (Mofford and Miller, 2015). 
By harnessing the intrinsic characteristics of luciferin analogs, and 
changing a single functional group, we have developed a sensor for a single 
enzyme in a live mouse. Further refinement of the luciferin structure and 
modification of the scissile bond should allow for the detection of other enzymatic 
activities, particularly those that release fatty acids. For example, one enzyme of 
interest is monoacylglycerol lipase (MAGL) (Blankman and Cravatt, 2013; 
Blankman et al., 2007). MAGL hydrolyzes the endocannabinoid 2-arachidonoyl 
glycerol to arachidonic acid (Figure 8.2) and is a drug target for the treatment of 
pain (Long et al., 2009). By replacing the free carboxylate of a luciferin with a 
glycerol ester, it should be possible to detect MAGL activity by bioluminescence. 
Structural optimization may be required to ensure selectivity, as there are a wide 
variety of esterases present in live cells and organisms and luciferin esters have 
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previously been used as luciferin delivery vehicles (Craig et al., 1991; Shinde et 
al., 2006). However, the successful detection of FAAH activity with our luciferin 
amides suggests that other enzymatic activities can be measured by employing 
other simple chemical modifications. 
 
 
Figure 8.2. Proposed bioluminescence MAGL activity assay. (A) MAGL 
hydrolyzes 2-arachidonoyl glycerol to arachidonic acid. (B) Proposed 
bioluminescent activity assay where MAGL hydrolyzes the pro-luciferin CycLuc1 
glycerol ester to release the luciferase substrate CycLuc1. 
 
In summary, the work described herein harnesses the power of synthetic 
luciferin analogs to both understand the fundamental properties of 
bioluminescence and improve its practical applications. Our synthetic substrates 
combine with mutant luciferases to generally improve on current technologies. 
We show that latent luciferase activity exists in luciferase homologs, allowing us 
to explore the evolutionary origins of light emission and providing a platform to 
determine what defines a luciferase. Finally, we developed a pro-luciferin 
approach to detect enzymes that release fatty acid products, allowing us to probe 
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their enzymatic activity via light production and revealing the utility of our 
synthetic luciferins for exploring biological environments. It is clear that the only 
limit to bioluminescence applications is the imagination. 
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